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ABSTRACT: The essential enzyme CYP121 is a target for
drug development against antibiotic resistant strains of
Mycobacterium tuberculosis. A triazol-1-yl phenol fragment 1
was identiﬁed to bind to CYP121 using a cascade of
biophysical assays. Synthetic merging and optimization of 1
produced a 100-fold improvement in binding aﬃnity, yielding
lead compound 2 (KD = 15 μM). Deconstruction of 2 into its
component retrofragments allowed the group eﬃciency of
structural motifs to be assessed, the identiﬁcation of more LE
scaﬀolds for optimization and highlighted binding aﬃnity
hotspots. Structure-guided addition of a metal-binding
pharmacophore onto LE retrofragment scaﬀolds produced
low nanomolar (KD = 15 nM) CYP121 ligands. Elaboration of
these compounds to target binding hotspots in the distal active site aﬀorded compounds with excellent selectivity against human
drug-metabolizing P450s. Analysis of the factors governing ligand potency and selectivity using X-ray crystallography, UV−vis
spectroscopy, and native mass spectrometry provides insight for subsequent drug development.
■ INTRODUCTION
Tuberculosis (TB) is responsible for the death of 1.5 million
people annually.1 The development of antibiotic resistant
strains of the causal pathogen Mycobacterium tuberculosis (Mtb)
and comorbidity with immunosuppressive conditions such as
HIV and diabetes are major contributors to the current crisis
and there is an urgent need for the development of new drugs
with novel mechanisms of action.
Cytochrome P450 enzymes (P450s or CYPs) are a currently
unexploited class of protein targets for TB therapeutics. The
Mtb genome encodes genes for 20 P450 isoforms, which is
more than 200 times as many as humans for the relative size of
the genome.2 The large proportion of genetic material
dedicated to P450s suggests that these enzymes might have
important functions for the survival and virulence of the
pathogen.3 Biochemical and genetic studies over the past 15
years have provided evidence of essential roles for Mtb P450s in
bacterial viability, the catabolism of host cholesterol, establish-
ment of infection, persistence in the granuloma, cellular stress
response mechanisms, and drug susceptibility.4−14 A number of
azole-containing antifungal compounds that have potent
antimycotic activity against Mtb H37Rv both in vitro and in
murine models of TB, have tight binding aﬃnity (KD) for a
number of the Mtb P450s, which provides further support for
these enzymes as potential drug targets.12,15,16 There is
correlation between the minimum inhibitory concentration
(MIC) values of the most potent azole compounds
clotrimazole, econazole, and miconazole, which have MICs of
11, 8, and 8 μg/mL, respectively, against Mtb H37Rv,12 and
their KD’s for the most strongly inhibited P450 CYP121 (KD =
73−136 nM).12,17 In addition, evidence that the gene encoding
CYP121 (rv2276) is essential for Mtb H37Rv viability12 implies
that this P450 is the major target responsible for the eﬃcacy of
these compounds. While azole antifungal drugs have promise as
treatments for TB, the speciﬁc compounds that have been
shown to have eﬃcacy against Mtb suﬀer from either low oral
bioavailability or cause signiﬁcant toxic side eﬀects because of
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their broad spectrum activity against human P450s or
steroidogenic inhibition.18,19 These properties make the azole
drugs incompatible with long-term dosing regimens required
for TB treatment. Consequently, there is interest in developing
more potent and selective inhibitors of Mtb P450s.
CYP121 is a soluble, monomeric enzyme, which has limited
similarity (≤34% protein sequence identity) to other Mtb
P450s.11 The enzyme catalyzes the cyclization of the dipeptide
cyclo-(L-Tyr-L-Tyr) (cYY) to form the diketopiperazine
mycocyclosin.11 While the function of mycocyclosin has not
been determined, diketopiperazine secondary metabolites often
have antimicrobial or cytotoxic activity, properties which might
be of importance for Mtb virulence.10 This combination of gene
essentiality, low sequence similarity to other P450s, and tight
azole binding aﬃnity has made the development of CYP121
inhibitors an area of interest in the search for new TB drugs and
the focus of the research presented here.
Fragment-based drug discovery (FBDD) is an established
technique in both academia and industry that has been applied
to a wide range of molecular targets.20−25 The availability of
high resolution crystal structures of CYP121, in both the
substrate-free and substrate/ligand-bound forms, make it
amenable to a fragment-based approach.26 We have previously
reported the development of low micromolar aﬃnity CYP121
inhibitors, developed from fragments that were identiﬁed in a
biophysical screen of our fragment library.27,28 Six fragment hits
were crystallized with CYP121, one of which was 4-(1H-1,2,4-
triazol-1-yl)phenol 1 (KD = 1.7 mM) (Figure 1). Fragment 1
bound in two diﬀerent overlapping orientations in the CYP121
active site, suggesting an approach based on fragment merging.
Synthesis of a range of analogues, guided by in silico screening
to optimize the binding interactions of the heterocyclic
fragment core, resulted in the identiﬁcation of the triphenol
pyrazole-amine 2 (KD = 15 μM). An X-ray crystal structure of 2
bound to CYP121 revealed that 2 maintained the binding mode
of the original fragment 1. The optimized hydrogen bonding
interactions between the 5-aminopyrazole core of 2 and distal
pocket residues Gln385, Ala167, and Thr77 represented a
privileged binding mode for an azole-containing compound,
which generally bind directly to the heme cofactor of P450s
using a heterocyclic nitrogen atom. The combination of the low
micromolar aﬃnity of 2 and its unique binding mode, which
was conserved with fragment 1, led us to pursue further
optimization of this compound series.
Despite a 100-fold improvement in binding aﬃnity between
fragment 1 and lead 2, the low ligand eﬃciency (LE)29,30 of 2
(LE = 0.23) led us to undertake a deconstruction−
reconstruction approach to identify more eﬃcient scaﬀolds
for subsequent optimization. Retrofragmentation of 2 to its
component “fragments” was used to assess the binding
contribution, or group eﬃciency (GE),31 of the three aromatic
rings that decorate the amino-pyrazole core, hereafter referred
to as Ar1, Ar2, and Ar3, as deﬁned in Figure 3.
GE analysis provided an assessment of the change in binding
aﬃnity per heavy atom that could be attributed to each of the
Ar1, Ar2, and Ar3 rings of lead 2, as the compound was
sequentially rebuilt from a series of retrofragments 3−6.31 X-ray
crystal structures of CYP121 in complex with retrofragments
3−6 were used to validate our GE analysis, enabled the
identiﬁcation of conserved binding hotspots within the enzyme
active site and was used to guide our subsequent optimization
of 2 using fragment growing and merging strategies. The
signiﬁcant improvements in binding aﬃnity and LE that can be
achieved by the structure-guided incorporation of a metal
binding pharmacophore into the newly identiﬁed minimal
scaﬀolds is illustrated. In contrast, fragment growing toward
Figure 1. Fragment merging and in silico directed optimization of fragment 1 (green, PDB 4G47) led to the discovery of low micromolar CYP121
inhibitor 2 (salmon, PDB 4KTL). Fragment 1 and lead 2 retained a conserved binding mode distal to the heme cofactor (magenta). Hydrogen
bonding interactions between the 5-aminopyrazole ring and CYP121 residues Gln385 and Ala167, and the phenol group with Asn85 and active site
water molecules are shown as yellow dashed lines. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC).
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pockets in the distal active site produced only modest
improvements in binding aﬃnity and resulted in the develop-
ment of a second series of compounds with a binding mode
that was distinct from the metal-coordinating ligands.
Investigation of the SAR governing these interactions and
knowledge of binding hot-spots were subsequently exploited to
improve the isoform selectivity of inhibitors against human
P450 enzymes, and also identiﬁed regions of the CYP121 active
site that were tolerant to structural modiﬁcation and which
could be exploited during the future optimization of these
compounds.
■ RESULTS
Retrofragmentation. Retrosynthetic fragmentation of lead
compound 2 indicated that the relative binding contributions of
Ar1, Ar2, and Ar3 could be determined from a combination of
monophenol and biphenol fragments 3, 4, 5, and 6 (Figure
3).32 The sequential reconstruction of 2 from these fragments
enabled the GE of each aromatic ring to be calculated from the
diﬀerence in the free energy of binding per heavy atom added
at each stage of reconstruction (GE = −ΔΔG/ΔHA).31
Retrofragments 3 and 5 were synthesized according to the
previously reported literature procedure,28,33 which was also
used to access fragment 4. Biphenol fragment 6 was synthesized
according to the general route for accessing 3,5-disubstituted
aminopyrazoles described by Johnson et al.34 X-ray crystal
structures of fragments 3−628 in complex with CYP121 (Figure
2a−c) were obtained in order to aid the interpretation of
binding aﬃnity and GE trends. Retrofragments 3−6 each
reproduced the privileged non-heme binding mode of lead
compound 2, which is unusual for P450 ligands containing
azole motifs. Analysis of the conserved and variable binding
interactions made by the retrofragments highlighted structural
features likely to be important for driving the binding aﬃnity of
2.32,35 Monophenol 4 bound in an orientation that overlapped
with that of Ar2 of the lead compound 2 (Figure 2a). The
water-bridged hydrogen bonding network between Asn85,
Thr229, and the heme propionate group with the 4-hydroxy
substituent of 4 was conserved, while the 5-aminopyrazole ring
was shifted toward the I-helix (highlighted yellow in Figure 2)
to enable hydrogen bonding interactions with Val228 and
aromatic interactions with Phe168 and Trp182, mimicking the
function originally fulﬁlled by Ar1 of lead compound 2. The
small shift in position of the aminopyrazole ring of 4 indicated
that interactions made at the Ar1 site might contribute more
signiﬁcantly to the aﬃnity of lead compound 2 than do the
hydrogen-bonding interactions made by 2 with Gln385.
A 1.65 Å X-ray crystal structure of retrofragment 3 in
complex with CYP121 was obtained, however incomplete
ligand occupancy prevented adequate reﬁnement of the
structure. The poorly resolved density of 3 suggested the
fragment likely acquired multiple diﬀerent binding orientations,
as had been previously observed for the original hit fragment 1
(Figure 1). Analysis of the ligand density suggested that 3
bound CYP121 in an orientation that overlapped with Ar1 of
lead 2. However, the 5-aminopyrazole ring was rotated 180°,
further indicating that hydrogen bonding to Gln385 probably
contributed less to binding aﬃnity than other conserved
interactions (Figure S1, Supporting Information). The fused
Ar1−Ar2 fragment 5 accurately recapitulated the binding mode
of 2, satisfying the oﬀset and edge-face π-stacking interactions
with Phe168 and Trp182 that were identiﬁed as important in
Figure 2. X-ray crystal structures of lead compound 2 and component retrofragments 4−6 in complex with CYP121. The I- (yellow), and F-, and G-
(blue) helices are shown in cartoon representation. (a) Overlaid structures of retrofragments 4 (purple) (PBD 4KTJ), 5 (yellow) (PDB 4KTF), and
6 (cyan) (PDB 5IBJ) with lead compound 2 (salmon) (PDB 4KTL), illustrating the conserved binding mode distal to the heme cofactor
(magenta).28 (b) Structures, binding aﬃnity, and ligand eﬃciency (LE) of compound 2 and retrofragments 4, 5, and 6. (c−e) X-ray crystal structures
of CYP121 in complex with retrofragments 4, 5, and 6, respectively, indicating polar interactions (yellow dashes) with active site residues (blue) and
solvent (red spheres). Co-crystallized sulfate (yellow lines) is also indicated in (d). The associated omit FoFc electron density map of fragment 6
contoured to 3σ has been provided in the Supporting Information, Figure S5. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC).
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the region occupied by Ar1, as well as the hydrogen bonding
networks formed by the Ar2 phenol and between the
aminopyrazole ring and Gln385 (Figure 2b). The conserved
binding mode of 5 in the absence of Ar3 suggested a minimal
contribution to binding from this motif and was consistent with
observations that Ar3 resided in a large, water-ﬁlled pocket in
the X-ray structure of 2 (Figure 1). This lack of binding
contribution was reﬂected in the low GE calculated for Ar3 on
reforming 2 from 5 (Figure 3).
The X-ray crystal structure of the Ar1−Ar3 fused fragment 6
showed that the fragment bound CYP121 in an orientation that
was ﬂipped 180° from that expected in lead 2. The 5-amino-
phenol ring that distinguished 6 from retrofragment 3 was
oriented toward the Ar1 site, instead of the Ar3 pocket, and the
original phenol of 3 was shifted into the Ar2 site (Figure 2c). In
this orientation, the pyrazole core formed new hydrogen
bonding interactions with I-helix residue Thr229, similar to
those observed for fragment 4. This change in binding mode
accounts for the good GE values calculated when elaborating
fragment 3 into 6 (vide infra). The 100-fold improvement in
binding aﬃnity obtained for 6 was thus attributed to optimizing
interactions at the Ar1 and Ar2 sites, demonstrating the
importance of obtaining structural data for the accurate
interpretation of GE analysis. From these data, it was concluded
that Ar1 and Ar2 formed highly conserved interactions that
could be exploited in the design of subsequent analogues. In
contrast, Ar3 contributed minimally to binding and would likely
be tolerant to structural modiﬁcations. As such, investigating
the SAR of Ar3 was a priority in order to identify more GE
replacements for the original phenol ring of lead compound 2.
The binding aﬃnity and LE of the retrofragments for
CYP121 was determined using ITC (Figure 3). Fragments 3
(KD = 1.3 mM, LE = 0.30) and 4 (KD = 1.9 mM, LE = 0.29)
were found to have comparable binding aﬃnities and LE to that
of the original fragment hit 4-(1H-1,2,4-triazol-1-yl)phenol 1,
indicating that substitution of the original triazole core of 1 for
a 5-aminopyrazole ring resulted in no signiﬁcant diﬀerence in
binding aﬃnity. The combination of any two phenol rings to
Figure 3. Deconstruction of lead compound 2 into retrosynthetic fragments 3−6 was used to assess the binding aﬃnity, ligand eﬃciency (LE), and
group eﬃciency (GE) contribution of the individual components. The three aromatic rings decorating the aminopyrazole core of lead compound 2
have been labeled Ar1, Ar2, and Ar3 as illustrated, which refers to the orientation the rings occupy in the X-ray crystal structure of 2 in complex with
CYP121 (Figure 1). Retrofragments 3 and 4 represent Ar1 and Ar2, respectively. The lower panel tabulates the binding aﬃnity (KD) and LE and GE
properties of compounds from the sequential reconstruction of lead 2 from component monoaryl (3 and 4) and biaryl (5 and 6) retrofragments. KD
values were determined using ITC. LE was calculated from the Gibbs free energy of binding divided by the number of heavy atoms (ΔG/HA).29,30
GE contributions of the three aromatic rings Ar1, Ar2, and Ar3 were calculated from the change in Gibbs free energy per added heavy atom
(−ΔΔG/ΔHA) as the retrofragments were progressively recombined to form lead compound 2.31 KD previously reported.28
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satisfy binding interactions at the Ar1 and Ar2 sites, as
exempliﬁed by biphenol retrofragment 5 (KD = 40 μM) or 6
(KD = 10.6 μM), resulted in an almost additive improvement in
binding aﬃnity. The small diﬀerence in the binding aﬃnity of 5
or 6 (ΔG ≈ −0.9−1.7 kJ mol−1) compared to that calculated
for the theoretical sum of 3 and 4 (ΔG3+4 (theor) ≈ −7.7 kJ
mol−1) can be attributed in part to binding contributions from
the 5-aminopyrazole motif that is common to the structures of
the monophenol fragments. The additive binding aﬃnity was
reﬂected in the good GE values (GE = 0.29−0.41) calculated
for the addition of an aromatic ring to a monophenol scaﬀold 3
or 4. Reduced torsional strain between the phenol rings was
suggested to account for the slightly lower KD value of
retrofragment 6 versus 5.28 The addition of a third aromatic
ring to fragment 5 or 6 to give lead 2 had a negligible eﬀect on
binding aﬃnity, as reﬂected in the small GE values of −0.03−
0.08 calculated for occupation of the Ar3 pocket.
The LE of retrofragments (LE ≈ 0.3) was comparable to that
of the original fragment hit 1 (LE = 0.32), indicating that both
mono- and biphenol scaﬀolds represented better starting points
for the optimization of CYP121 inhibitors than did lead
compound 2 (LE = 0.24). Retrofragments 4 and 5 were
selected as the most favorable scaﬀolds for further optimization
because of the consistency of their binding modes relative to
lead compound 2 and because of the opportunities these
scaﬀolds provided for elaboration toward the heme iron from
Ar2 and from the exocyclic pyrazole-5-amino group to explore
the Ar3 pocket. The change in the binding mode of
retrofragment 6 relative to lead 2 led us to deprioritize further
optimization based on this scaﬀold despite its slightly better
binding aﬃnity compared to 5. This combination of GE
analysis, assessment of LE, and interrogation of X-ray crystal
structures facilitated a rational strategy for the independent
optimization of each aromatic ring Ar1, Ar2, and Ar3 of lead 2,
Figure 4. Proposed optimization strategies for Ar1, Ar2, and Ar3 of lead CYP121 inhibitor 2. (a) Overlaid X-ray crystal structures of biaryl fragment
5 (yellow) (PDB 4KTF) and benzamide fragment 7 (green) (PDB 5EDT) bound to CYP121. The associated omit Fo−Fc electron density map of
fragment 7 contoured to 3σ can be found in Supporting Information Figure S5. (b) Overlaid X-ray crystal structures of CYP121 in complex with
retrofragment 5 (yellow) and with heme binding fragments 8 (copper) (PDB 4G44) and 9 (cyan) (PDB 4G45),27 indicating the proposed meta-
attachment point for substituents and distance (6.5 Å) to the heme coordinating position (yellow dashed line). (c) Docking of Ar3 analogues of lead
2, elaborating from the 5-aminopyrazole group of retrofragment 5 (gray) with carbonyl (orange) or methylene (green) linkages to enhance binding
interactions with the distal active site pocket (Asn74, Thr65, gray sticks) of CYP121. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC).
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guided by insights into the key binding interactions and activity
hotspots.
Analogue Design Rationale. Our approach to developing
potent CYP121 inhibitors focused on three independent series
of analogues, each optimizing the interactions of the Ar1, Ar2,
and Ar3 rings of lead compound 2, respectively (Figure 4a−c).
Analogues were designed as derivatives of either the biaryl
scaﬀold 5, which had been identiﬁed as the most LE
retrofragment that also retained the original binding mode of
2, or the monoaryl 4 scaﬀold, which had been identiﬁed to
participate in a conserved hydrogen-bonding network and
bound to CYP121 in close proximity to the heme cofactor.
Ar1 Analogues. Analogues in the Ar1 series were designed
to probe the eﬀect of electronics and hydrogen bonding on the
conserved π-stacking interactions formed between this motif
and Phe168 and Trp182 and the potential to form polar
interactions with Thr77 and Asp185, residues residing on the
substrate selective F/G-helices.36 The crystal structure of a
substituted benzamide fragment 7 (KD = 3.4 mM), which had
been identiﬁed during our initial fragment screen on CYP121
(PDB 5EDT),27 indicated that meta-substitution or elaboration
from the para-position would be most favorable (Figure 4a).
Ligand docking simulations37 were used to support our design
and indicated that changing the position of the aromatic
substituent was unlikely to cause conformational strain or
perturb the global geometry of the ligands (Figure S2,
Supporting Information).
Ar2 Analogues. The proximity and orientation of Ar2 in
relation to the heme cofactor, and the conserved hydrogen
bonding interactions made by the 4-hydroxy substituent with
Asn85 and the water-bridged heme propionate group, indicated
that Ar2 could provide an ideal anchor for the incorporation of
a metal-binding functional group. Compounds which interact
with both active site residues and the heme cofactor are
generally considered to be more eﬀective than inhibitors that
only utilize one form of interaction and it was proposed that
exploiting the high enthalpic contribution of metal coordination
could signiﬁcantly improve the potency of CYP121 ligands.36
Comparison of the X-ray crystal structures of 2, 4, and 5 with
those of heme binding fragments 8 and 9, which had been
identiﬁed during our original fragment screen on CYP121,27
indicated that extending from the meta-position of Ar2 with
substituents 5.5−6.5 Å in length would provide the appropriate
proximity for metal binding (Figure 4b). A range of
Scheme 1. Synthesis of Biaryl-aminopyrazole Analogues (Ar1)a
aReagents and conditions: (a) NaH, THF, 60 °C, 20−48 h; (b) HCl (37%), NH2NH2·xH2O, EtOH, 90 °C, 14 h; (c) BBr3 (1.0 M in DCM), DCM,
0 °C, 6 h. Synthesis and characterization of 14d previously described.28
Scheme 2. Synthesis of Ar2 Analogues Based on the Core Scaﬀold of (i) Monoaryl Fragment 4 or (ii) Biaryl Fragment 5a
aReagents and conditions: (a) ethyl formate, NaOEt, EtOH, 0−90 °C, 22 h; (b) AcOH, NH2NH2·xH2O, EtOH, 75 °C, 3 h; (c) aryl-boronic acid,
Pd(PPh3)4, Na2CO3, 1,4-dioxane:H2O (1:1 v/v), μw, 180 min; (d) SnCl2·2H2O, EtOH, 75 °C, 15 h; (e) BBr3 (1.0 M in DCM), DCM, 0 °C, 4 h;
(g) methyl 4-methoxybenzoate, NaH, THF, 60 °C, 48 h; (h) HCl (37%), NH2NH2·xH2O, EtOH, 90 °C, 16 h.
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substituents containing aromatic or basic nitrogen atoms were
selected as functional groups commonly occurring in heme
binding P450 inhibitors. Primary anilines were prioritized
because of the prevalence of this chemotype in fragment hits
identiﬁed during our original fragment screen on CYP121 and
also from our subsequent optimization attempts which had
yielded several co-crystal structures of CYP121 with aniline
ligands.27
Analogues derived from both monoaryl 4 and biaryl 5
fragment scaﬀolds were proposed to maximize LE and to allow
the importance of Ar1 on the binding mode, aﬃnity, and
selectivity of the compounds to be investigated (Figure 4b). A
range of analogues in which the 4-hydroxy group of Ar2 was
removed were also designed in order to determine whether
torsional strain resulting from interactions between the 4-
hydroxy group and metal-binding substituents introduced ortho
to this might perturb the geometry required for metal
coordination. It was hypothesized that the loss of enthalpic
contributions from hydrogen bonds made by the 4-hydroxy
group of Ar2 was likely to be small in comparison to that gained
by metal-coordination.38
Ar3 Analogues. A fragment growing approach was devised
to explore the SAR of Ar3 and to improve the GE of this motif
by potentially introducing binding interactions with residues in
the back of the active site. Interrogation of the X-ray crystal
structure of lead 2 and ligand docking studies37 were used to
select an appropriate linker-length for growing, with methylene
or carbonyl linkers being prioritized. A range of ﬁve- and six-
membered (hetero)aromatic groups were selected to incorpo-
rate onto these linkers, including phenols as direct mimics of
lead 2 and the natural cYY substrate, phenol bioisosteres, and
substituents that were predicted by docking simulations to form
favorable cation−π interactions with a nearby Arg386 residue,
or polar interactions with amide groups of the protein
backbone (Figure 4c).37
Synthetic Chemistry. Analogues varying at Ar1 were
synthesized according the published procedure for biaryl
retrofragment 5 (Scheme 1).28,33 In brief, the Claisen
condensation of 4-methoxyphenylacetonitrile 11 with the
appropriately substituted benzoate ester 10a−d aﬀorded the
β-ketonitrile intermediates 12a−d. Reaction of 12a−d with
hydrazine hydrate and concentrated hydrochloric acid gave the
5-aminopyrazoles 13a−d in excellent yields (91−97%).
Subsequent deprotection of the aryl-methyl ether(s) with
BBr3 (1.0 M in DCM) gave the desired phenol analogues 5 and
14b−d in near quantitative yields.
The syntheses of analogues incorporating a metal binding
functional group at the meta position of Ar2 are summarized in
Scheme 2 (i) and (ii) for analogues based on the monoaryl 4 or
biaryl 5 retrofragment scaﬀolds, respectively. Analogues
retaining the 4-hydroxy substituent of Ar2 were synthesized
from the appropriately protected 4-benzyloxy 15b or 4-
methoxy 15c substituted 3-bromophenylacetonitrile starting
materials, which were either obtained directly from commercial
sources or synthesized in two steps by deprotection of the aryl
methyl ether using BBr3 followed by benzyl protection under
Finkelstein conditions. Synthesis of the common 5-amino-
pyrazole ring followed a similar route to that employed to
access Ar1 analogues (Scheme 1). Claisen condensation of
phenylacetonitriles 15a−c with either ethyl formate or methyl
4-methoxybenzoate aﬀorded the 3-oxopropanenitrile 16a−c or
β-ketonitrile 21a−b intermediates, respectively. The crude
Scheme 3. Synthesis of Benzyl-amine Analoguesa
aReagents and conditions: (a) aldehyde (0.9−1.1 equiv), AcOH*, Na(OAc)3BH, DMF, DCE, rt, 24−48 h (b) aldehyde (1 equiv), AcOH,
NaCNBH3, MeOH, rt, 15−24 h; (c) BBr3 (1.0 M in DCM), DCM, 0 °C, 2−24 h. *No AcOH with 26d.
Scheme 4. Synthesis of Benzamide Analoguesa
aReagents and conditions: (a) (4-OMe)-benzoyl chloride, Et3N, DCM, 0 °C−rt, 3.5 h; (b) nicotinic acid, oxalyl chloride, DMF, DCM, 0 °C−rt, 2 h,
then Et3N, DCM, 0 °C−rt, 14 h; (c) BBr3 (1.0 M in DCM), DCM, −78 °C−rt, 14 h.
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products were treated with hydrazine hydrate at acidic pH and
heated under reﬂux to give the 5-aminopyrazole compounds
17a−c and 22a−b in yields of 48−67% and 77−95%,
respectively, over two reaction steps. A microwave-assisted
Suzuki−Miyaura cross-coupling reaction was used to introduce
a range of nitrogen-containing heterocycles 18e−i or nitro-
substituted aromatics 18a−d, 23a−b from their boronic acid
precursors. Nitroarenes were subsequently reduced using
tin(II) chloride to reveal the heme binding anilines 19a−d,
24a−b in yields up to 77%. Removal of the methyl or benzyl
protecting groups using BBr3 aﬀorded the 4-hydroxyphenyl Ar2
analogues 20a and 25a−b, which were puriﬁed by ﬂash
chromatography to give 46−50% yields. However, the presence
of inorganic contaminants in 20a prevented the testing of this
compound.
Ar3 analogues containing a methylamine-linked substituent
26a−f were synthesized from the reductive alkylation of biaryl
retrofragment 5 with the respective aldehyde (Scheme 3).
Reaction conditions, including solvent polarity, acid catalyst,
and use of either sodium triacetoxyborohydride or sodium
cyanoborohydride reducing reagents were optimized for
individual substrates.39,40 Analogues 26g and 26h were
synthesized in good yields (78−95%) under similar conditions
by reductive alkylation of the dimethoxy protected precursor
13a. Subsequent deprotection of intermediates 27a−b with
BBr3 revealed the diphenols 26g−h in 61−68% yields.
A series of 5-amidopyrazole analogues 29a−c containing a
carbonyl linker were synthesized from 5-aminopyrazole 13a
and the respective benzoyl chloride to give 28a−c (Scheme 4).
Benzoyl chloride electrophiles were either purchased or
synthesized in situ from the corresponding benzoic acid
precursor using oxalyl chloride and catalytic DMF. Yields of
the desired 5-amido regioisomers were low (27−34%), but
signiﬁcant polarity diﬀerences enabled easy separation from
endocyclic 1N-substituted byproducts using column chroma-
tography. Subsequent deprotection of the aryl-ethers with BBr3
aﬀorded the analogues 29a−c.
Inhibitor Binding Mode and Selection of Heme
Binding Functional Groups for Ar2 Analogues. The
binding mode of analogues was initially characterized using
UV−vis spectroscopy to allow the identiﬁcation of ligands that
interacted with the ferric iron, or with the axial water ligand of
the heme cofactor, from changes in the optical spectrum of
CYP121. P450 inhibitors which displace the axial water ligand
and directly coordinate to the ferric iron of the heme cofactor,
typically by the lone pair electrons of a nitrogen atom, stabilize
an inactive state of the enzyme by sterically blocking the active
site and usually lowering the reduction potential of the
enzyme.36 This binding mode (type II) produces a red-shift
in the Soret band of the P450 optical spectrum, the magnitude
(Δλmax, nm) of which is dependent on both the aﬃnity (KD)
and concentrations of the ligand and P450 under speciﬁc assay
conditions.41 In contrast, ligands which interact with the heme
cofactor via water-bridged hydrogen bonding to the axial water
ligand, or which displace the axial water but do not directly
coordinate to the ferric iron, can produce reverse type I and
type I spectra, respectively.42
A single shot UV−vis absorbance assay was used to rapidly
identify Ar2 substituents with the appropriate properties and
coordination geometry for heme binding interactions (Table
1). A preliminary series of Ar2 analogues, substituted at the
meta-position with aniline or heteroaromatic groups, were
synthesized based on the monoaryl scaﬀold 4 (Scheme 2 (i)).
Only primary 3- or 4-aminophenyl analogues 19a and 19d were
found to cause a signiﬁcant red-shift (Δλmax > 1 nm) in the
Soret band of CYP121, which occurs at 416.5 nm in the water-
ligated resting state.17 Indole 18g,h, pyrazole 18i, and 3-pyridyl
18e substituents showed no heme binding interactions (Δλmax
= 0 nm), and only minor perturbation of the Soret band was
observed for the 4-pyridyl isomer 18f (Δλmax = 1 nm).
The binding aﬃnities of the 3-aminophenyl 19a (KD = 14
μM) and 4-aminophenyl 19d (KD = 230 μM) substituted
analogues were determined by optical titration according to the
previously described procedure.17,41 The 16-fold diﬀerence in
aﬃnity between the two regioisomers clearly indicated that the
3-aminophenyl substituent provided a better geometry for
heme ligation, and consequently this functional group was
incorporated into all subsequent analogues in the Ar2 series.
All subsequent Ar2 analogues containing a 3-aminophenyl
substituent (19b,c, 24a, 25a,b) caused type II shifts in the
CYP121 optical spectrum, allowing their binding aﬃnity to be
determined by optical titration in addition to ITC (Table 2 and
Figure 5). The magnitude of the type II shift decreased with
increasing steric bulk ortho to the 3-aminophenyl substituent.
These results supported the hypothesis that torsional strain in
the biphenyl system, or the steric bulk of the benzyl or methyl
hydroxy protecting groups, in analogues 19b and 19c,
respectively, prevented the ligands approaching the cofactor
for heme coordination.
The only analogue in the Ar1 or Ar3 series of compounds to
perturb the Soret band was the 3(4)-imidazole-methylamine
substituted compound 26h. The type II shift observed was
small (Δλmax 26h (100 μM) = +1.5 nm) compared to that
observed for the 3-aminophenyl substituted Ar2 analogues
(Δλmax 25a [100 μM] = +5.0 nm), which was consistent with
results observed for heteroaromatic nitrogen substituents
during our initial selection of a heme binding functional
group for Ar2 analogues (Table 1). A 2.0 Å X-ray crystal
structure of 26h in complex with CYP121 indicated that the
compound must adopt multiple diﬀerent binding modes, as the
Table 1. Identiﬁcation of Heme Binding Functional Groups
Using UV−Vis Spectroscopya
aAnalogues were prepared as 0.1−1 mM stocks in DMSO-d6. The
change in the wavelength of the Soret band (Δλmax, nm) of CYP121 (5
μM) was calculated as the diﬀerence of that found in the presence of
analogues compared to 1% v/v DMSO-d6 alone (λmax = 416.5 nm).
Binding aﬃnities (KD) for selected compounds were calculated from
the titration of compounds (0.2 μL aliquots of 10−100 mM stocks)
into CYP121 (5 μM). Full details are provided in the Experimental
Section.
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3(4)-imidazole substituent of the crystallized compound
resided in the Ar3 pocket, distal to the heme cofactor (Figure
8b). These competing binding modes might account for the
weak aﬃnity of 26h (KD = 274 μM) compared to the
Table 2. Binding Aﬃnity and Ligand Eﬃciency Values of CYP121 Inhibitorsc
aBinding aﬃnity of 14d previously reported.28 bPoor solubility prevented KD being determined for 24a using ITC.
cBinding aﬃnity (KD, μM) values
for all analogues were measured by ITC. The KD values for the Ar2 series of heme binding compounds were also determined by UV−vis optical
titration as described previously.17 Ligand eﬃciency (LE) was calculated from the Gibbs free energy of binding divided by number of heavy atoms
(ΔG/HA).29,30 Full details are provided in the Experimental Section.
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structurally similar 3-thiophenyl 26c or 2-furanyl 26d methyl-
amine analogues, which did not perturb the optical spectrum of
CYP121 (Table 2). Owing to a lack of spectral perturbation,
the binding aﬃnity of all other Ar1 and Ar3 analogues was
assumed to result from binding interactions made with residues
in the distal active site pocket and provided support that these
analogues retained a similar binding mode to lead 2.
Binding Aﬃnity and X-ray Crystallography. The
binding aﬃnity (KD) of analogues for CYP121 was determined
by ITC (Table 2, Figure 6a−c). The KDs of heme binding Ar2
analogues were also determined by UV−vis optical titration
(Table 2, Figure 5).43−45 Comparison of the KDs obtained for
the Ar2 series by ITC and optical titration enabled robust
comparisons to be made with the aﬃnity of the non-heme
binding Ar1 and Ar3 series of analogues, as well as with
previously reported type II inhibitors in the literature.12,27,28 In
general, KD values obtained by optical titration were 10−100-
fold lower than those measured in ITC, consistent with
previous reports in the literature.45 Variations in aﬃnity data
generated using diﬀerent biophysical techniques have been
previously attributed to the kinetically signiﬁcant but spectrally
silent, multistep binding interactions of P450s with ligands, the
potential presence of heterogeneous enzyme populations in
solution, requirement for conformational change, and/or
enzyme cooperativity.45,46 High resolution (1.6−2.2 Å) X-ray
crystal structures of CYP121 in complex with a number of
analogues were obtained, allowing inhibitor binding modes to
be conﬁrmed and enabling robust comparison of the SAR
contributing to binding aﬃnity (Figure 7,8).
Ar1 Analogues. Changing the position of the original 4-
hydroxy group to the 3-position 14b resulted in a moderate
reduction in binding aﬃnity, while substitution with a 3-ﬂuoro
substituent increased the KD of 14c 5-fold compared to 5.
These results suggest that aromatic stacking interactions made
by Ar1 contribute to binding aﬃnity in this region. The change
in π-electron density from the introduction of m-hydroxy or m-
ﬂuoro substituents would likely weaken both oﬀset face-to-face
aromatic interactions with Phe168 and edge-to-face interactions
with Trp182, in addition to disrupting hydrogen bonding
interactions with two conserved water molecules shown to
solvate the p-hydroxy substituent of fragments 1, 5, and lead
compound 2 (Figure 1 and 2d).47 Disubstitution of Ar1 with
hydroxy groups in the 2- and 4-positions, 14d, also lowered the
binding aﬃnity (KD = 180 μM) despite introducing polar
interactions with residues Thr77 and Ala167 as shown in the X-
ray crystal structure of 14d.28 Intramolecular hydrogen bonding
between the 2-hydroxy group and the 1-NH-pyrazole hetero-
cycle might account for this result by favoring the 3-
aminopyrazole tautomer and thus weaken bonding interactions
to Gln385. No overall change in the conformation of the
ligands was observed due to changes made to Ar1 substituents,
consistent with our initial docking results.28 The sensitivity of
Ar1 to even minor structural changes conﬁrmed our previous
predictions from retrofragmentation and GE analysis that
binding interactions in this region represented a key aﬃnity
hotspot for CYP121 that might be of use during later stages of
compound development. We thus directed our attention
toward investigating the Ar2 and Ar3 aromatic rings.
Figure 5. Optical titration diﬀerence spectra (top panel) and concentration-dependent changes in CYP121 absorbance (bottom panel) for
representative heme binding ligands (a) 24a, (b) 25b, and (c) 19a. Absorption spectra of CYP121 (5 μM) were collected between 250 and 800 nm
after sequential additions of 0.2 μL aliquots of DMSO-d6 stock solutions (0.15−83 mM) of ligands. Diﬀerence spectra were obtained from the
subtraction of the ligand-free CYP121 spectra from those obtained over the course of the titration. The maximum change in absorbance from each
diﬀerence spectrum was plotted against ligand concentration and data were ﬁtted using a modiﬁed version of the Morrison equation for tight binding
ligands 24a and 25b17 or a hyperbolic function for 19a.
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Ar2 Analogues. Incorporation of a 3-aminophenyl sub-
stituent onto the Ar2 ring of the monoaryl scaﬀold 4 or the
biaryl scaﬀold 5 resulted in a more than 100-fold improvement
in binding aﬃnity. Analogue 19a had an equivalent KD of 14
μM (LE = 0.35) by optical titration to that of lead compound 2
and was made signiﬁcantly more LE by removal of the Ar3
motif. The reincorporation of the Ar1 phenol ring to give
compound 25b (KD = 0.29 μM) resulted in a further 50-fold
improvement in binding aﬃnity, as had been previously
observed during our lead-deconstruction analysis when the
Ar1 and Ar2 fragments 3 and 4 were fused to give biaryl
retrofragment 5 (Figure 3). Removal of the Ar2 4-hydroxy
group of 25b to relieve torsional strain in the heme binding
biphenyl-amine system improved CYP121 aﬃnity a further 20-
fold to produce the low nanomolar, high LE compounds 24a
and 25a. While the 4-hydroxy analogue of 19a was not
analyzed, the eﬀect of ortho-substitution on weakening heme
binding interactions was made apparent through assessment of
the 4-benzyloxy and 4-methoxy substituted analogues 19b and
19c. While both 19b and 19c caused type II shifts in the
CYP121 Soret band at high concentrations (100−1000 μM),
the bulky protecting groups clearly prevented ligands obtaining
the optimal geometry for heme ligation and a KD could not be
obtained for these compounds by optical titration within
solubility limits. The relatively good binding aﬃnity of 19b (KD
= 28 μM) determined by ITC suggested that this compound
might instead adopt an alternative “heme-silent” binding mode
in the distal active site.45
The improved LE of 19a, 24a, and 25a−b compared to lead
2 (LE = 0.24) was reﬂected in the good GE value of 0.42
calculated for the 3-aminophenyl substituent based on the
introduction of seven heavy atoms to retrofragment 5.31,48
Comparison with the low GE of 0.08 calculated previously for
the Ar3 phenol (Figure 3), which had the same number of
heavy atoms, demonstrated the utility of our lead deconstruc-
tion-elaboration approach in allowing the identiﬁcation of
maximally eﬃcient scaﬀolds and in targeting binding hotspots.
The 2.1 Å crystal structure of 25b (Figure 7a), the
structurally most similar compound to retrofragment 5, in
complex with CYP121 revealed that the analogue accurately
replicated the conserved binding mode of the lead 2 (Figure 1).
All intermolecular interactions that had been identiﬁed as
binding hotspots, such as aromatic stacking of Ar1 with Phe168
and Trp182, interaction of the Ar2 4-hydroxy group with a
water-bridged heme propionate network, and hydrogen
bonding between the aminopyrazole ring and Gln385 were
satisﬁed. The 3-aminophenyl substituent was located 2.5 Å
from the heme-iron and at an angle of 36°, consistent with that
required for tetrahedral NH2−Fe(III) coordination.
49 Hydro-
gen bonding interactions were also identiﬁed between the 3-
amino group of 25b and Ser237, which is thought to be the
conserved alcohol residue of CYP121 required for the catalysis
Figure 6. Representative ITC binding isotherms and integrated enthalpy plots for (a) fused Ar1−Ar3 fragment 6 (500 μM); (b) non-heme binding
Ar3 analogue 26a (1 mM); (c) heme binding analogue 25a (500 μM). The isotherm of each compound titrated into buﬀer alone was subtracted
from that containing CYP121 (50 μM). The integrated enthalpy change for each injection plotted as a function of molar ratio of ligand-to-CYP121
was ﬁtted using a one-site equilibrium binding model to calculate binding aﬃnity (KD). The binding stoichiometry (N) was allowed to vary for
analogues 6, 26a, and 25a.
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of proton transfer to the heme iron and for organization of the
axial water ligand.12,36
The 1.6 Å crystal structure of 25a conﬁrmed that removal of
the Ar2 4-hydroxy group resulted in a 30° reduction in the
Figure 7. X-ray crystal structures of heme binding Ar2 analogues 25b (PDB 5IBJ), 25a (PDB 5IBE), and 19a (PDB 5IBF) in complex with CYP121.
(a) 25b (cyan) closely recapitulated the binding of lead 2, forming polar contacts (yellow dashes) with amino acids (blue sticks) in binding hotspots
as well as additional binding contacts to Ser237, Val228, and the heme iron. (b) 25a (orange) was rotated away from the I-helix (yellow cartoon),
placing the 5-aminopyrazole ring in the Ar3 pocket. Polar contacts to the heme iron and Ser237 are indicated (yellow dashes). (c) Two molecules of
19a bound per active site, each ligand fulﬁlling a subset of the interactions identiﬁed as binding hotspots. Inset: Heme binding 19a recapitulated the
binding mode of 25a while the non-heme binding 19a ligand satisﬁed aromatic interactions in the Ar1 pocket, as well as the hydrogen bonding
interactions of fragment 7. (d) Extracted structures of 25b, 25a, and 19a annotated to show metal coordination (yellow dashes) distance, angle of
approach to the porphyrin ring (yellow angle), and dihedral torsion in the biphenyl-aniline motif. Removal of the Ar2 4-hydroxy group reduced the
dihedral angle of the biphenyl aniline system in 19a and 25a by 30° compared to 25b and allowed the analogues to approach the plane of the
porphyrin at a sharper angle (31−33°). The omit Fo − Fc electron density maps of ligands 19a, 25a, and 25b contoured to 3σ have been provided in
Supporting Information Figure S5. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC).
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dihedral angle of the biphenylamine motif (Figure 7b,d). As for
analogue 25b, the 3-aminophenyl substituent of 25a bound in
close proximity (2.3 Å) and at an appropriate orientation (34°)
for heme coordination. However, reduced rotation in the
biphenyl system allowed a slightly sharper angle of approach to
the heme ring. Close overlap between the aniline ring of 25a
and the sterically unhindered aniline-containing fragments 8
and 9 suggested that aromatic stacking interactions were
optimized by the removal of the 4-hydroxy substituent from
25b. These improved interactions might account for the 9-fold
improvement in potency between the two analogues and
illustrate the utility of fragments as tools for elucidating
preferred binding motifs (Figure 4b, and Figure S3, Supporting
Information). The combination of improved heme interactions
and removal of functional groups identiﬁed to interact with
binding hotspots, such as the Ar2 4-hydroxy group, resulted in a
change in orientation of 25a compared to the conserved
position of 25b and lead 2. Analogue 25a was tilted sideways to
place the exocyclic 5-amino group of the pyrazole ring into the
pocket normally occupied by Ar3, resulting in a loss of
interactions with Gln385. The fact that 24a retained good
aﬃnity despite this loss of interactions with Gln385 was
consistent with observations made about the binding of
retrofragments during lead deconstruction (vide supra). The
equipotent (KD = 33 nM) 4-methoxy protected precursor 24a
was found to bind in an identical orientation to 25a,
demonstrating some tolerance of the Ar1 group to substituent
variation (Figure S4, Supporting Information).
Two molecules of analogue 19a, which can be considered a
fragment of 25a (lacking only the Ar1 ring), were found to bind
within each active site of the CYP121 crystallographic dimer
(Figure 7c). The orientation of the two overlapping molecules
of 19a illustrated both the importance of the Ar1 region as a
binding hotspot and also demonstrated optimization strategies
which might further improve selectivity. One molecule of 19a
ligated the heme iron as observed for 25a, with a coordination
distance of 2.4 Å and a 32° angle of approach to the heme ring.
The 5-aminopyrazole group similarly occupied the water-
ligated Ar3 site. The second molecule of 19a satisﬁed the
requirements of the remaining binding hotspots, including
hydrogen-bonding interactions with Gln385 and aromatic
stacking interactions in the Ar1 site. Extension of the 3-
aminobiphenyl system into the Ar1 pocket demonstrated a
route to achieving the additional hydrogen bonding interactions
with the F/G-helix residues Thr77, Ala178, and Asp185 that
had earlier been suggested by the identiﬁcation of hit fragment
7 (Figure 7c, inset and Figure 2a).
Ar3 Analogues. The binding aﬃnity of Ar3 analogues was
largely unaﬀected by the structural changes made to the 5-
aminopyrazole substituent. Analogues substituted with a range
of aromatic or heteroaromatic groups maintained low micro-
molar binding aﬃnities (KD < 100 μM), and a number of
compounds (26b−d) had comparable potency to lead 2 (KD =
15 μM) (Table 2). Eﬀorts to grow further out into the active
site pocket occupied by Ar3 by the addition of a methylene
linker resulted in a small improvement in binding aﬃnity with a
KD of 6.3 μM determined for the 4-hydroxybenzyl analogue
26a, making it the most potent non-heme binding CYP121
ligand described to date. The poorly deﬁned electron density of
the 4-hydroxybenzyl ring in the X-ray crystal structure of 26a
suggested that it was conformationally ﬂexible and only
interactions with active site solvent molecules were observed
(Figure 8a). All Ar3 analogues containing methylamine-linked
aromatic substituents were more potent than their carbonyl-
linked amido-pyrazole counterparts 29a−c. For example,
comparison of 4-hydroxy-benzyl 26a and benzamide 29b
analogues or 4-pyridinyl-methylamine 26g and isonicotinamide
29c analogues revealed a 2.5−16-fold loss in aﬃnity,
respectively, for the carbonyl-linked analogues. Increased
conformational rigidity enforced by the 5-amido group or
changes to the hydrogen bond donor−acceptor interactions of
the 5-amino-NH with Gln385 was used to rationalize these
SAR. A preference for 4-hydroxy substituted aromatics was
observed in both the methylamine (26) and amide-linked (29)
analogues, which was unsurprising considering the structure of
the natural cYY CYP121 substrate.10,11 The addition of
bromine ortho to the 4-hydroxy group in analogue 26b had
little eﬀect on binding aﬃnity and indicated that larger
substituents could be tolerated in this region of the active
site. Indole 26e and indazole 26f bioisosteres of the 4-
hydroxyphenyl group resulted in a 3−4-fold increase in KD,
possibly indicating that the greater acidity or hydrogen bonding
Figure 8. X-ray crystal structures of Ar3 analogues (a) 26a (PDB 5IBI) and (b) 26h (PDB 5IBH) in complex with CYP121. Both compounds
closely recapitulated the binding mode of lead 2. Ar3 substituents remained ﬂexible, interacting only with active site water molecules for 26a or
forming novel interactions with active site residues Ala75 and Asn74 for 26h. The omit Fo − Fc electron density maps of ligands 26a and 26h
contoured to 3σ have been provided in Supporting Information Figure S5. Figures prepared using PyMOL v1.7.4 (Schrödinger, LLC).
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ability of the hydroxyl group was favorable for binding. Further
supporting this assumption, analogues containing basic
aromatic nitrogens, such as the pyridinyl 26g or 3(4)-imidazole
26h methylamine-linked analogues, signiﬁcantly weakened
CYP121 binding aﬃnity.
As previously highlighted, a 2.0 Å X-ray crystal structure of
26h in complex with CYP121 was obtained that showed the
imidazole ring binding distal to the heme cofactor in the Ar3
pocket (Figure 8b). Hydrogen bonding interactions with Asn74
and Ala75 had not been previously observed in other CYP121−
ligand structures and could provide a new route for compound
optimization. Despite these novel interactions the binding
aﬃnity of 26h was weak (KD = 274 μM), which could have
been the result of the mixed binding modes suggested by UV−
vis spectral analysis (vide supra). The consistency of the
binding mode of 26a and 26h with lead 2 demonstrated in X-
ray crystallography provided conﬁdence when interpreting the
SAR of the remainder of the Ar3 analogues. The binding
Figure 9. Representative native mass spectra of CYP121 and selected compounds 26a, 25a, and 19a demonstrated that compounds formed stable
complexes with both monomeric (m/z 5250−6750) and dimeric (m/z 5250−6750) CYP121. The number of bound ligands (orange spheres)
increased in a concentration-dependent manner and was proportionate to the binding aﬃnity (KD) of the compounds. Spectra were collected for
CYP121 (8.7 or 5 μM) at three diﬀerent ligand-to-protein ratios (0.5:1, 1:1, and 25:1) and in the presence of DMSO-d6 (2.2% or 5% v/v) alone. The
concentration of protein or DMSO-d6 did not aﬀect the quality of the spectra or ligand binding interactions, but higher concentrations of DMSO-d6
reduced the charge state of the protein. Ligand binding stoichiometry was calculated from the diﬀerence in mass of ligand-bound and unbound
(orange dashed lines) protein peaks divided by the molecular weight of ligands (Table S1, Supporting Information).
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aﬃnity of thiophenyl−26c or furanyl−26d methylamine-linked
analogues was comparable to that of lead 2 and tolerance to
these smaller, hydrophobic heterocycles might enable the
pharmacokinetic properties of subsequent analogues to be
modulated during later phases of drug development. The
insensitivity of the Ar3 pocket to structural modiﬁcations could
indicate a functional adaption of the enzyme to enable the
accommodation of diﬀerent substrates. Recent evidence that
CYP121 binds a number of other cyclic dipeptides, including
cYF and cYW, supports this proposal.50
Inhibitor Aﬃnity and Stoichiometry. The relative
aﬃnity of lead compounds, their binding stoichiometry to
CYP121 and their eﬀect on the oligomerization state of the
enzyme were investigated using native mass spectrometry. Most
bacterial P450s are monomeric and soluble cytosolic proteins.
However, some form higher homomeric oligomerization states,
heterodimers with their cognate reductase proteins, or are
expressed as fusion products covalently linked to a reductase
domain.36,51 We have previously reported that CYP121 exists
predominantly as a dimer in solution, with a small percentage
of monomeric protein present.52 Dimeric CYP121 forms
complexes with two ligand molecules simultaneously and the
dimer interface does not appear to occlude the substrate entry
channel. The stability of the dimer is reduced by the binding of
azole antifungal compounds. In contrast, other small molecule
CYP121 inhibitors and the CYP121 substrate (cYY) form
stable complexes with the protein and do not aﬀect the
oligomerization state.52
Native mass spectra were collected for CYP121 with the
most potent Ar3 analogue 26a, Ar2 analogues 19a, 24a, 25a,
and 25b and the biaryl retrofragment 6 (Figure 9a−c). All
analogues formed stable complexes with the CYP121 monomer
and dimer. The proportion of ligand-bound CYP121 increased
in a concentration-dependent manner as the ratio of ligand-to-
protein was increased from sub- (0.5:1) to superstoichiometric
(25:1) values. The relative occupancy of monomeric and
dimeric CYP121 and binding stoichiometry observed at three
diﬀerent ligand concentrations allowed analogues to be ranked
in terms of their relative binding aﬃnities (Table S1,
Supporting Information). The rank order of aﬃnities correlated
well with KD values calculated previously by ITC and UV−vis
optical titration (Table 2). Both the CYP121 monomer and
dimer were entirely in the bound state at stoichiometric ligand-
to-protein concentrations of Ar2 analogues 25a and 25b,
consistent with the low nanomolar aﬃnities of these
compounds. In contrast, complete occupancy of the CYP121
dimer by the more weakly binding analogues 19a and 26a was
not achieved until ligands were present in 25-fold excess ligand-
to-protein concentrations. Despite the comparable KD of
retrofragment 6 to Ar2 analogue 19a, the CYP121 dimer
remained singly bound even at 25-fold excess concentration of
6. This apparent diﬀerence in binding strength between 6 and
19a observed by native mass spectrometry might reﬂect the
diﬀerent binding mode of the two analogues. Heme binding
interactions made by 19a would likely be strengthened in the
gas phase of the mass spectrometer, while the closer proximity
of 6 to the entrance of the active site could allow the ligand to
be displaced more easily during ionization. The double-
occupancy of the CYP121 monomer observed for analogue
19a in X-ray crystallography was not detected within the
concentration ranges tested in native mass spectrometry
experiments (2.5−218 μM ligand).
No signiﬁcant change in the oligomerization state of CYP121
was observed for any of the analogues compared to that
previously noted with the azole antifungals (Table S2,
Supporting Information).52 The diﬀerent eﬀects of Ar2
analogues and azole antifungal compounds on the oligomeriza-
tion state might reﬂect the nature of the metal binding
functional group in each series. Greater conformational
reorganization of the CYP121 active site might be expected
in order to accommodate axial coordination of an sp2-
hybridized imidazole ring (∼75°),49 while the primary aniline
present in the current analogues approaches the porphyrin at a
sharper angle (∼31−36°, Figure 7d).46,49
Selectivity against Mtb P450s. Selectivity screening
against oﬀ-target microbial P450s is far less common during
pharmaceutical development than screening against mammalian
P450s and consequently the functions and promiscuity of these
enzymes remain largely uncharacterized. All of the Mtb P450s
that have been studied to date bind with varying aﬃnity to
Table 3. Binding of Select Retrofragments and CYP121 Ligands to Mtb P450 Isoformsa
aThe binding mode of compounds is indicated as type II heme binding (II, orange), binding to the distal pocket (N, green), or nonbinding (X,
unshaded). Binding was determined using a single shot UV−vis assay in which analogues (100 μM or 1 mM) were added to a solution of each P450
enzyme (2.5−5 μM) and the absorbance spectrum was collected between 800 and 250 nm. Compounds were prepared as DMSO-d6 stocks and
added to give a maximum concentration of 1% v/v DMSO-d6. The change in the maximum wavelength of the Soret band (Δλmax, nm) compared to
that measured for each P450 in buﬀer containing 1% v/v DMSO-d6 was used to assess the binding mode and the relative strength of binding.
Compounds that did not change the Soret λmax were tested in competition with known type II inhibitors (50 μM), with compounds that decreased
the Δλmax compared to that observed in the presence of the type II inhibitor alone being designated as “non-heme binding” (N) competitive ligands.
The binding aﬃnity of analogue 25a was calculated by direct or competitive optical titration, as described previously, depending on the mode of
binding to each P450 respectively.17,58,59 *KD calculated by ITC for analogue 25b.
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compounds from the azole series of antifungal drugs, but there
have been few reports detailing their interactions with non-
imidazole/triazole ligands.4,7,9,12,49,53−55 Compounds from our
development of CYP121 inhibitors were screened against a
panel of Mtb P450s using UV−vis spectroscopy (Table 3) to
both assess their selectivity and also to aid the development of
chemical tools which could be used to help characterize these
P450 systems in Mtb.
A qualitative assessment of the binding promiscuity of the
CYP121 ligands developed in this study was obtained by
measuring the change in the absorbance maximum (Δλmax, nm)
of the characteristic Soret band of each P450 isoform when
incubated with the ligands (100 μM to 1 mM) compared to a
DMSO (1% v/v) control. Binding interactions made by the
compounds with the distal part of the P450 active site, which
do not directly perturb the heme environment or λmax of the
Soret band, were characterized by measuring the decrease in
the Δλmax caused by known type II ligands when Mtb P450s
were coincubated with mixtures of the type II ligand and the
novel CYP121 inhibitors. The binding aﬃnity of the most
potent CYP121 compound 25a has been provided to give a
quantitative assessment of ligand selectivity across the diﬀerent
P450 isoforms. Experiments were performed as direct titrations
for Mtb P450s CYP121, CYP126, and CYP142, or in
competition with a known type II inhibitor where 25a
exhibited a binding mode that did not inﬂuence the λmax of
the heme absorbance spectrum, as in the case of Mtb P450
isoforms CYP124 and CYP125. Owing to the weak binding
aﬃnity of 25a for the Mtb P450 CYP144, a KD was obtained
instead for the related compound 25b by ITC.
Subsequent to commencing work on these compounds, the
original 4-(1H-1,2,4-triazol-1-yl)phenol fragment hit 1 for
CYP121 had been identiﬁed to bind to all of the P450s
reported here in ligand-observed NMR experiments (unpub-
lished data). The biaryl retrofragment 5, which consisted of the
fused Ar1 and Ar2 motifs of lead 2 and could be seen to
represent a “merged” analogue of hit fragment 1, was less
promiscuous, only binding to ﬁve of the seven P450s screened.
Elaboration of 5 to include an Ar3 substituent, as seen in the 4-
hydroxybenzyl substituted analogue 26a, further enhanced
CYP121 selectivity. In contrast, the incorporation of a heme
binding 3-aminophenyl substituent onto the scaﬀold of 5, as in
25a and 25b, reduced the selectivity for inhibitors for CYP121,
as might be expected from the introduction of a binding group
targeting a conserved active site feature. While type II spectral
changes were identiﬁed for 4 of the 7 P450s studied, 25a and
25b bound in positions that did not perturb the P450 heme
spectrum in 3 of the 7 isoforms tested, illustrating the
preference of diﬀerent P450s for certain metal-binding
pharmacophores and the impact of protein microenvironment
on metal chelation.49,56 The KD of 25a varied between 0.44 and
27 μM across the diﬀerent P450 isoforms, which gave a 30−
1800-fold selectivity ratio (SR = oﬀ-target binding aﬃnity/on-
target binding aﬃnity) for CYP121.57 The low solubility of Ar2
analogue 19a limited testing to the lower concentration of 100
μM which, in combination with the small size of the
compound, possibly accounted for the apparently greater
selectivity observed in the single-shot UV−vis assay. These
results demonstrated how optimizing ligand aﬃnity by targeting
binding interactions made in the distal pocket, as through the
introduction of Ar1 or Ar3 motifs, can enhance drug selectivity
between P450s.
Selectivity against Human P450s. Drug−drug inter-
actions resulting from the inhibition of human P450s, or
toxicities resulting from the metabolic activation of drugs by
human P450s, are leading causes of attrition during
pharmaceutical development. Thus, understanding the SAR
inﬂuencing P450 promiscuity and isoform selectivity is a topic
of signiﬁcant interest. The ﬁve human P450s CYP1A (CYP1A1
and CYP1A2 isoforms), CYP2C9, CYP2C19, CYP2D6, and
CYP3A4 are responsible for the phase I metabolism of more
than 80% of marketed drugs.36 Compounds 19a, 25a, and 26a
were screened for inhibitory activity against these ﬁve human
P450s and were found to have good selectivity proﬁles, showing
weak or no inhibition (IC50 > 10 μM) against all ﬁve human
P450 isoforms (Table 4).60 The exception was compound 19a,
which was a moderately potent (1 μM < IC50 < 10 μM)
inhibitor of CYP1A (IC50 = 1.22 μM), an isoform which has a
documented preference for aromatic and heterocyclic amine
substrates.36 The reincorporation of Ar1 into analogue 19a to
give potent analogue 25a resulted in a 20-fold increase in IC50
against CYP1A (IC50 25a = 21.4 μM). When the corresponding
improvement in CYP121 binding aﬃnity for the two
compounds was also taken into account, this amounted to an
approximate 15000-fold better apparent selectivity ratio (app
SR = oﬀ-target potency/on-target potency).57 The 4-hydrox-
ybenzyl substituted Ar3 analogue 26a did not inhibit any of the
human P450s by 50% within the tested concentration range.
Taken together, the improved selectivity from reintroducing
Ar1 to the heme binding analogue 19a to give 25a, and the high
selectivity of the non-heme binding analogue 26a, supported
our hypothesis that targeting variable residues and hotspots in
the distal pocket of the CYP121 active site could be used to
achieve P450 isoform selectivity. Aromatic amines, such as
Table 4. Selectivity of CYP121 Ligands against Drug-Metabolizing Human P450 Isoformsa
IC50 (μM) KD (μM) app SR
CYP1A CYP2C9 CYP2C19 CYP2D6 CYP3A4 CYP121 (IC50/KD)
19a 1.22 >25 >25 >25 >25 14.0 0.09
25a 21.4 >25 >25 >25 11.3 0.015 1427
26a >25 >25 >25 >25 >25 6.3 >4
aThe concentration of analogues 19a, 25a, and 26a required to inhibit the activity of human P450s by 50% (IC50, μM) was calculated from a seven-
point dose−response curve. Compounds that did not achieve 50% inhibition over the tested concentration range 0−25 μM were considered non-
inhibitors.60 Studies were performed in human liver microsomes. Turnover of human P450 substrates (CYP1A, ethoxyresoruﬁn; CYP2C9,
tolbutamide; CYP2C19, mephenytoin; CYP2D6, dextromethorphan; CYP3A4, midazolam) was detected by LC-MS/MS or ﬂuorescence for CYP1A.
Reported CYP1A activity represents the combined activities of both the CYP1A1 and CYP1A2 isoforms. The apparent selectivity ratio (app SR =
oﬀ-target potency (IC50)/on-target potency (KD)) was calculated as a ratio of the IC50 (μM) of each compound for CYP1A versus their respective
CYP121 KD (μM).
57 The IC50 values of known inhibitors were determined as positive controls and are listed in Table S3 of the Supporting
Information. Experiments were conducted by Cyprotex (Cheshire, UK).
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those present in the potent CYP121 ligands 25a, 24a, 25b, and
19a, are commonly identiﬁed as potential toxicophores.
However, considering 13% of marketed drugs contain aniline
functional groups, it is premature to exclude all compounds
with this functional group from drug-like chemical space.61 The
toxicity of aniline structures requires metabolic activation,
which is primarily mediated by human P450s.62 The good
selectivity of CYP121 inhibitors, particularly compound 25a,
demonstrated here against human P450s, is promising for the
development of this series of CYP121 inhibitors, however
further assessment against other P450, monooxygenase, and
peroxidase enzymes is warranted. The selectivity of compounds
derived from lead 2 against human P450s was good compared
to that of other classes of P450 inhibitors that have been
reported recently63,64 and suggests that the careful optimization
of metal binding functional groups and targeting active site
residues are methods which could reduce P450 liability during
drug development.
Cellular Potency. The antimycobacterial activity of the
most potent analogues 19a, 24a, 25a, 25b, 26a, and biaryl
retrofragment 5 was assessed in vitro against Mtb H37Rv. No
signiﬁcant inhibition of bacterial growth was detected for any of
the lead compounds (MIC90 ≥ 50 μM) over the tested
concentration range (0−100 μM) (Table S4, Supporting
Information). Achieving adequate intracellular drug exposure
is a particular challenge for TB therapeutics because of the
unique cell-wall structure of the bacterium and the expression
of numerous multisubstrate eﬄux transporters.65,66 Eﬀorts to
determine whether low membrane permeability or eﬄux might
account for the poor cellular activity of the potent CYP121
ligands described here are currently in progress.
■ CONCLUSIONS
Using a fragment-based approach, a novel series of potent and
isoform selective inhibitors of the essential Mtb enzyme
CYP121 have been developed. An initial fragment screen and
synthetic optimization strategy yielded the previously reported
non-heme binding lead 2, which had micromolar aﬃnity for
CYP121 but low LE. The deconstruction of lead compound 2
and synthesis of component retrofragments 3−6 allowed the
GE of individual structural motifs Ar1, Ar2, and Ar3 to be
assessed. Analysis of the binding mode of retrofragments
enabled the identiﬁcation of activity hotspots and the selection
of more LE scaﬀolds for synthetic optimization. The rational
incorporation of a metal-binding functional group onto Ar2,
guided by X-ray crystallography and UV−vis spectroscopy, was
used to achieve a 1000-fold improvement in binding aﬃnity
over lead compound 2, while the incorporation of structural
groups that projected into the Ar1 or Ar3 regions of the distal
active site was shown to modulate the isoform selectivity of
inhibitors against human P450s. Extensive characterization of
analogues by X-ray crystallography, UV−vis spectroscopy, and
native mass spectrometry validated our design strategy,
demonstrating that analogues maintained binding interactions
in identiﬁed activity hotspots and formed stable complexes with
the native CYP121 dimer. Analogues with low nanomolar
potency (KD = 15 nM) for CYP121 are reported, and these
molecules have good selectivity against human drug metaboliz-
ing P450s and a 30-fold selectivity ratio for CYP121 over other
Mtb P450 isoforms. Analysis of selectivity data from this series
provides insight into factors governing the selectivity of P450s,
including the eﬀect of the protein microenvironment and
preference for speciﬁc metal-binding pharmacophores,56,67
which has relevance more broadly for drug development.
Further structural optimization to improve the cellular activity
of these analogues is ongoing with the aim of developing novel
classes of anti-TB agents.
■ EXPERIMENTAL SECTION
General Chemistry. All reagents were purchased from Sigma-
Aldrich Company Ltd. (Poole, UK) or Alfa Aesar (Heysham, UK)
unless otherwise speciﬁed. Unless otherwise stated, reactions were
conducted under positive pressure of a dry nitrogen atmosphere.
Temperatures of 0 °C, −10 °C, and −78 °C were obtained by cooling
the reaction vessel in a bath of ice, salt, and ice or acetone and dry ice
(CO2(s)), respectively. Anhydrous DCM was prepared by distillation
over calcium hydride. THF was freshly distilled over calcium hydride
and lithium aluminum hydride, using triphenylmethane as an indicator.
Other anhydrous solvents were purchased directly from commercial
sources and used without further puriﬁcation.
Analytical thin layer chromatography (TLC) was performed using
Merck glass-backed silica (Kieselgel 60 F254 0.25 mm) plates.
Compounds were visualized using short wave (254 nm) or long wave
(365 nm) ultraviolet light or potassium permanganate stain. Retention
factors (Rf) are quoted with respect to the solvent system used to
develop the plate. Flash column chromatography was performed using
an Isolera Spektra One/Four puriﬁcation system and the appropriately
sized Biotage SNAP column containing KP-silica gel (50 μm).
Solvents are reported as volume/volume eluent mixture where
applicable. Reactions were monitored by TLC and LCMS to
determine consumption of starting materials.
Infrared absorption spectra were recorded on a Bruker ALPHA FT-
IR or Spectrum One FT-IR (PerkinElmer) spectrometer by attenuated
total reﬂectance (ATR) using a diamond crystal. Data are reported as
vibrational frequency (cm−1) and intensity (strong, medium, weak, or
broad) for the assigned functional group.
Nuclear magnetic resonance (NMR) spectra were recorded at 300
K unless otherwise stated, using either a Bruker 400 MHz AVANCE
III HD Smart Probe, 400 MHz QNP cryoprobe, or 500 MHz DCH
cryoprobe spectrometer. Spectra acquired on the 500 MHz DCH
cryoprobe have been converted to analogue and back to reduce
baseline roll. All spectra were recorded in the deuterated solvent
indicated. Data are reported as chemical shift in parts per million (δ
ppm) relative to the residual protonated solvent resonance peak. The
relative integral, multiplicity, coupling constants (J Hz), and
assignment of peaks has been provided where possible. Assignment
of 1H NMR and 13C NMR spectra was assisted by DEPT,
homonuclear (COSY), and heteronuclear (edited 1H−13C-HSQC
and 1H−13C HMBC) 2D-NMR experiments. 13C NMR spectra were
processed with line broadening (LB) of 1−12 Hz for individual
compounds to enable resolution of signals from slowly relaxing
quaternary pyrazole carbons C3, C4, and C5 and resolution of closely
overlapping aromatic signals. LB has been noted for relevant spectra
and 13C signals requiring LB for resolution have been noted as broad
(br). 13C signals that were obscured or were only identiﬁed through
proton relaxation in 2D-NMR experiments are also noted.
Liquid chromatography mass spectrometry (LCMS) was carried out
using an AQUITY UPLC H-class system (Waters, Manchester UK).
Samples were run using a gradient of water (1−5%) (+0.1% formic
acid) in acetonitrile over a period of 4 min. High resolution mass
spectra (HRMS) were recorded using a Micromass Quadrapole-Time-
of-Flight (Q-Tof) spectrophotometer or an Orbitrap LCMS
spectrometer attached to a Dionex Ultimate 3000 HPLC. The mass
to charge ratio (m/z) of the molecular ion and diﬀerence from
calculated mass (δ ppm) have been quoted.
All ﬁnal compounds had a purity greater than 98% by LCMS
analysis, except for compounds 14b, 18g, 18f, 19c, and 26b, which
were 92−98% pure by LCMS analysis.
Synthesis of Retrofragment (3). 4-(5-Amino-1H-pyrazol-3-yl)-
phenol. Step 1: Synthesis of 3-(4-methoxyphenyl)-3-oxopropanenitrile.
Methyl 4-methoxybenzoate (831 mg, 5 mmol) and acetonitrile (1 mL)
were added to a stirred suspension of NaH (60% dispersion in mineral
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oil, 490 mg, 12.25 mmol) in anhydrous THF (25 mL). The reaction
was stirred at 60 °C for 40 h, and then the volatiles were removed
under reduced pressure. The crude residue was diluted with H2O (15
mL) and acidiﬁed with 1 M HCl, and then the product was extracted
into DCM (3 × 20 mL). The combined organic fractions were washed
with brine (5 mL), dried over anhydrous Na2SO4, and the solvent
removed under reduced pressure. The crude product was puriﬁed by
ﬂash chromatography (40−100% v/v DCM in petroleum ether) to
yield 3-(4-methoxyphenyl)-3-oxopropanenitrile as a white solid (578
mg, 3.30 mmol, 66%), Rf 0.30 (1:2 v/v EtOAc in petroleum ether).
LCMS (ESI−) m/z 174.1 [M − H]−, retention time 1.68 min (100%).
HRMS (ESI+): m/z (calcd C10H10NO2 [M + H]
+ = 176.0712), obsd
176.0703 (δ ppm = 5.1). 1H NMR (500 MHz, CDCl3) δ 7.90 (d, J =
9.0 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 4.02 (s, 2H), 3.90 (s, 3H) ppm.
13C NMR (125 MHz, CDCl3) δ 185.5, 164.9, 131.1, 127.4, 114.5,
114.2, 55.8, 29.2 ppm. IR (thin ﬁlm) vmax 3083, 3020, 2942, 2844 (w,
C−H), 2259 (w, nitrile C−N), 1685 (s, CO), 1623 (w, CC),
1596 (s), 1514 (s), 1465, 1450 (s, CH3), 1439 (m, CC), 1326 (s,
CH3), 1268 (s, C−O, CH2), 1224, 1172 (s, C−O), 1011 (s, C−O,
CH2), 930, 828, 814 (s, C−H) cm−1.
Step 2: Synthesis of 3-(4-methoxyphenyl)-1H-pyrazol-5-amine. Con-
centrated HCl (37% v/v, 2.4 mL) was added slowly to a stirred
solution of 3-(4-methoxyphenyl)-3-oxopropanenitrile (552 mg, 3.15
mmol) in absolute EtOH (20 mL). The reaction was heated to reﬂux,
and then hydrazine hydrate (750 μL, 15.5 mmol) was added dropwise
over 10 min. The reaction was heated under reﬂux for 5 h and then
concentrated under reduced pressure (5 mL), diluted with H2O (10
mL), and brought to pH 8.0 using saturated NaHCO3. The product
was extracted into EtOAc (3 × 20 mL), and the combined organic
fractions were washed with brine (5 mL), dried over anhydrous
Na2SO4, and the solvent removed under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography (0−5% v/v MeOH in
DCM) to yield 3-(4-methoxyphenyl)-1H-pyrazol-5-amine as a white
solid (512 mg, 2.71 mmol, 86%), Rf 0.18 (5% v/v MeOH in DCM).
LCMS (ESI+) m/z 190.2 [M + H]+, retention time 1.27 min (100%).
HRMS (ESI+): m/z (calcd C10H12N3O [M + H]
+ = 190.0975), obsd
190.0970 (δ ppm = 2.4). 1H NMR (500 MHz, MeOD) δ 7.50 (br, s,
1H), 7.38 (d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H)
ppm. 13C NMR (125 MHz, MeOD) δ 159.4, 152.7, 128.9 (2 × C),
127.0, 115.2, 109.6, 55.7 ppm. IR (thin ﬁlm) vmax 3397, 3148 (m, br,
N−H), 2962, 2839 (m, C−H), 1615 (m, N−H), 1505, 1479, 1462 (s,
N−H, C−H, CC), 1439 (m, CC), 1284 (m, C−N, C−O), 1244
(s, C−N, C−O), 1177, 1111 (m, C−H), 1028 (s, C−O), 831, 817,
769 (s, C−H), 710 (m, C−H) cm−1.
Step 3: Synthesis of 4-(5-Amino-1H-pyrazol-3-yl)phenol (3). A
solution of 1 M BBr3 in DCM (12.5 mL, 12.5 mmol) was added
dropwise over a period of 10 min to a stirred solution of 3-(4-
methoxyphenyl)-1H-pyrazol-5-amine (473 mg, 2.5 mmol) in anhy-
drous DCM (22 mL) at 0 °C. The reaction was stirred at 0 °C and
allowed to come to room temperature over 14 h. When complete, the
reaction was quenched with saturated NaHCO3 and extracted into
EtOAc (3 × 30 mL). The organic phase was combined, washed with
brine (10 mL), dried over anhydrous Na2SO4, and the solvent
removed under reduced pressure to yield 4-(5-amino-1H-pyrazol-3-
yl)phenol 3 as an oﬀ-white solid (342 mg, 1.95 mmol, 75%), Rf 0.35
(10% v/v MeOH in EtOAc). LCMS (ESI+) m/z 176.2 [M + H]+,
retention time 0.81 min (100%). HRMS (+ ESI): m/z (calcd
C9H10N3O [M + H]
+ = 176.0824), obsd 176.0823 (δ ppm = 0.6). 1H
NMR (500 MHz, DMSO-d6) δ 9.49 (s, 1H), 7.44 (d, J = 9.0 Hz, 2H),
6.76 (d, J = 8.5 Hz, 2H), 5.63 (s, 1H) ppm. 13C NMR (125 MHz,
DMSO-d6) δ 156.9, 153.6, 145.2, 126.1, 122.7, 115.4, 86.9 ppm. IR
(thin ﬁlm) vmax 3305, 3141 (w, br, N−H, O−H), 1615 (m, N−H, C
C), 1519 (s, N−H), 1489 (s, N−H), 1377 (w, O−H), 1279, 1244 (m,
C−N, C−O), 1179 (m, C−O), 1111, 1014 (m, C−H), 834 (s, C−H),
765 (s, C−H) cm−1
Synthesis of Retrofragment (6). 4-((3-(4-Hydroxyphenyl)-1H-
pyrazol-5-yl)amino)phenol. Step 1: Synthesis of methyl 3-(4-methox-
yphenyl)-3-oxopropanoate. Dimethyl carbonate (1.26 mL, 15 mmol)
was added to a stirred suspension of NaH (60% dispersion in mineral
oil, 600 mg, 15 mmol) in anhydrous toluene (2 mL). The reaction was
brought to reﬂux, and a solution of 4-methoxyacetophenone (0.90 g, 6
mmol) in anhydrous toluene (3 mL) was added dropwise. The
reaction was heated at reﬂux for a further 15 min and then allowed to
cool to room temperature. The reaction was quenched with a solution
of AcOH (0.5 mL) in water (2 mL). The organic layer was separated,
and the aqueous fraction was extracted with Et2O (2 × 5 mL). The
organics were combined, washed with a solution of saturated K2CO3,
dried over anhydrous Na2SO4, and the solvent removed under reduced
pressure. The crude product was puriﬁed by ﬂash chromatography
(10−50% v/v EtOAc in petroleum ether) to yield methyl 3-(4-
methoxyphenyl)-3-oxopropanoate as a yellow oil (1.05 g). The
product was 90% pure by 1H NMR integration and was taken forward
without further puriﬁcation; Rf 0.18 (20% v/v EtOAc in petroleum
ether). LCMS (ESI+) m/z 207.2 [M − H]−, retention time 1.75 min
(96%). HRMS (ESI+): m/z (calcd C11H13O4 [M + H]
+ = 209.0808),
obsd 209.0803 (δ ppm = 2.4). 1H NMR (500 MHz, CDCl3) δ 7.92 (d,
J = 9.0 Hz, 2H), 6.94 (d, J = 9.0 Hz, 2H), 3.96 (s, 2H), 3.87 (s, 3H),
3.74 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 190.9, 168.3, 164.2,
130.0, 129.2, 114.1, 55.7, 52.6, 45.7 ppm. IR (thin ﬁlm) vmax 2954,
2842 (w, C−H), 1739 (s, CO), 1675 (s, CO), 1599 (s, CC),
1575, 1511 (m, CC), 1437, 1421 (m, CH2, CH3), 1323 (m, C−O,
C−H), 1258 (s, C−O), 1215 (m), 1147, 1170 (s, C−O, C−H), 1025
(m, C−O), 986 (m), 840 (m, C−H) cm−1.
Step 2: Synthesis of N,3-Bis(4-methoxyphenyl)-3-oxopropanamide. A
solution of 4-methoxyaniline (406 mg, 3.3 mmol) in m-xylene (6 mL)
was added to a stirred solution of methyl 3-(4-methoxyphenyl)-3-
oxopropanoate (623 mg, 3 mmol) in m-xylene (6 mL), and the
reaction was heated to 150 °C for 20 h. The product precipitated on
cooling to room temperature and was puriﬁed by trituration at 0 °C
with ice-cold EtOAc:hexane (1:5 v/v). The precipitate was collected
by vacuum ﬁltration, washed with 1:5 EtOAc:hexane followed by 1:3
EtOAc:hexane, and dried under reduced pressure to give N,3-bis(4-
methoxyphenyl)-3-oxopropanamide as a brown powder (567 mg, 1.9
mmol, 63%), Rf 0.06 (1:2 EtOAc:petroleum ether). LCMS (ESI+) m/
z 322.0 [M + Na]+, retention time 1.87 min (100%). HRMS (ESI+):
m/z (calcd C17H18NO4 [M + H]
+ = 300.1236), obsd 300.1251 (δ ppm
= 5.0). 1H NMR (500 MHz, CDCl3) δ 9.26 (s, 1H), 8.02 (d, J = 8.9
Hz, 2H), 7.48 (d, J = 9.0 Hz, 2H), 6.97 (d, J = 8.9 Hz, 2H), 6.86 (d, J
= 9.0 Hz, 2H), 4.04 (s, 2H), 3.89 (s, 3H), 3.79 (s, 3H) ppm. 13C NMR
(125 MHz, CDCl3) δ 195.1, 164.7, 164.0, 156.6, 131.2, 130.9, 129.2,
122.0, 114.3, 114.2, 55.8, 55.6, 45.1 ppm. IR (thin ﬁlm) vmax 3279 (w,
N−H), 3144, 2963, 2840 (w, C−H), 1685 (m, CO), 1598 (s, C
C), 1556 (m, CC), 1509 (s, N−H), 1465, 1419 (w, CH2, CH3),
1323, 1263, 1246, 1217, 1170 (m, CC, C−O, C−N), 1028, 1013
(C−O), 826 (s, C−H) cm−1.
Step 3: Synthesis of N,3-Bis(4-methoxyphenyl)-1H-pyrazol-5-amine.
Lawesson’s reagent (419 mg, 1.04 mmol) was added to a stirred
solution of N,3-bis(4-methoxyphenyl)-3-oxopropanamide (120 mg,
0.4 mmol) in dry THF (20 mL). The reaction was heated to reﬂux for
4 h and then concentrated under reduced pressure to give a red oil.
The sulphonamide intermediate was redissolved in absolute EtOH (5
mL), and glacial AcOH (69 μL, 1.3 mmol) was added. The ﬂask was
evacuated, ﬂushed with N2 gas, and then hydrazine monohydrate (66
μL, 1.3 mmol) added. The reaction was heated to reﬂux for 3 h and
then allowed to stir at room temperature for 24 h. When complete, the
reaction was concentrated under reduced pressure. The crude orange
oil was diluted with DCM (20 mL) and made basic with a satd
NaHCO3 solution (5 mL). The phases were separated, and the
aqueous layer was extracted with DCM (2 × 2 mL). The organic
fractions were combined, dried over anhydrous Na2SO4, and the crude
product dried directly onto silica gel. Flash chromatography (25−80%
v/v EtOAc in petroleum ether) yielded an oﬀ-white solid that was
further puriﬁed by trituration with Et2O to give N,3-bis(4-
methoxyphenyl)-1H-pyrazol-5-amine as a white powder (41 mg,
0.14 mmol, 35%), Rf 0.11 (2:1 v/v EtOAc in petroleum ether). LCMS
(ESI+) m/z 296.3 [M + H]+, retention time 1.95 min (100%). HRMS
(ESI+): m/z (calcd C17H18N3O2 [M + H]
+ = 296.1399), obsd
296.1393 (δ ppm = 2.0). 1H NMR (500 MHz, acetone-d6) δ 11.42 (s,
1H), 7.67 (d, J = 8.7 Hz, 2H), 7.35 (m, 2H), 6.99 (d, J = 8.9 Hz, 2H),
6.81 (d, J = 9.0 Hz, 2H), 6.13 (d, J = 1.2 Hz, 1H), 3.83 (s, 3H), 3.73
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(s, 3H) ppm. 13C NMR (125 MHz, acetone-d6) δ 160.9, 154.2, 144.7,
139.2, 127.7, 124.6, 118.0, 117.97, 115.42, 115.40, 91.0, 56.1, 56.0
ppm. 13C peak at 144.7 identiﬁed from 1H−13C-HMBC spectrum. IR
(thin ﬁlm) vmax 3402 (m, N−H), 3270 (br, w, N−H), 2968, 2840 (w,
C−H), 1612, 1598, 1587 (m, CC), 1554, 1505, 1464, 1427 (s, C−
H, CN), 1294 (m, C−N), 1239 (s, C−O), 1182 (s, C−N), 1111
(m), 1026 (s, C−O), 959 (m), 823, 762 (s, C−H) cm−1.
Step 4: 4-((3-(4-Hydroxyphenyl)-1H-pyrazol-5-yl)amino)phenol (6).
A 1 M solution of BBr3 in DCM (1.4 mL, 1.4 mmol) was added
dropwise over a period of 15 min to a stirred suspension of N-3-bis(4-
methoxyphenyl)-1H-pyrazol-5-amine (104 mg, 0.35 mmol) in dry
DCM (7.5 mL) at 0 °C. The reaction was allowed to come slowly to
room temperature and stirred for 8 h, then quenched with ice water
(40 mL). EtOAc (20 mL) was added, and the aqueous phase was
made slightly basic with satd NaHCO3. The phases were separated,
and the aqueous fraction was extracted with EtOAc (3 × 15 mL). The
organic fractions were combined, dried over anhydrous Na2SO4, and
the solvent removed under reduced pressure. The crude product was
puriﬁed by ﬂash chromatography (5−10% v/v MeOH in DCM,
followed by 5% MeOH in EtOAc) to yield 4-((3-(4-hydroxyphenyl)-
1H-pyrazol-5-yl)amino)phenol (6) as an oﬀ-white solid (43 mg, 0.16
mmol, 46%), Rf 0.52 (10% v/v MeOH in EtOAc). LCMS (ESI+) m/z
268.2 [M + H]+, retention time 1.37 min (100%). HRMS (ESI+): m/z
(calcd C15H14N3O2 [M + H]
+ = 268.1081), obsd 296.1070 (δ ppm =
4.0). 1H NMR (500 MHz, MeOD) δ 7.49 (d, J = 8.5 Hz, 2H), 7.05 (d,
J = 8.0 Hz, 2H), 6.82 (d, J = J = 8.7 Hz, 2H), 6.70 (d, J = 8.9 Hz, 2H),
6.03 (s, 1H) ppm. 13C NMR (125 MHz, MeOD) δ 158.9, 155.5 (br),
152.0, 145.5 (br), 137.9, 127.8, 122.8, 119.2, 116.6, 116.6, 90.7 (br)
ppm. IR (thin ﬁlm) vmax 3417 (s, br, O−H), 3292 (s, br, N−H), 1607,
1615 (w, CC), 1574 (s, CC, N−H), 1522 (s, CC, N−H), 1383
(w, C−O), 1254 (m, br, C−O, C−N), 1107 (w, C−H), 830 (s, C−
H), 759 (m, O−H) cm−1.
General Procedure A. Synthesis of β-Ketonitriles 12a−c and
21a−b. 2,3-Bis(4-methoxyphenyl)-3-oxopropanenitrile (12a). 2-(4-
Methoxyphenyl)acetonitrile 11 (2.32 mL, 17.1 mmol) and methyl 4-
methoxybenzoate 10a (2.58 g, 15.5 mmol) were added to a stirred
suspension of NaH (60% in mineral oil, 1.34 g, 33.6 mmol) in
anhydrous THF (30 mL). The reaction was heated to 60 °C for 20 h
then cooled to 0 °C and quenched with H2O (10 mL). The
suspension was concentrated under reduced pressure then diluted with
dichloromethane (50 mL) and acidiﬁed with 3 M HCl to pH 2−3.
The organic layer was separated oﬀ, and the aqueous phase was
extracted with dichloromethane (3 × 50 mL). The organic fractions
were combined, washed with brine (10 mL), dried over anhydrous
MgSO4, and the solvent removed under reduced pressure to yield 2,3-
bis(4-methoxyphenyl)-3-oxopropanenitrile 12a as a yellow gum (3.84
g, 13.7 mmol, 88%). The crude oxopropanenitriles 12a was used in
subsequent reactions without further puriﬁcation, although other
analogues were puriﬁed by ﬂash chromatography eluting with the
solvent system speciﬁed. LCMS (+ ESI): m/z 280.2 [M + Na]+;
retention time 2.11 min (93%). HRMS (+ ESI): m/z (calcd
C17H16NO3 [M + H]
+ = 282.1130), obsd 282.1135 (δ ppm =1.8).
1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 9.0 Hz, 2H), 7.34 (d, J =
8.8 Hz, 2H), 6.92 (d, J = 7.8 Hz, 2H), 6.90 (d, J = 7.8 Hz, 2H), 5.50 (s,
1H), 3.85 (s, 3H,), 3.78 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ
187.6, 164.5, 160.1, 131.8, 129.5, 126.5, 122.7, 117.2, 115.1, 114.3,
55.7, 55.5, 45.8 ppm. IR (thin ﬁlm) vmax 3008, 2936, 2839 (w, C−H),
2248 (w, nitrile CN), 1677 (m, CO), 1597, 1510 (s, CC), 1462,
1422 (w), 1305 (m, C−O), 1254, 1237, 1173 (s, C−O), 1027 (m),
939, 822, 780 (m) cm−1.
3-(3-Methoxyphenyl)-2-(4-methoxyphenyl)-3-oxopropanenitrile
(12b). Prepared as an orange oil (0.703 g, 2.50 mmol, 83%) according
to general procedure A. The crude product was puriﬁed by ﬂash
chromatography (0−50% v/v EtOAc in petroleum ether), Rf 0.55
(50% v/v EtOAc in petroleum ether). LCMS (ESI−) m/z 294.2 [M +
H]+, retention time 2.13 min. 1H NMR (400 MHz, CDCl3) δ 7.49 (d,
J = 7.6 Hz, 1H), 7.45 (app t, J = 2.4, 1.6 Hz, 1H), 7.34 (m, 3H), 7.11
(d, J = 8.4, 2.0 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 5.53 (s, 1H), 3.82 (s,
3H), 3.78 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3) δ 189.1, 160.2,
160.1, 135.1, 130.0, 129.6, 122.3, 121.8, 121.0, 116.9, 115.2, 113.7,
55.6, 55.5, 46.2 ppm.
3-(3-Fluorophenyl)-2-(4-methoxyphenyl)-3-oxopropanenitrile
(12c). Prepared as an orange solid (229 mg, 0.852 mmol, 85%)
according to general procedure A. The crude product was puriﬁed by
ﬂash chromatography (10−50% v/v EtOAc in petroleum ether).
LCMS (ESI+) m/z 270.2 [M + H]+, retention time 2.08 min (89%).
HRMS (ESI+) m/z (calcd C16H13FNO2 [M + H]
+ = 270.0930), obsd
270.0933 (δ ppm = 1.1). 1H NMR (500 MHz, CDCl3) δ 7.71 (d, J =
8.0 Hz, 1H), 7.61 (d, J = 9.0 Hz, 1H), 7.43 (m, 1H), 7.33 (d, J = 8.8
Hz, 2H), 7.29 (m, 1H), 6.91 (d, J = 8.9 Hz, 2H), 5.49 (s, 1H), 3.79 (s,
3H) ppm. 13C NMR (125 MHz, CDCl3) δ 188.1, 162.8 (d, JC−F = 248
Hz), 160.4, 135.6 (JC−F = 6.4 Hz), 130.8 (d, JC−F = 8 Hz), 129.5, 125.1
(d, JC−F = 2 Hz), 121.6 (d, JC−F = 10 Hz), 121.5, 116.5, 116.0 (d, JC−F
= 23 Hz), 115.3, 55.5, 46.4 ppm. 13C NMR processed with LB = 3 Hz.
IR (thin ﬁlm) vmax 3076, 2959, 2936, 2840 (w, C−H), 2248, 2207 (w,
nitrile CN), 1694 (m, CO), 1608, 1588 (m, CC), 1510 (s), 1439,
1304 (m), 1252 (s), 1149, 1030 (m, C−O), 885 (w), 834, 803, 788
(m) cm−1.
2-(3-Bromophenyl)-3-(4-methoxyphenyl)-3-oxopropanenitrile
(21a). Prepared as a yellow semisolid (2.18 g) according to general
procedure A and used in subsequent reactions without further
puriﬁcation. The crude product contained 15% unreacted starting
material by 1H NMR integration; Rf 0.18 (50% v/v EtOAc in
petroleum ether). LCMS (ESI−) m/z 328.1 [M − H]−, retention time
2.23 min (59%). 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.9 Hz,
2H), 7.62 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.8 (d, J = 7.8 Hz, 1H),
7.27 (m, 1H), 6.95 (d, J = 8.9 Hz, 2H), 5.53 (s, 1H), 3.89 (s, 3H)
ppm. 13C NMR (100 MHz, CDCl3) δ 186.7, 164.9, 132.9, 132.4,
131.9, 131.3, 127.0, 126.3, 123.6, 121.7, 116.4, 114.6, 55.8, 45.7 ppm.
IR (thin ﬁlm) vmax 2937, 2842 (w, C−H), 2252 (w, CN), 1679 (m,
CO), 1597 (s), 1572, 1512, 1424, 1323 (m, CC, C−H), 1264,
1238, 1172 (s, C−N, C−O), 1026 (m), 941, 833, 775, 692 (m, C−H)
cm−1.
2-(4-(Benzyloxy)-3-bromophenyl)-3-(4-methoxyphenyl)-3-oxo-
propanenitrile (21b). Prepared as an orange semisolid (0.845 g, 1.56
mmol, quant.) according to general procedure A and either used
directly in subsequent reactions or further puriﬁed by ﬂash
chromatography (0−10% v/v MeOH in DCM). LCMS (ESI+): m/z
436.1 [M + H]+, retention time 2.44 min (94%). HRMS (ESI+): m/z
(calcd C23H19BrNO3 [M + H]
+ = 436.0548), obsd 436.0561 (δ ppm =
3.0). 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 8.9 Hz, 2H), 7.63 (d,
J = 2.4 Hz, 1H), 7.44 (d, J = 7.4 Hz, 2H), 7.38 (appt, J = 7.6, 7.2 Hz,
2H), 7.34−7.30 (m, 2H), 6.93 (m, 3H), 5.45 (s, 1H), 5.13 (s, 2H),
3.87 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 186.8, 164.6, 155.6,
136.0, 133.1, 131.8, 128.7, 128.3, 128.1, 126.9, 126.2, 124.2, 116.7,
114.5, 114.3, 113.5, 70.9, 55.7, 44.9 ppm. IR (thin ﬁlm) vmax 3064,
3033, 2935, 2840 (w, C−H), 2249 (w, nitrile C−N), 1678 (m, C
O), 1597 (s), 1572, 1510 (m, CC), 1492 (s), 1454 (m), 1382 (w,
C−N), 1261, 1220, 1173 (s, C−N, C−O), 1052, 1024 (m, C−O),
808, 735 (m) cm−1.
General Procedure B. Synthesis of Bisphenyl-1H-pyrazol-5-
amines 13a−c and 22a−b. 3,4-Bis(4-methoxyphenyl)-1H-pyrazol-
5-amine (13a).28,33 Concentrated HCl (37% v/v, 6.25 mL) was added
slowly to a stirred solution of crude 2,3-bis(4-methoxyphenyl)-3-
oxopropanenitrile 12a (4.16g, ∼11.84 mmol, 1 equiv) in absolute
EtOH (63 mL). The reaction was then heated to reﬂux, and hydrazine
hydrate (3.6 mL, 74 mmol, 5 equiv) was added dropwise over 10 min.
After heating at reﬂux until all starting material had been consumed
(typically 5−15 h), the reaction was cooled to room temperature and
concentrated under reduced pressure (20 mL). The reaction was
diluted in water (15 mL) and brought to pH 8.0 using saturated
NaHCO3. The aqueous emulsion was extracted with EtOAc (3 × 20
mL). The organic fractions were combined and washed with brine (10
mL), dried over anhydrous MgSO4, and the solvent removed under
reduced pressure. The crude product was puriﬁed by ﬂash
chromatography (40% v/v EtOAc in petroleum ether, then 0−10%
v/v MeOH in EtOAc) to yield 3,4-bis(4-methoxyphenyl)-1H-pyrazol-
5-amine 13a as a yellow solid (3.171 g, 10.7 mmol, 91%), Rf 0.29 (10%
v/v MeOH in DCM). LCMS (ESI+): m/z 296.1 [M + H]+; retention
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time 2.01 min (95%). HRMS (ESI+): m/z (calcd C17H18N3O2 [M +
H]+ = 296.1399), obsd 296.1392 (δ ppm = 2.4). 1H NMR (500 MHz,
DMSO-d6) δ 11.77 (s, br, 1H), 7.22 (d, J = 8.8 Hz, 2H), 7.10 (d, J =
8.5 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.39 (s,
br, 2H), 3.75 (s, 3H), 3.74 (s, 3H) ppm. 13C NMR (125 MHz,
DMSO-d6) δ 158.6, 157.4, 152.6, 139.4, 130.5, 128.3, 125.9, 123.8,
114.0, 113.8, 103.0, 55.6, 55.0 ppm. 13C NMR processed with LB = 12
Hz. IR (solid) vmax 3432, 3349 (w, N−H), 3210 (w, br, N−H), 3932,
2833 (w, C−H), 1622 (w, CC), 1513, 1489 (m, N−H, C−H),
1303, 1284 (w), 1241 (s, C−O, C−N), 1179 (s, C−O), 1111 (w),
1020 (s, C−O), 964 (w, C−H), 834 (s, C−H), 798, 735 (m, C−H)
cm−1.
3-(3-Methoxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-5-amine
(13b). Prepared as an orange amorphous solid (680 mg, 2.30 mmol,
92%) according to general procedure B. The crude material was
carried forward without further puriﬁcation. LCMS (ESI+) m/z 296.2
[M + H]+, retention time 1.80 min (93%). HRMS (ESI+) m/z (calcd
C17H18N3O2 [M + H]
+ = 296.1394), obsd 296.1381 (δ ppm = 4.4). 1H
NMR (500 MHz, MeOD) δ 7.19−7.12 (m, 3H), 6.90 (m, 3H), 6.85
(dd, J = 2.6, 1.5 Hz, 1H), 6.80 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.77 (s,
3H), 3.62 (s, 3H) ppm. 13C NMR (125 MHz, MeOD) δ 161.0, 160.0,
153.1 (br), 143.3 (br), 133.4 (br), 132.2, 130.6, 126.4, 120.8, 115.3,
115.0, 113.8, 106.3 (br), 55.7, 55.5 ppm. 13C NMR spectrum
processed with LB = 12 Hz. IR (thin ﬁlm) vmax 3422, 3336, 3182 (m,
br, N−H), 2999, 2938, 2834 (m, C−H), 1607, 1578, 1525, 1488,
1464, 1285 (m, CC), 1243 (s, C−N), 1177, 1040, 1022 (m, C−O),
834, 788, 749, 694 (m) cm−1.
3-(3-Fluorophenyl)-4-(4-methoxyphenyl)-1H-pyrazol-5-amine
(13c). Prepared as an orange solid (142 mg, 0.50 mmol, 97%)
according to general procedure B. The crude product was puriﬁed by
ﬂash chromatography (0−5% v/v MeOH in DCM). LCMS (ESI+) m/
z 284.2 [M + H]+, retention time 1.82 min (100%). HRMS (ESI+) m/
z (calcd C16H15FN3O [M + H]
+ = 284.1199), obsd 284.1188 (δ ppm
= 3.9). 1H NMR (500 MHz, CDCl3) δ 7.24 (m, 1H), 7.19 (d, J = 8.7
Hz, 2H), 7.12 (dt, J = 7.7, 1.3 Hz, 1H), 7.03 (ddd, J = 9.8, 2.6, 1.6 Hz,
1H), 6.97 (app tdd, J = 8.4, 2.6, 1.0 Hz, 1H), 6.91 (d, J = 8.7 Hz, 2H),
3.83 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 162.9 (d, JC−F =
249 Hz), 158.7, 152.8, 140.2, 132.7 (d, JC−F = 8 Hz), 130.9, 130.4 (d,
JC−F= 8 Hz), 124.4, 123.0 (d, JC−F = 3 Hz), 115.2 (d, JC−F = 21 Hz),
114.6, 114.3 (d, JC−F = 23 Hz), 106.3, 55.4 ppm.
19F-NMR (376 MHz,
CDCl3) δ −112.4 ppm. IR (thin ﬁlm) vmax 3310, 3190 (m, br, N−H),
3000, 2934, 2836 (m, C−H), 1613 (m, CC), 1579, 1524 (m, N−
H), 1488 (m, CC), 1286 (m), 1245 (s, C−N, C−O), 1176, 1021
(m), 864, 835 (m, C−H), 788, 751 (m, C−H), 690, 605 (w) cm−1.
4-(3-Bromophenyl)-3-(4-methoxyphenyl)-1H-pyrazol-5-amine
(22a). Prepared as a brown amorphous solid (1.86 g, 5.42 mmol, 77%
over two reaction steps from 3-bromophenylacetonitrile). The crude
product was puriﬁed by ﬂash chromatography (50−100% v/v EtOAc
in petroleum ether), Rf 0.08 (50% v/v EtOAc in petroleum ether).
LCMS (ESI+) m/z 346.1 [M (81Br) + H]+, retention time 1.96 min
(100%). HRMS (ESI+) m/z (calcd C16H15
79BrN3O [M + H]
+ =
344.0393), obsd 344.0385 (δ ppm = 2.5). 1H NMR (500 MHz,
MeOD) δ 7.37 (m, 2H), 7.24−7.19 (m, 4H), 6.88 (d, J = 7.2 Hz, 2H),
3.78 (s, 3H) ppm. 13C NMR (125 MHz, MeOD) δ 161.3, 152.6 (br),
144.2 (br), 137.1, 133.4, 131.4, 130.2 (2C), 129.5, 124.2 (br), 123.6,
115.1, 104.6 (br), 55.7 ppm. 13C NMR processed with LB = 12 Hz. IR
(thin ﬁlm) vmax 3063, 2936, 2841 (w, C−H), 2250 (w, nitrile C−N),
1677 (m, CO), 1596 (s), 1574, 1510, 1474, 1423 (m, CC), 1322
(m), 1264, 1239 (s, C−O), 1173 (s), 1027 (m, C−O), 941 (m), 832,
772, 693 (m) cm−1.
4-(4-(Benzyloxy)-3-bromophenyl)-3-(4-methoxyphenyl)-1H-pyra-
zol-5-amine (22b). Prepared as a yellow foam (881 mg, 1.96 mmol,
95%) according to general procedure B. No further puriﬁcation by
ﬂash chromatography was required. LCMS (ESI+) m/z 450.2, 452.2
[M + H]+, retention time 2.17 min (98%). HRMS (ESI+): m/z (calcd
C23H21BrN3O2 [M + H]
+ = 450.0817), obsd 450.0811 (δ ppm = 1.3).
1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 2.1 Hz, 1H), 7.49 (d, J =
7.3 Hz, 2H), 7.40 (app t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 7.24
(d, J = 8.7 Hz, 2H), 7.11 (dd, J = 8.4, 2.1 Hz, 1H), 6.91 (d, J = 8.4 Hz,
1H), 6.84 (d, J = 8.8 Hz, 2H), 5.16 (s, 2H), 3.80 (s, 3H) ppm. 13C
NMR (125 MHz, CDCl3) δ 159.9, 153.9, 152.8, 141.4, 136.6, 134.3,
129.9, 128.8, 128.7, 128.1, 127.2, 126.9, 122.3, 114.4, 114.2, 112.9,
104.1, 71.0, 55.4 ppm. 13C NMR processed with LB = 3 Hz. IR (thin
ﬁlm) vmax 3419, 3197 (w, br, N−H), 2933, 2836 (w, C−H), 1613 (m,
CC), 1523 (s, N−H), 1454 (m), 1381 (w), 1280, 1249 (s, C−N),
1178, 1031 (m, C−O), 834, 737, 697 (m) cm−1.
General Procedure C. Synthesis of Oxopropanenitriles 16a−c.
2-(3-Bromophenyl)-3-oxopropanenitrile (16a). 2-(3-Bromophenyl)-
acetonitrile 15a (1.09 g, 5.5 mmol) was added to a freshly prepared
solution of sodium metal (139 mg, 6.05 mmol) in EtOH (7.5 mL) at 0
°C. After the reaction was stirred on ice for 5 min, ethyl formate (1.11
mL, 13.8 mmol) was added and the reaction was heated to reﬂux for
15−24 h. When no starting material remained, the reaction was cooled
and concentrated under reduced pressure. The residue was diluted
with H2O (5 mL) and acidiﬁed to pH 4 using 1 M HCl. The aqueous
phase was extracted with Et2O or EtOAc (3 × 10 mL), and the
combined organic fractions were washed with brine (5 mL), dried over
anhydrous Na2SO4, and the solvent evaporated to yield an oﬀ-white
solid (1.18 g, 5.26 mmol, 96%). The crude product was carried
forward into subsequent reaction steps as a mixture of enantiomers
and some acetonitrile starting material; Rf 0.08 (50% v/v EtOAc in
petroleum ether). LCMS (ESI−) m/z 222.0 [M − H]−, retention time
2.01 min (97%). HRMS (ESI−): m/z (calcd C9H6BrNO [M − H]− =
221.9560), obsd 221.9556 (δ ppm = 1.7). 1H NMR (400 MHz,
MeOD) δ 7.94 (s, 1H), 7.90 (s, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.59
(m, 1H), 7.57 (s, 1H), 7.54 (m, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.44−
7.33 (m, 4H), 7.33−7.20 (m, 3H), 4.76 (d, J = 7.4 Hz, 1H) ppm. IR
(thin ﬁlm) vmax 3103, 2977 (m, C−H), 2725 (w, aldehyde C−H),
2223 (m, nitrile C−N), 1644 (m, CO), 1594, 1558 (m, CC),
1473 (m), 1378 (s, aldehyde C−H), 1253 (s), 1194, 1073 (m), 874
(w), 771 (s), 680 (m) cm−1.
Synthesis of 2-(4-(Benzyloxy)-3-bromophenyl)acetonitrile (15b).
Step 1: Synthesis of 2-(3-bromo-4-hydroxyphenyl)acetonitrile.10 A
solution of BBr3 in DCM (1 M, 6.64 mL) was added dropwise to a
cooled (−78 °C) solution of 2-(3-bromo-4-methoxyphenyl)-
acetonitrile (500 mg, 2.2 mmol) in DCM (2.2 mL). The reaction
was allowed to warm to room temperature and stirred for 14 h or until
all starting material had been consumed. The reaction was quenched
by slowly pouring into ice−water (15 mL). The aqueous phase was
extracted with DCM (3 × 10 mL). The organic fractions were
combined, washed with water (10 mL) and brine (10 mL), and then
dried over anhydrous MgSO4. The solvent was evaporated under
reduced pressure to yield 2-(3-bromo-4-hydroxyphenyl)acetonitrile as
white crystals (0.460 g, 2.17 mmol, 98%), Rf 0.23 (1:2 EtOAc:hexane).
LCMS (ESI−) m/z 210.0 [M − H]−; retention time 1.76 min (95%).
1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 1.8 Hz, 1H), 7.18 (dd, J =
8.2 Hz, 1.9 Hz, 1H), 7.02 (d, J = 8.4 Hz, 1H), 5.57 (s, 1H), 3.67 (s,
2H) ppm. 13C NMR (125 MHz, CDCl3) δ 152.4, 131.5, 129.0, 123.4,
117.6, 116.8, 110.7, 22.6 ppm. IR (thin ﬁlm) vmax 3305 (s, br, O−H),
2924, 2904 (w, C−H), 2272 (w, nitrile CN), 1613 (w), 1511, 1423,
1410 (s, CC), 1356 (m, C−N), 1279 (s), 1219 (m, C−O), 802 (s),
658 (m) cm−1.
2-(4-(Benzyloxy)-3-bromophenyl)acetonitrile (15b). Potassium
carbonate (1.94 g, 14.0 mmol), potassium iodide (1.28 g, 7.70
mmol), and benzyl bromide (1.67 mL, 14.0 mmol) were added to a
stirred solution of 2-(3-bromo-4-hydroxyphenyl)acetonitrile (1.48 g,
7.00 mmol) in acetone (65 mL). The suspension was heated to reﬂux
for 15 h, at which point all of the starting material had been consumed.
The reaction was concentrated in vacuo, and the resulting residue was
diluted with EtOAc (120 mL). The organic fraction was washed with
water (3 × 50 mL) and brine (50 mL), then dried over anhydrous
MgSO4. The solvent was evaporated under reduced pressure to yield a
brown oil. The crude product was puriﬁed by ﬂash chromatography
(0−30% v/v EtOAc in petroleum ether) to yield 2-(4-(benzyloxy)-3-
bromophenyl)acetonitrile 15b as a pale-yellow oil (1.960 g, 6.49
mmol, 93%), Rf 0.44 (1:2 EtOAc:hexane). LCMS (ESI+) m/z 306,
308 [M + H, reduced nitrile]+; retention time 2.60 min (98%). HRMS
(ESI+): m/z (calcd C15H13BrNO [M + H]
+ = 302.0181), obsd
302.0166 (δ ppm = 5.0). 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J =
2.2 Hz, 1H), 7.45 (m, 2H), 7.39 (app t, J = 7.4 Hz, 6 Hz, 2H), 7.34 (t,
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J = 7.3 Hz, 1H), 7.20 (dd, J = 8.5 Hz, 2.2 Hz, 1H), 6.92 (d, J = 8.4 Hz,
1H), 5.18 (s, 2H), 3.60 (s, 2H) ppm. 13C NMR (100 MHz, CDCl3) δ
154.9, 136.2, 133.0, 128.8, 128.2, 128.1, 127.1, 123.6, 117.7, 114.2,
113.2, 71.0, 22.6 ppm. IR (thin ﬁlm) vmax 3089, 3064, 2915, 2869 (w,
C−H), 2253 (w, nitrile CN), 1604 (m), 1493 (s), 1454, 1413, 1382
(m, C−N), 1282, 1254 (s), 1157 (w), 1051 (s, C−O), 1006 (m), 806
(m), 737, 696 (s, C−Br) cm−1.
2-(4-(Benzyloxy)-3-bromophenyl)-3-oxopropanenitrile (16b).
Prepared as an orange residue (334 mg, 1.01 mmol, 51%) according
to general procedure C. The crude product was puriﬁed by ﬂash
chromatography (0−5% v/v MeOH in DCM) to give a mixture of
isomers; Rf 0.07 (1:2 v/v EtOAc in petroleum ether). LCMS (ESI−)
m/z 330.0 [M − H]−, retention time 2.28 min (100%). HRMS (ESI
+): m/z (calcd C16H13BrNO2 [M + H]
+ = 330.0130), obsd 330.0140
(δ ppm = 3.0). 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 2.2 Hz,
1H), 7.54 (m, 2H), 7.46 (m, 5H), 7.43−7.36 (m, 5H), 7.33 (m, 2H),
7.21 (dd, J = 8.6, 2.4 Hz, 1H), 6.94 (d, J = 9.0 Hz, 1H), 6.91 (d, J = 8.4
Hz, 1H), 5.17 (m, 4H), 3.52 (s, 1H), 3.45 (d, J = 3.2 Hz, 1H) ppm. IR
(thin ﬁlm) vmax 3142 (br), 3034 (w, C−H), 2722 (w, C−H aldehyde),
2216 (w, nitrile, C−N), 1644 (m, CO), 1599 (w, CC), 1494 (s),
1379 (w, C−H aldehyde), 1285 (s), 1079, 1003, 808 (m), 731 (s), 694
(s, C−Br) cm−1.
2-(3-Bromo-4-methoxyphenyl)-3-oxopropanenitrile (16c). Pre-
pared as a cream-colored solid (508 mg) according to general
procedure C. The crude product was taken forward without further
puriﬁcation; Rf 0.11 (1/3 v/v EtOAc in petroleum ether). LCMS
(ESI−) m/z 253.1 [M − H]−, retention time 1.96 min (100%).
HRMS (ESI+): m/z (calcd C10H9BrNO2 [M + H]
+ = 253.9817), obsd
253.9829 (δ ppm = 4.7). 1H NMR (400 MHz, MeOD) δ 7.98 (d, J =
2.2 Hz, 1H), 7.77 (s, 1H), 7.66 (dd, J = 8.7, 2.2 Hz, 1H), 7.60 (dd, J =
6.3, 2.2 Hz, 1H), 7.56 (s, 1H), 7.49 (s, 1H), 7.38 (dt, J = 8.8, 2.4 Hz,
1H), 7.34 (dt, J = 8.8, 2.4 Hz, 1H), 7.06 (d, J = 8.8 Hz, 3H), 4.73 (d, J
= 6.6 Hz, 1H), 3.95−3.80 (m, 10H) ppm. IR (solid) vmax 3243 (m, br),
3063, 2968, 2838 (w, C−H), 2216 (m, CN), 1845 (w), 1654 (m, C
O), 1602 (m), 1499 (s, C−N, C−H), 1438, 1375, 1349 (w, CC,
N−H), 1289 (m), 1256 (s, C−O), 1208 (m), 1056, 1013 (s, C−O),
870 (m), 803 (s, C−H), 686 (m) cm−1.
General Procedure D. Synthesis of Phenyl-1H-pyrazol-5-amines
17a−c. 4-(3-Bromophenyl)-1H-pyrazol-5-amine (17a). Glacial
AcOH (679 μL, 12.9 mmol) followed by hydrazine hydrate (500
μL, 10.3 mmol) was added to a stirred solution of the crude 2-(3-
bromophenyl)-3-oxopropanenitrile 16a (1.15 g, 5.14 mmol) in EtOH
(7 mL) at room temperature. The reaction was heated to 85 °C for 3−
5 h, and then the solvent was removed under reduced pressure. The
residue was diluted with water (10 mL) and Et2O or EtOAc (10 mL),
and brought to pH 8.0 with a satd NaHCO3 solution. The phases were
separated, and the aqueous phase was extracted with Et2O or EtOAc
(3 × 10 mL). The combined organic fractions were washed with brine
(5 mL), dried over anhydrous Na2SO4, and the solvent removed under
reduced pressure. The product was puriﬁed by trituration with
petroleum ether and DCM to yield 4-(3-bromophenyl)-1H-pyrazol-5-
amine 17a (865 mg, 3.70 mmol, 67% over two reactions steps from 3-
bromophenylacetonitrile) as a pink solid; Rf 0.09 (2:1 v/v EtOAc in
petroleum ether). LCMS (ESI+) m/z 240.1 [M (81Br) + H]+,
retention time 1.61 min (100%). HRMS (ESI+) m/z (calcd C9H9BrN3
[M + H]+ = 237.9980), obsd 237.9984 (δ ppm = 1.7). 1H NMR (500
MHz, MeOD) δ 7.67 (s, 1H), 7.62 (s, br, 1H), 7.46 (d, J = 7.4 Hz,
1H), 7.32 (d, J = 7.8 Hz, 1H), 7.26 (app t., J = 7.8 Hz, 1H) ppm. 13C
NMR (125 MHz, MeOD) δ 153.2 (br), 139.6 (br), 137.2, 131.5,
130.1, 129.4, 126.0 (br), 123.8, 108.4 (br) ppm. 13C NMR processed
with LB = 12 Hz. IR (thin ﬁlm) vmax 3392, 3227 (m, br, N−H), 2900
(w, C−H), 1600, 1567, 1496 (m, CC, C−N), 1409 (w), 1079 (w),
872 (m), 779 (s), 687 (m) cm−1.
4-(4-(Benzyloxy)-3-bromophenyl)-1H-pyrazol-5-amine (17b).
Prepared as a cream solid (648 mg, 1.88 mmol, 94%) according to
general procedure D. The crude product was used without further
puriﬁcation; Rf 0.23 (10% v/v MeOH in DCM). LCMS (ESI+): m/z
346.1 [M + H]+, retention time 1.94 min (100%). HRMS (ESI+): m/z
(calcd C16H15N3OBr [M + H]
+ = 344.0398), obsd 344.0387 (δ ppm =
−3.2). 1H NMR (500 MHz, MeOD) δ 7.69 (d, J = 2.2 Hz, 1H), 7.54
(s, 1H), 7.49 (d, J = 7.5 Hz, 2H), 7.36 (m, 3H), 7.30 (t, J = 7.4 Hz,
1H), 7.09 (d, J = 8.5 Hz, 1H), 5.17 (s, 2H) ppm. 13C NMR (125 MHz,
MeOD) δ 154.4, 138.3, 132.3, 129.5, 129.1, 128.9, 128.3, 127.7, 115.6,
113.6, 107.3, 71.9 ppm. 13C NMR processed with LB = 3 Hz. IR (thin
ﬁlm) vmax 3400, 3318 (m, N−H), 3165 (m, br, C−H), 3061, 3036 (m,
C−H), 2889 (m, C−H), 1600, 1565, 1500 (m, CC), 1486 (s, N−
H), 1396, 1381, 1367 (w), 1292, 1257 (s, C−N), 1047 (s, C−O),
1013, 872 (m), 802 (s), 726, 704, 641 (m) cm−1.
4-(3-Bromo-4-methoxyphenyl)-1H-pyrazol-5-amine (17c). Pre-
pared as a white solid (339 mg, 1.26 mmol, 66% over two reaction
steps) according to general procedure D. The crude material was
puriﬁed by ﬂash chromatography (2−10% v/v MeOH in EtOAc), Rf
0.05 (50% v/v EtOAc in petroleum ether). LCMS (ESI+) m/z 268.1
[M + H]+, retention time 1.59 min (100%). HRMS (ESI+): m/z
(calcd C10H11BrN3O [M + H]
+ = 268.0080), obsd 268.0071 (δ ppm =
3.4) 1H NMR (500 MHz, acetone-d6) δ 11.05 (br, s), 7.72 (d, J = 2.1
Hz, 1H), 7.63 (s, 1H), 7.49 (dd, J = 8.5, 2.2 Hz, 1H), 7.07 (d, J = 8.5
Hz, 1H), 4.38 (br, s, 2H), 3.88 (s, 3H) ppm. 13C NMR (126 MHz,
Acetone-d6) δ 153.6, 150.0 (br), 130.6, 128.4, 126.3, 124.3, 112.6,
112.5, 111.4, 105.5 (br), 55.7 ppm. One 13C signal unresolved. 13C
NMR processed with LB = 3.0 Hz. IR (solid) vmax 3407, 3333, 3225
(m, br, N−H), 2937, 2841 (w, C−H), 1619 (w, CC), 1574 (m, N−
H), 1516 (m), 1482 (s, CC, C−H), 1383 (w, CH3), 1286 (m, C−
N/C-O), 1250 (s, C−N, C−O), 1184 (w), 1045, 1015 (m, C−O, C−
H), 744 (m, C−H), 680 (s, C−Br) cm−1.
General Procedure E. Suzuki−Miyaura Coupling to Synthesize
Biphenyl-1H-pyrazol-5-amines 18a,b, 18d−i and 23a−b. 4-(3′-
Nitro-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine (18a). 4-(3-Bromo-
phenyl)-1H-pyrazol-5-amine 17a (238 mg, 1 mmol), 3-nitrophenyl
boronic acid (150 mg, 1.5 mmol) (1−2 equiv), Na2CO3 (318 mg, 3
mmol), and Pd(PPh3)4 (116 mg, 0.1 mmol) were combined in a
microwave reaction vessel in a 1:1 v/v mixture of 1,4-dioxane:water
(12 mL). The reaction was heated at 120 °C in a microwave reactor
for 1.5−3 h. The reaction was then allowed to cool to room
temperature and diluted with DCM (20 mL) and water (5 mL). The
phases were separated, and the aqueous phase was extracted with
DCM (3 × 3 mL). The organic fractions were combined, washed with
brine (3 mL), dried over anhydrous MgSO4, and the solvent removed
under reduced pressure. The crude product was puriﬁed by ﬂash
chromatography (0−5% v/v MeOH in DCM) to yield 4-(3′-nitro-
[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine 18a as a yellow amorphous
solid (152 mg, 0.50 mmol, 54%), Rf 0.28 (10% v/v MeOH in DCM).
LCMS (ESI+) m/z 281.2 [M + H]+, retention time 1.82 min (100%).
HRMS (ESI+) m/z (calcd C15H13N4O2 [M + H]
+ = 281.1033), obsd
281.1023 (δ ppm = 3.6). 1H NMR (500 MHz, CDCl3) δ 8.46 (app t, J
= 2.0, 2.0 Hz, 1H), 8.21 (ddd, J = 8.3, 2.0, 2.0 Hz, 1H), 7.93 (ddd, J =
7.3, 1.5, 1.0 Hz, 1H), 7.70 (s, 1H), 7.62 (app t, J = 8.0, 7.5 Hz, 1H),
7.59 (s, 1H), 7.53−7.48 (m, 3H) ppm. 13C NMR (125 MHz, CDCl3)
δ 151.2 (br), 148.8, 142.8, 139.6, 134.1, 133.2, 129.9, 129.9, 128.8 (br),
126.9, 125.7, 125.1, 122.3, 122.1, 108.5 (br) ppm. 13C NMR processed
with LB = 3 Hz. IR (thin ﬁlm) vmax 3182 (m, br, N−H), 2952 (m, C−
H), 1606 (m, N−H), 1524 (s, NO2), 1470, 1438 (w, CC), 1345 (s,
NO2), 1290, 1265 (w, C−N), 1087, 1055, 1026 (w, C−H), 793, 738,
685 (m, C−H) cm−1.
4-(6-(Benzyloxy)-3′-nitro-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-
amine (18b). Prepared as a yellow−brown foam (76 mg, 0.20 mmol,
70%) according to general procedure E. The crude product was
puriﬁed by ﬂash chromatography (0−5% v/v MeOH in DCM). LCMS
(ESI+): m/z 387.0 [M + H]+, retention time 2.07 min (94%). HRMS
(ESI+): m/z (calcd C22H19N4O3 [M + H]
+ = 387.1457), obsd
387.1456 (δ ppm = 0.3). 1H NMR (500 MHz, MeOD) δ 8.51 (app t, J
= 2.0, 2.0 Hz, 1H), 8.18 (ddd, J = 8.3, 2.0, 1.0 Hz, 1H), 7.97 (ddd, J =
8.0, 1.5, 1.0 Hz, 1H), 7.63 (app t, J = 8.0, 7.0 Hz, 1H, 16-CH), 7.52−
7.48 (m, 2H), 7.35 (m, 2H), 7.30−7.26 (m, 2H), 7.24 (d, J = 8.4 Hz,
1H), 5.15 (s, 2H) ppm. One aromatic 1H unresolved. 13C NMR (125
MHz, MeOD) δ 155.0, 152.8, 149.3, 141.6, 138.4, 136.9, 130.3, 130.2,
129.9, 129.5 (2C), 129.1, 128.48, 128.4, 128.3, 125.6, 122.6, 115.1,
71.8 ppm. IR (thin ﬁlm vmax 3415, 3325, 3193 (br, m, N−H), 3033,
2941, 2880 (w, C−H), 1613, 1578 (w, CC), 1525 (s, NO2), 1525
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(m), 1380 (s, NO2), 1287, 1260 (m, C−N, C−O), 1055, 1021 (w, C−
O), 890 (w), 811, 735, 688 (m) cm−1.
4-(6-Methoxy-3′-nitro-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine
(18c). Prepared as a yellow amorphous solid (165 mg, 0.53 mmol,
53%) according to general procedure E, except that the reactions was
carried out at 120 °C using conventional heating over 14 h. The crude
product was puriﬁed by ﬂash chromatography (0−5% v/v MeOH in
DCM), Rf 0.21 (10% v/v MeOH in DCM). LCMS (ESI+) m/z 311.2
[M + H]+, retention time 1.83 min (100%). HRMS (ESI+): m/z
(calcd C16H15N4O3 [M + H]
+ = 311.1144), obsd 311.1139 (δ ppm =
1.6). 1H NMR (500 MHz, MeOD) δ 8.41 (d, J = 2.2 Hz, 1H), 8.17 (d,
J = 8.2 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.68−7.55 (m, 2H), 7.51 (d,
J = 8.6 Hz, 1H), 7.47 (s, 1H), 7.14 (d, J = 8.5 Hz, 1H), 3.84 (s, 3H)
ppm. 13C NMR (125 MHz, MeOD) δ 156.0, 152.8, 149.4, 141.7,
136.9, 130.2, 129.9, 129.7, 129.2, 128.8, 127.7, 125.3, 122.6, 113.2,
109.2, 56.2 ppm. 13C NMR processed with LB = 3.0 Hz. IR (thin ﬁlm)
vmax 3421, 3182 (m, br, N−H), 2952 (m, C−H), 1613, 1577 (w, N−H,
CC), 1525 (s, NO2), 1348 (s, NO2), 1260 (m, C−O, C−N), 1181
(w, C−H), 1022 (m, C−O), 814, 747, 688 (m, C−H) cm−1.
4-(4′-Nitro-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine (18d). Pre-
pared according to general procedure E and crudely puriﬁed by elution
through a short silica plug (0−5% v/v MeOH in DCM) to remove
inorganic byproducts. The product mixture was then carried forward
with further puriﬁcation and characterization performed after
reduction of the aromatic nitro group. LCMS (ESI+): m/z 281.4
[M + H]+, retention time 3.89 min (52%).
4-(3-(Pyridin-3-yl)phenyl)-1H-pyrazol-5-amine (18e). Prepared
according to general procedure E. The crude product was puriﬁed
by ﬂash chromatography (0−5% v/v MeOH in DCM) to yield 18e
(0.030 g, 0.13 mmol, 61%). LCMS (ESI+): m/z 237.3 [M + H]+,
retention time 1.12 min (100%). 1H NMR (400 MHz, CDCl3): δ 8.84
(dd, J = 2.4, 0.8 Hz, 1H), 8.58 (dd, J = 4.9, 1.4 Hz, 1H), 7.86 (ddd, J =
7.9, 2.3, 1.7 Hz, 1H), 7.64 (m, 1H), 7.54 (s, 1H), 7.46 (m, 2H), 7.42
(m, 1H), 7.35 (ddd, J = 8.0, 4.8, 0.8 Hz, 1H), 5.65 (br s, 3H) ppm. 13C
NMR (100 MHz, CDCl3): δ 150.8, 148.5, 148.2, 138.5, 136.6, 134.6,
134.0, 129.7, 129.1, 126.4, 125.5, 124.8, 123.7, 108.2 ppm. IR (neat)
vmax 3365 (w, N−H), 3149 (w, br, N−H), 2932 (w, br, C−H), 1608
(m), 1506 (w), 1463 (m), 1400, 1380 (w), 1188, 1123, 1059, 1044,
1027 (w), 843 (m), 774, 708, 695 (s, C−H) cm−1.
4-(3-(Pyridin-4-yl)phenyl)-1H-pyrazol-5-amine (18f). Prepared
according to general procedure E. The crude product was puriﬁed
by ﬂash chromatography (0−5% v/v MeOH in DCM) to yield 18f
(0.014 g, 0.060 mmol, 29%). LCMS (ESI+): m/z 237.2 [M + H]+
(calcd for C14H12N4, 237.1), retention time 1.04 min (96%).
1H NMR
(500 MHz, MeOD): δ 8.58 (d, J = 1.6 Hz, 1H), 8.57 (d, J = 1.6 Hz,
1H), 7.87 (t, J = 1.6 Hz, 1H), 7.77 (d, J = 1.6 Hz, 1H), 7.76 (d, J = 1.6
Hz, 1H), 7.70 (s, 1H), 7.56−7.61 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H)
ppm. 13C NMR (125 MHz, MeOD) δ 151.3, 151.2, 150.3, 139.3,
135.9, 132.0, 128.5, 126.0, 125.3, 123.4, 108.2 ppm. one unresolved
quaternary 13C. IR (thin ﬁlm) vmax 3458, 3159 (m, br, N−H), 291 (m,
C−H), 1618 (m, CC), 1594 (s, N−H, C−H)), 1561 (m), 1508,
1402 (s, C−N), 1334, 1223, 1054, 1023 (m), 789, 701 (s, C−H) cm−1.
4-(3-(1H-Indol-5-yl)phenyl)-1H-pyrazol-5-amine (18g). Prepared
according to general procedure E. The crude product was puriﬁed by
ﬂash chromatography (0−5% v/v MeOH in DCM) to yield 18g
(0.029 g, 0.11 mmol, 50%). LCMS (ESI+): m/z 275.3 [M + H]+,
retention time 1.74 min (94%). HRMS (ESI+): m/z (calcd for
C17H15N4 [M + H]
+ = 275.1297), obsd 275.1297 (δ ppm = 0). 1H
NMR (500 MHz, MeOD): δ 7.82 (app s, 1H), 7.75 (app t, 1H), 7.65
(s, 1H), 7.37−7.49 (m, 5H), 7.25 (d, J = 3.1 Hz, 1H), 6.49 (d, J = 3.2
Hz, 1H) ppm. 13C NMR (125 MHz, MeOD) δ 151.2, 144.8, 137.3,
134.8, 133.7, 131.5, 130.1, 130.0, 126.4, 126.3, 125.6, 125.3, 122.0,
119.7, 112.4, 109.2, 102.8 ppm. IR (thin ﬁlm) vmax 3405, 3181 (m, br,
N−H), 2936 (m, C−H), 1602 (s), 1504, 1462, 1415, 1307 (m, CC,
N−H), 1016 (s), 879 (m), 787, 763, 728, 667 (s, C−H) cm−1.
4-(3-(1H-Indol-6-yl)phenyl)-1H-pyrazol-5-amine (18h). Prepared
according to general procedure E. The crude product was puriﬁed by
ﬂash chromatography (0−5% v/v MeOH in DCM) to yield 18h
(0.026 g, 0.095 mmol, 45%). LCMS (ESI+): m/z 275.3 [M + H]+,
retention time 1.82 min (100%). HRMS (ESI+): m/z (calcd C17H14N4
[M + H]+ = 275.1297), obsd 275.1288 (δ ppm = 3.3). 1H NMR (500
MHz, MeOD): δ 7.76 (app t, J = 1.8 Hz, 1H), 7.65−7.66 (m, 2H),
7.60 (dd, J = 8.3, 0.6 Hz, 1H), 7.49−7.33 (dt, J = 7.0, 1.8 Hz; 1H),
7.44 (m, 2H), 7.33 (dd, J = 8.2, 1.6 Hz, 1H), 7.25 (d, J = 3.2 Hz, 1H),
6.45 (dd, J = 3.2, 0.9 Hz, 1H) ppm. 13C NMR (125 MHz, MeOD): δ
151.1, 144.5, 138.3, 135.9, 134.8, 131.6, 130.2, 128.9, 126.4, 126.3,
125.7, 125.6, 121.4, 119.8, 110.6, 109.2, 102.2 ppm. IR (thin ﬁlm) vmax
3384 (s, N−H), 3175 (m, br, N−H), 1602 (s, N−H, CC), 1567,
1455 (s, CC), 1350, 1310 (m, C−N), 1227, 1198 (w), 1096, 1055,
1015 (m, C−N), 863 (m), 785, 722 (s, C−H) cm−1.
4-(3-(1H-Pyrazol-4-yl)phenyl)-1H-pyrazol-5-amine (18i). Prepared
according to general procedure E. The crude product was puriﬁed by
ﬂash chromatography (0−5% v/v MeOH in DCM) to yield 18i (0.012
g, 0.05 mmol, 37%). LCMS (ESI+): m/z 226.2 [M + H]+, retention
time 1.30 min (100%). HRMS (ESI+): m/z (calcd for C12H12N5 [M +
H]+ = 226.1093), obsd 226.1104 (δ ppm = 4.9). 1H NMR (400 MHz,
MeOD): δ 7.99 (s, 2H), 7.69 (s, 1H), 7.65 (s, 1H), 7.42 (dt, J = 7.0,
1.9 Hz, 1H), 7.39−7.30 (m, 2H) ppm. 13C NMR (100 MHz, MeOD):
δ 151.1, 135.1, 134.5, 131.6, 130.3, 125.5, 124.6, 123.9, 123.7, 108.9
ppm. One 13C signal unresolved. IR (neat) vmax 3131 (w, br, N−H),
2917 (w, C−H), 2547, 2358, 2247 (m, br), 1607, 1588 (m, N−H, C
C), 1503 (s), 1437, 1373, 1299 (w, C−N), 1034, 903 (m), 860, 787,
694, 667 (s, C−H) cm−1.
3-(4-Methoxyphenyl)-4-(3′-nitro-[1,1′-biphenyl]-3-yl)-1H-pyra-
zol-5-amine (23a). Prepared according to general procedure E. The
crude product was puriﬁed by ﬂash chromatography (0−5% v/v
MeOH in DCM) and then triturated with petroleum ether and DCM
to yield 23a as a cream-colored solid (434 mg, 1.12 mmol, 37%).
LCMS (ESI+) m/z 387.3 [M + H]+, retention time 2.08 min (100%).
HRMS (ESI+): m/z (calcd C22H19N4O3 [M + H]
+ = 387.1452), obsd
387.1443 (δ ppm = 2.2). 1H NMR (500 MHz, CDCl3) δ 8.30 (app t, J
= 2.0, 2.0 Hz, 1H), 8.17 (ddd, J = 8.2, 1.3, 1.0 Hz, 1H), 7.81 (ddd, J =
7.7, 1.6, 1.1 Hz, 1H), 7.57 (app t, J = 8.0, 8.0 Hz, 1H), 7.49 (m, 3H),
7.38 (app dt, J = 6.9, 2.0, 1.7 Hz, 1H), 7.30 (d, J = 8.9 Hz, 2H), 6.89
(d, J = 8.9 Hz, 2H), 3.82 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3)
δ 160.0, 153.0, 148.7, 142.6, 141.4, 139.2, 133.9, 133.0, 129.7, 129.3,
128.9, 128.2, 125.2, 122.3, 122.1, 122.0, 114.4, 105.3, 55.3 ppm. 13C
NMR processed with LB = 3 Hz. IR (thin ﬁlm) vmax 3500−3194 (w,
br, N−H), 3056, 2970, 2835 (w, C−H), 1605 (m, N−H), 1524, 1506
(s, NO2), 1436 (m, CC), 1347 (s, NO2, C−N), 1246 (s, C−N, C−
O), 1176 (s), 1119 (m), 1029 (m, C−O), 835, 795 (m C−H), 735,
721 (s, C−H) cm−1.
4-(6-(Benzyloxy)-3′-nitro-[1,1′-biphenyl]-3-yl)-3-(4-methoxy-
phenyl)-1H-pyrazol-5-amine (23b). Prepared according to general
procedure E. The crude product was puriﬁed by ﬂash chromatography
(0−5% v/v MeOH in DCM) to yield 23b as a brown amorphous solid
(459 mg, 0.93 mmol, 46%). LCMS (ESI+) m/z 493.3 [M + H]+,
retention time 2.28 min (100%). HRMS (ESI+): m/z (calcd
C29H25N4O4 [M + H]
+ = 493.1876), obsd 493.1890 (δ ppm = 2.8).
1H NMR (500 MHz, CDCl3) δ 8.29 (app t, J = 2.0, 1.9 Hz, 1H), 8.05
(ddd, J = 8.3, 2.3, 1.0 Hz, 1H), 7.70 (dt, J = 7.8, 1.5, 1.2 Hz, 1H), 7.41
(app t, J = 8.0, 8.0 Hz, 1H), 7.35 (m, 4H), 7.33−7.29 (m, 4H), 7.28
(m, 1H), 7.23 (m, 1H), 7.21 (m, 3H), 7.19 (s, 1H), 7.00 (d, J = 8.5
Hz, 1H), 6.81 (d, J = 8.8 Hz, 1H), 5.13 (s, 2H), 3.83 (s, 3H) ppm. 13C
NMR (125 Hz, CDCl3) δ 159.9, 154.2, 153.2, 148.0, 141.1, 139.7,
136.5, 135.6, 131.8, 130.7, 128.9, 128.8, 128.7, 128.6, 128.0, 127.1,
126.0, 124.7, 122.4, 121.8, 114.3, 113.5, 104.9, 70.6, 55.3 ppm. 13C
NMR processed with LB = 3 Hz. IR (thin ﬁlm) vmax 3422, 3337, 3202
(w, br, N−H), 2955, 2932, 2853 (w, C−H), 1614 (m), 1523 (s, NO2),
1348 (s, NO2), 1250 (s), 1178, 1028 (m, C−O), 835, 734, 690, 629
(m) cm−1.
General Procedure F. Reduction of Nitrophenyl Analogues
19a−d, 24a,b. 4-(3′-Amino-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-
amine (19a). Tin(II) chloride dihydrate (564 mg, 2.5 mmol) was
added to a solution of 4-(3′-nitro-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-
amine 18a (140 mg, 0.5 mmol) in absolute EtOH (50 mL). The
reaction was heated to 85 °C for 1.5−16 h until all starting material
had been consumed. The reaction was then concentrated under
reduced pressure (∼10 mL) and then diluted with EtOAc (50 mL),
brine (50 mL), and saturated sodium potassium tartrate solution (40
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mL). The product was extracted into EtOAc (2 × 20 mL), the
combined organic fractions were dried over anhydrous Na2SO4, and
the solvent removed under reduced pressure. The crude material was
puriﬁed by ﬂash chromatography (0−10% v/v MeOH in DCM) to
give 4-(3′-amino-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine 19a as a
yellow amorphous solid (63 mg, 0.25 mmol, 52%), Rf 021 (10% v/v
MeOH in DCM). LCMS (ESI+) m/z 251.2 [M + H]+, retention time
1.21 min (100%). HRMS (ESI+) m/z (calcd C15H15N4 [M + H]
+ =
251.1291), obsd 251.1284 (δ ppm = 2.9). 1H NMR (500 MHz,
MeOD3) δ 7.68 (d, J = 1.5 Hz, 1H), 7.63 (s, 1H), 7.42 (m, 3H), 7.17
(app t, J = 8.0, 7.5 Hz, 1H), 7.02 (app t, J = 2.0, 2.0 Hz, 1H), 6.98
(appdt, J = 7.5, 1.5, 1.0 Hz, 1H), 6.72 (ddd, J = 8.0, 2.3, 1.0 Hz, 1H)
ppm. 13C NMR (125 MHz, MeOD) δ 151.3 (br), 149.0, 143.5, 143.4,
135.0, 131.5 (br), 130.5, 130.1, 126.3, 126.1, 125.3, 118.2, 115.7, 115.2,
108.9 ppm. 13C NMR processed with LB = 3 Hz. IR (thin ﬁlm) vmax
3341, 3206 (m, br, NH2), 2972, 2940 (w, C−H), 1602 (s, N−H),
1506, 1475 (m, CC, N−H), 1314 (w, C−N), 1213 (w, C−N, C−
H), 1165, 1052 (w, C−H), 782, 700 (m, C−H) cm−1.
4-(3′-Amino-6-(benzyloxy)-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-
amine (19b). Prepared according to general procedure F. The crude
product was puriﬁed by ﬂash chromatography (0−10% v/v MeOH in
DCM) to yield 19b as a cream-colored solid (99 mg, 0.28 mmol,
58%), Rf 0.33 (10% v/v MeOH in DCM). LCMS (ESI+): m/z 357.2
[M + H]+, retention time 1.64 min (100%). HRMS (ESI+): m/z
(calcd C22H21N4O [M + H]
+ = 357.1715), obsd 357.1724 (δ ppm =
2.5). 1H NMR (500 MHz, acetone-d6) δ 10.99 (br, s, 2H), 7.62 (s,
1H), 7.47 (d, J = 2.4 Hz, 1H), 7.45−7.39 (m, 3H), 7.33 (app t, J = 7.6
Hz, 2H), 7.27 (t, J = 7.3 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 7.08 (app t,
J = 7.8 Hz, 1H), 6.95 (app t, J = 2.0 Hz, 1H), 6.86 (d, J = 7.6 Hz, 1H),
6.63 (dd, J = 7.7, 2.2 Hz, 1H), 5.12 (s, 2H), 4.58 (br, s, 2H), 4.32 (br,
s, 2H) ppm. 13C NMR (125 MHz, d6-acetone) δ 154.7, 151.3 (br),
149.2, 140.8, 139.1, 133.5, 129.8, 129.6, 129.5, 128.7, 128.6, 128.3,
127.2, 125.4 (br), 119.6, 117.1, 115.2, 114.2, 108.0 (br), 71.5 ppm. 13C
NMR spectrum processed with LB = 1−10 Hz. IR (thin ﬁlm) vmax
3334, 3196 (m, br, N−H), 3033, 2944 (m, C−H), 1602, 1584 (s, C
C), 1498, 1481, 1452 (m, CC), 1379 (s, C−N), 1280 (s, C−N),
1145 (w), 1021 (m, C−O), 871 (w), 787, 734 (m), 696, 655 (s) cm−1
4-(3′-Amino-6-methoxy-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-
amine (19c). Prepared according to general procedure F. The crude
product was puriﬁed by ﬂash chromatography (0−10% v/v MeOH in
DCM) to yield 19b as a white amorphous solid (103 mg, 0.38 mmol,
77%), Rf 0.34 (10% v/v MeOH in EtOAc). LCMS (ESI+) m/z 282.3
[M + H]+, retention time 1.30 min (100%). HRMS (ESI+): m/z
(calcd C16H17N4O [M + H]
+ = 281.1397), obsd 281.1388 (δ ppm =
3.3). 1H NMR (500 MHz, MeOD) δ 7.53 (s, 1H), 7.39 (dd, J = 8.4,
2.3 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.12 (app t, J = 7.8 Hz, 1H),
7.06 (d, J = 8.5 Hz, 1H), 6.91 (app t, J = 2.0 Hz, 1H), 6.86 (d appt, J =
7.6, 1.3 Hz, 1H), 6.69 (ddd, J = 7.9, 2.4, 1.0 Hz, 1H), 3.78 (s, 3H)
ppm. 13C NMR (125 MHz, MeOD) δ 156.2, 152.7, 148.1, 140.8,
132.9, 130.1, 129.5, 128.6 (br), 127.7, 127.2, 121.0, 118.1, 115.4, 113.2,
109.4, 56.2 ppm. IR (thin ﬁlm) vmax 3340, 3210 (m, br, N−H), 2953
(m, C−H), 1603, 1584 (s, N−H), 1500 (m, N−H, CC), 1482 (s,
N−H), 1454 (m, CC), 1282 (m, C−N), 1246 (s, C−N, C−O),
1380 (w, CH3), 1055, 1021 (m, C−O), 873 (w, C−H), 814, 798, 700
(m, C−H) cm−1.
4-(4′-Amino-[1,1′-biphenyl]-3-yl)-1H-pyrazol-5-amine (19d). Pre-
pared according to general procedure F. The crude product was
puriﬁed by ﬂash chromatography (0−8% v/v MeOH in DCM) to
yield 19d (0.005 g, 0.020 mmol, 10%, over two steps). LCMS (ESI+):
m/z 251.2 [M + H]+; retention time 1.30 min (100%). HRMS (ESI+):
m/z (calcd C15H15N4 [M + H]
+ = 251.1297), obsd 251.1300 (δ ppm =
1.2). 1H NMR (500 MHz, MeOD): δ 7.66−7.59 (m, 2H), 7.42 (d, J
8.6 Hz, 1H), 7.39−7.32 (m, 3H), 6.79 (d, J = 8.5 Hz, 2H) ppm. 13C
NMR (125 MHz, MeOD): δ 148.4, 143.2, 134.9, 132.2, 130.1, 128.7,
125.31, 125.28, 124.6, 116.8, 109.1 (br) ppm. Two 13C signals
unresolved, 13C NMR processed with LB = 1−12 Hz.
4-(3′-Amino-[1,1′-biphenyl]-3-yl)-3-(4-methoxyphenyl)-1H-pyra-
zol-5-amine (24a). Prepared according to general procedure F. The
crude product was puriﬁed by ﬂash chromatography (0−5% v/v
MeOH in DCM) to yield 24a as a brown amorphous solid (65 mg,
0.18 mmol, 22%). Impure fractions (157 mg), which contained
approximately 90% product, were also retained for use in subsequent
synthetic steps, with easier chromatographic puriﬁcation achieved after
deprotection of the aryl methyl ether; Rf 0.32 (10% v/v MeOH in
DCM). LCMS (ESI+) m/z 357.2 [M + H]+, retention time 1.60 min
(100%). HRMS (ESI+): m/z (calcd C22H21N4O [M + H]
+ =
357.1710), obsd 357.1698 (δ ppm = 3.5). 1H NMR (500 MHz,
MeOD) δ 7.43 (m, 2H), 7.37 (dd, J = 7.8, 7.5 Hz, 1H), 7.29 (d, J = 8.8
Hz, 2H), 7.20 (d, J = 7.6 Hz, 1H), 7.10 (app t, J = 7.8 Hz, 1H), 6.87
(m, 3H), 6.81 (d, J = 7.4 Hz, 1H), 6.68 (ddd, J = 7.9, 2.3, 1.0 Hz, 1H),
3.77 (s, 3H) ppm. 13C NMR (125 MHz, MeOD) δ 161.2, 154.4 (br),
149.0, 143.3, 143.2, 142.1 (br), 134.8, 130.5, 130.2, 130.1, 129.4, 129.3,
126.0, 123.8 (br), 118.1, 115.7, 115.1 (2C), 106.7 (br), 55.8 ppm. 13C
NMR processed with LB = 3 Hz. IR (thin ﬁlm) vmax 3341 (br, m, N−
H), 3207 (br, m, N−H), 2833 (w, C−H), 1601 (s, N−H, CC),
1520 (s, CC, N−H), 1506 (s, CC, N−H), 1436 (m, CC),
1290 (w, C−N), 1247 (s, C−O), 1178 (m, C−H), 1113 (m, C−H),
1029 (m, C−O), 972 (m), 834 (m, C−H), 783 (m, C−H), 701 (m,
C−H) cm−1.
4-(3′-Amino-6-(benzyloxy)-[1,1′-biphenyl]-3-yl)-3-(4-methoxy-
phenyl)-1H-pyrazol-5-amine (24b). Prepared according to general
procedure F. The crude product was puriﬁed by ﬂash chromatography
(0−5% v/v MeOH in DCM) to yield 24b as a brown amorphous solid
(370 mg, 0.80 mmol, 65%), Rf 0.16 (10% v/v MeOH in DCM).
LCMS (ESI+) m/z 463.3 [M + H]+, retention time 1.95 min (100%).
HRMS (ESI+) m/z (calcd C29H27N4O2 [M + H]
+ = 463.2134), obsd
463.2141 (δ ppm = 1.5). 1H NMR (500 MHz, MeOD) δ 7.33−7.27
(m, 6H), 7.23 (app t, J = 7.1 Hz, 1H), 7.13 (m, 2H), 7.08−7.04 (m,
2H), 6.89−6.82 (m, 3H), 6.80 (dt, J = 7.7, 1.2 Hz, 1H), 6.66 (ddd, J =
7.9, 2.3, 1.0 Hz, 1H), 5.03 (s, 2H), 3.75 (s, 3H) ppm. 13C NMR (125
MHz, MeOD) δ 161.1, 155.6, 154.4, 148.0, 141.8, 140.6, 138.8, 133.4,
133.2, 130.6, 130.1, 129.5, 129.4, 128.6, 128.2, 127.2, 123.9, 121.1,
118.1, 115.4, 115.3, 115.0, 106.3, 71.7, 55.8 ppm. 13C NMR processed
with LB = 3 Hz. IR (thin ﬁlm) vmax 3349, 3211 (br, w, N−H), 2929,
2833 (br, w, C−H), 1603 (s), 1585, 1507 (s, CC, C−H), 1453 (s),
1244, 1177 (s, C−N, C−O), 1024 (s, C−O), 833, 735, 696 (s, C−H)
cm−1.
General Procedure G. Reductive Amination Procedure (1) for
the Synthesis of Ar3 Analogues 26a−e. 4,4′-(5-((4-Hydroxybenzyl)-
amino)-1H-pyrazole-3,4-diyl)diphenol (26a). 4-Hydroxybenzalde-
hyde (83 mg, 0.68 mmol) and glacial acetic acid (72 μL, 1.4 mmol)
were added to a stirred solution of 4,4′-(5-amino-1H-pyrazole-3,4-
diyl)diphenol 5 (200 mg, 0.75 mmol) in DMF (0.5 mL) and DCE (7
mL). The reaction was stirred at room temperature for 20−60 min
then cooled to 0 °C, and Na(OAc)3BH (360 mg, 1.7 mmol) was
added as a single portion. The reaction was allowed to warm to room
temperature and stirred for 20 h. For some substrates, an additional
equivalent of Na(OAc)3BH was then added and the reaction was
stirred for a further 7 h at room temperature until all aldehyde had
been consumed. The reaction was then diluted with EtOAc (50 mL)
and water (10 mL) and brought to pH 7−8 using saturated NaHCO3
solution. The phases were separated, and the aqueous fraction was
extracted with EtOAc (2 × 5 mL). The combined organic fractions
were dried over anhydrous Na2SO4, and the solvent was removed
under reduced pressure. The crude material was puriﬁed by ﬂash
chromatography (50−100% EtOAc in petroleum ether) to yield 4,4′-
(5-((4-hydroxybenzyl)amino)-1H-pyrazole-3,4-diyl)diphenol 26a as a
cream-colored powder (184 mg, 0.49 mmol, 72%), Rf 0.13 (10% v/v
MeOH in DCM). LCMS (ESI+): m/z 374.2 [M + H]+, retention time
1.25 min (100%). HRMS (ESI+): m/z (calcd C22H20N3O3 [M + H]
+
= 374.1505), obsd 374.1495 (δ ppm = 2.7). 1H NMR (500 MHz,
MeOD) δ 7.19−7.11 (m, 4H), 7.01 (d, J = 8.5 Hz, 2H), 6.76 (d, J =
8.5 Hz, 2H), 6.70 (m, 4H), 4.24 (s, 2H) ppm. 13C NMR (125 MHz,
MeOD) δ 158.6, 157.5, 157.3, 156.1 (br), 142.3 (br), 132.3 (2 × CH),
129.9, 125.3, 123.1 (br), 116.7, 116.2, 116.1, 105.7 (br), 49.9 ppm.
One quaternary 13C signal obscured. 13C NMR processed with LB =
1−9 Hz. IR (thin ﬁlm) vmax 3270 (s, br, O−H, N−H), 2940 (w, C−
H), 1612, 1596 (m, CC), 1511 (s, N−H), 1441 (m, CC), 1370
(m), 1234 (s, C−O, C−N), 1171, 1102, 1011 (m, C−O), 834 (s, C−
H) cm−1.
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4,4′-(5-((3-Bromo-4-hydroxybenzyl)amino)-1H-pyrazole-3,4-
diyl)diphenol (26b). Prepared according to general procedure G. The
crude product was puriﬁed by ﬂash chromatography (50−100% v/v
EtOAc in petroleum ether) to yield 26b as a yellow solid (229 mg,
0.51 mmol, 74%), Rf 0.11 (10% v/v MeOH in DCM). LCMS (ESI+)
m/z 454.2 [M + H]+, retention time 1.59 min (92%). HRMS (ESI+):
m/z (calcd C22H19BrN3O3 [M + H]
+ = 452.0610), obsd 452.0603 (δ
ppm = 1.5). 1H NMR (500 MHz, MeOD) δ 7.41 (d, J = 2.1 Hz, 1H),
7.16 (d, J = 8.7 Hz, 2H), 7.10 (dd, J = 1.9, 8.4 Hz, 1H), 7.03 (d, J = 8.7
Hz, 2H), 6.80 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 8.6 Hz, 2H, 6.69 (d, J =
8.7 Hz, 2H), 4.24 (s, 2H) ppm. 13C NMR (125 MHz, MeOD) δ
158.6, 157.3, 155.5, 154.1, 142.6, 134.5, 133.2, 132.3, 129.9, 128.9,
125.2, 123.1, 117.0, 116.7, 116.2, 110.6, 105.8, 48.3 ppm. 13C NMR
processed with LB = 12.0 Hz. IR (thin ﬁlm) vmax) 3230 (br, s, N−H,
O−H), 2928 (m, C−H), 1651, 1612, 1590 (m, CC), 1527, 1494,
1432 (s, N−H), 1383, 1343 (m), 1255, 1233 (s, C−N, C−N), 1171
(m), 1105, 1010 (m, C−O), 835 (s, C−H), 666, 527 (m, C−Br) cm−1.
4,4′-(5-((Thiophen-3-ylmethyl)amino)-1H-pyrazole-3,4-diyl)-
diphenol (26c). Prepared according to general procedure G. The
crude product was puriﬁed by ﬂash chromatography (50−90% v/v
EtOAc in petroleum ether) to yield 26c as a white solid (156 mg, 0.43
mmol, 63%), Rf 0.33 (10% v/v MeOH in DCM). LCMS (ESI+) m/z
364.2 [M + H]+, retention time 1.71 min (100%). HRMS (ESI+): m/z
(calcd C20H18N3O2S [M + H]
+ = 364.1120), obsd 364.1107 (δ ppm =
3.6). 1H NMR (500 MHz, DMSO-d6DMSO-d6) δ 11.71 (s, br, 1H, 1-
NH), 9.50 (s, br, 1H), 9.30 (s, br, 1H), 7.45 (dd, J = 4.8, 2.8 Hz, 1H),
7.26 (d, J = 2.0 Hz, 1H), 7.10 (m, 3H), 6.98 (d, J = 8.4 Hz, 2H), 6.72
(d, J = 8.4 Hz, 2H), 6.68 (d, J = 8.4 Hz, 2H), 4.49 (s, br, 1H), 4.27 (d,
J = 4.27 Hz, 2H) ppm. 13C NMR (125 MHz, DMSO-d6) δ157.0,
155.6, 154.1, 142.7, 139.1, 130.7, 128.3, 128.0, 125.5, 123.9, 121.3,
115.6, 115.2, 103.5, 42.8 ppm. 13C NMR processed with LB = 3 Hz. IR
(thin ﬁlm) vmax 3306 (s, br, O−H, N−H), 3101, 2928, 2855 (w, C−
H), 1613, 1591 (m, CC), 1529, 1512 (s, C−N, C−O), 1436 (C
C),1375 (m), 1262, 1239 (s, C−N, C−O), 1172 (m, C−O), 836 (s,
C−H) cm−1.
4,4′-(5-((Furan-2-ylmethyl)amino)-1H-pyrazole-3,4-diyl)diphenol
(26d). Prepared according to general procedure G, however no AcOH
was added to the reaction and no NaHCO3 was used during reaction
workup. The crude product was puriﬁed by ﬂash chromatography
(50−90% v/v EtOAc in petroleum ether) to yield 26d as a yellow
amorphous solid (82 mg, 0.24 mmol, 38%), Rf 0.54 (10% v/v MeOH
in EtOAc). LCMS (ESI+) m/z 348.2 [M + H]+, retention time 1.54
min (100%). HRMS (ESI+): m/z (calcd C20H18N3O3 [M + H]
+ =
348.1348), obsd 348.1356 (δ ppm =2.3). 1H NMR (500 MHz,
MeOD) δ 7.38 (d, J = 1.8 Hz, 1H), 7.16 (d, J = 8.8 Hz, 2H), 7.01 (d, J
= 8.6 Hz, 2H), 6.78 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 8.8 Hz, 2H), 6.30
(m, 1H), 6.18 (d, J = 3.2 Hz, 1H), 4.33 (s, 2H) ppm. 13C NMR (125
MHz, MeOD) δ 158.6, 157.3, 155.6 (br), 154.9, 142.8, 142.2 (br),
132.3, 129.9, 125.1, 122.9 (br), 116.7, 116.2, 111.2, 107.6, 106.0 (br),
42.5 ppm, 13C NMR processed with LB = 6 Hz. IR (thin ﬁlm) vmax
3290 (s, br, N−H, O−H), 2935, 2816 (w, C−H), 1614 (m, CC),
1529, 1500 (s, N−H), 1434 (m), 1378, 1343 (w), 1261, 1238 (s, C−
N, C−O), 1172 (m, C−O), 1012 (w), 836 (s, C−H), 739 (m, furan,
C−H) cm−1.
4,4′-(5-(((1H-Indol-5-yl)methyl)amino)-1H-pyrazole-3,4-diyl)-
diphenol (26e). Prepared according to general procedure G. The
product was puriﬁed by two sequential ﬂash chromatography columns,
eluting with 0−5% v/v MeOH in DCM, followed by 50−100% v/v
EtOAc in petroleum ether, to yield 26e as a brown solid (52 mg, 0.13
mmol, 52%), Rf 0.14 (10% v/v MeOH in DCM). LCMS (ESI+) m/z
397.3 [M + H]+, retention time 1.53 min (100%). HRMS (ESI+): m/z
(calcd C24H21N4O2 [M + H]
+ = 397.1665), obsd 397.1653 (δ ppm =
3.0). 1H NMR (500 MHz, MeOD) δ 7.50 (d, J = 0.8 Hz, 1H), 7.31 (d,
J = 8.3 Hz, 1H), 7.19 (d, J = 3.2 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H),
7.09 (dd, J = 8.4, 1.7 Hz, 1H), 7.01 (d, J = 8.5 Hz, 2H), 6.75 (d, J = 8.6
Hz, 2H), 6.70 (d, J = 8.7 Hz, 2H), 4.41 (s, 2H) ppm. 13C NMR (125
MHz, MeOD) δ 158.6, 157.3, 156.4 (br), 142.1 (br), 137.0, 132.3,
131.7, 130.0, 129.5, 125.9, 125.3, 123.0 (br), 122.6, 120.4, 116.7, 116.2,
112.1, 105.7 (br), 102.3, 50.5 ppm. 13C NMR processed with LB = 6
Hz. IR (thin ﬁlm) vmax 3406 (s, br, N−H, O−H), 2927 (w, C−H),
1613, 1594 (m, CC), 1529, 1511 (s) 1451, 1435, 1349 (m), 1262,
1240 (s, C−O, C−N), 1172 (m, C−O), 837 (s, C−H), 731 (m) cm−1.
General Procedure H. Reduction Amination Procedure (2) For
the Synthesis of Ar3 Analogues 27a−b and 26f. 3,4-Bis(4-
methoxyphenyl)-N-(pyridin-4-ylmethyl)-1H-pyrazol-5-amine (27a).
Glacial AcOH (1 mL) was added to a suspension of 3,4-bis(4-
methoxyphenyl)-1H-pyrazol-5-amine 13a (222 mg, 0.75 mmol) and
pyridine-4-carbaldehyde (71 uL, 0.75 mmol) in dry MeOH (7.5 mL).
The reaction was stirred at room temperature for 30−90 min, and then
NaCNBH3 (47 mg, 0.75 mmol) was added as a single portion. The
reaction was stirred at room temperature for 14−24 h and then
concentrated under reduced pressure. The crude product was
redissolved in EtOAc (40 mL) and washed with water (10 mL) that
had been made basic with saturated NaHCO3 solution. The aqueous
phase was then extracted with EtOAc (2 × 10 mL), and the combined
organic fractions were washed with brine (5 mL). The solvent was
removed under reduced pressure to dry the product directly onto silica
gel. Flash chromatography (0−5% v/v MeOH in EtOAc) yielded 3,4-
bis(4-methoxyphenyl)-N-(pyridin-4-ylmethyl)-1H-pyrazol-5-amine
27a as a yellow amorphous solid (226 mg, 0.59 mmol, 78%), Rf 0.13
(5% v/v MeOH in EtOAc). LCMS (ESI+) m/z 386.6 [M + H]+,
retention time 1.49 min (100%). HRMS (ESI+) m/z (calcd
C23H23N4O2 [M + H]
+ = 387.1821), obsd 387.1819 (δppm = 0.5).
1H NMR (500 MHz, CDCl3) δ 8.53 (d, J = 5.5 Hz, 2H), 7.30 (d, J =
5.7 Hz, 2H), 7.22 (m, 4H), 6.91 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.9
Hz, 2H), 4.49 (s, 2H), 3.82 (s, 3H), 3.78 (s, 3H) ppm. 13C NMR (125
MHz, CDCl3) δ 159.8, 158.6, 154.8, 149.9, 140.8, 131.0, 128.7, 124.7,
122.5, 122.4, 114.6, 114.3, 104.7, 55.4 (2 ×C), 47.1 ppm. One
quaternary 13C signal unresolved. 13C NMR processed with LB = 1
Hz. IR (thin ﬁlm) vmax 3414 (br, w, N−H), 3001, 2934, 2835 (w, C−
H), 1604 (w), 1525, 1511 (s), 1461, 1361 (m), 1285 (s, C−N), 1245,
1032 (m, C−O), 834 (s), 801 (m) cm−1.
N-((1H-Imidazol-4-yl)methyl)-3,4-bis(4-methoxyphenyl)-1H-pyra-
zol-5-amine (27b). Prepared according to general procedure H. The
crude product was puriﬁed by ﬂash chromatography (0−20% v/v
MeOH in DCM) to yield 27b as a white amorphous solid (484 mg,
1.29 mmol, 95%). LCMS (ESI+) m/z 376.3 [M + H]+, retention time
1.61 min (100%). HRMS (ESI+): m/z (calcd C21H22N5O2 [M + H]
+
= 376.1773), obsd 376.1766 (δ ppm = 2.1). 1H NMR (500 MHz,
MeOD) δ 7.75 (br, d, J = 1.5 Hz, 1H), 7.24 (d, J = 8.8 Hz, 2H), 7.12
(d, J = 8.8 Hz, 2H), 7.00 (br, d, J = 0.9 Hz, 1H), 6.89 (d, J = 8.7 Hz,
2H), 6.84 (d, J = 8.8 Hz, 2H), 4.34 (s, 2H), 3.78 (s, 3H), 3.77 (s, 3H)
ppm. 13C NMR (125 MHz, MeOD) δ 161.0, 159.9, 155.2, 142.8,
137.2, 136.2, 132.2, 130.0, 126.3, 124.2, 118.2, 115.3, 114.9, 105.6,
55.7, 55.7, 42.0 ppm. 13C NMR processed with LB = 3 Hz. IR (thin
ﬁlm) vmax 3145 (w, br, N−H), 2902, 2835 (w, C−H), 1612, 1590 (w,
CC), 1526, 1511 (s, N−H), 1462 (m, CC), 1246 (s, C−O, C−
N), 1177, 1031 (m, C−O), 834 (m, C−H) cm−1.
4,4′-(5-(((1H-Indazol-4-yl)methyl)amino)-1H-pyrazole-3,4-diyl)-
diphenol (26f). Prepared according to general procedure H except
that 4,4′-(5-amino-1H-pyrazole-3,4-diyl)diphenol 5 was used as the
amine component. The crude product was puriﬁed by ﬂash
chromatography (80−100% v/v EtOAc in petroleum ether, followed
by 0−5% v/v MeOH in EtOAc) to yield 26f as a white solid (93 mg,
0.24 mmol, 47%), Rf 0.45 (10% v/v MeOH in EtOAc). LCMS (ESI+)
m/z 398.1 [M + H]+, retention time 1.48 min (100%). HRMS (ESI+):
m/z (calcd C23H20N5O2 [M + H]
+ = 398.1617), obsd 398.1612 (δ
ppm = 1.3). 1H NMR (500 MHz, MeOD) δ 8.11 (d, J = 1.0 Hz, 1H),
7.41 (d, J = 8.4 Hz, 1H), 7.30 (dd, J = 8.4, 6.9 Hz, 1H), 7.16 (d, J = 8.7
Hz, 2H), 7.09 (dd, J = 6.9, 1.0 Hz, 1H), 7.01 (d, J = 8.7 Hz, 2H), 6.75
(d, J = 8.6 Hz, 2H), 6.70 (d, J = 8.7 Hz, 2H), 4.72 (s, 2H) ppm. 13C
NMR (125 MHz, MeOD) δ 158.7, 157.3, 155.7 (br), 142.8 (br),
141.9, 134.9, 133.7, 132.3, 129.9, 127.9, 125.2, 123.1, 123.0 (br), 116.7,
116.2, 109.9, 105.7, 47.6 (br) ppm. 13C NMR processed with LB = 1−
12 Hz. IR (solid) vmax 3432, 3443 (m, N−H, O−H), 2986, 2797, m,
C−H), 1612, 1589 (m, CC), 1528, 1509 (s, CC, N−H), 1450,
1383, 1262, 1240 (s, C−O, C−N), 1173, 1086, 1003 (m, C−O, C−
N), 949 (m), 821 (s, C−H), 777, 739 (m, C−H) cm−1.
Procedures for the Synthesis of Pyrazol-5-yl-benzamide Ana-
logues 28a−c. N-(3,4-Bis(4-methoxyphenyl)-1H-pyrazol-5-yl)-
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benzamide (28a). Benzoyl chloride (31 μL, 0.263 mmol) and
triethylamine (42 μL, 0.3 mmol) were added sequentially to a stirred
solution of 3,4-bis(4-methoxyphenyl)-1H-pyrazol-5-amine 13a in
anhydrous DCM (1.25 mL) at 0 °C. The reaction was stirred at 0
°C for 5 min and then allowed to warm to room temperature and
stirred for 3.5 h. The reaction was then diluted with DCM (10 mL),
washed with water (3 mL) and brine (3 mL), and the solvent removed
under reduced pressure. The crude product was puriﬁed by ﬂash
chromatography (0−5% v/v MeOH in DCM) to yield 28a as a white
solid (31 mg, 0.08 mmol, 31%), Rf 0.16 (5% v/v MeOH in DCM).
LCMS (ESI+) m/z 400.2 [M + H]+, retention time 2.03 min (100%).
HRMS (ESI+): m/z (calcd C24H22N3O3 [M + H]
+ = 400.1661), obsd
400.1662 (δ ppm = 0.2). 1H NMR (500 MHz, DMSO-d6) δ 13.00 (s,
1H), 9.95 (s, 1H), 7.88 (d, J = 6.3 Hz, 2H), 7.56 (app t, J = 7.5, 6.9 Hz,
1H), 7.47 (appt, J = 7.5, 6.9 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.14 (d,
J = 8.4 Hz, 2H), 6.96 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H),
3.76 (s, 3H), 3.69 (s, 3H) ppm. 13C NMR (125 MHz, DMSO-d6) δ
166.8, 159.1, 157.9, 144.2, 139.3, 134.0, 131.6, 130.3, 128.6, 128.4,
127.5, 124.6, 122.1, 114.2, 113.8, 113.7 (partially obscured), 55.2, 54.9
ppm. 13C NMR processed with LB = 3 Hz. IR (thin ﬁlm) vmax 3216
(w, br, N−H), 3004, 2932, 2836 (w, C−H), 1657 (m, CO), 1602,
1579 (m, CC), 1509 (s, N−H), 1463 (m, CC), 1247 (s, C−N),
1178, 1027 (m, C−O), 835 (m, C−H), 7−9 (m) cm−1.
N-(3,4-Bis(4-methoxyphenyl)-1H-pyrazol-5-yl)-4-methoxybenza-
mide (28b). 4-Methoxybenzoyl chloride (90 mg, 0.525 mmol) and
triethylamine (84 μL, 0.6 mmol) were added sequentially to a stirred
solution of 3,4-bis(4-methoxyphenyl)-1H-pyrazol-5-amine 13a in
anhydrous DCM (2.5 mL) at 0 °C. The reaction was stirred at 0
°C for 5 min and then allowed to warm to room temperature and
stirred for 5 h. The reaction was then diluted with DCM (10 mL),
washed with water (5 mL) and brine (5 mL), dried over anhydrous
MgSO4, and the solvent removed under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography (80−100% v/v EtOAc
in petroleum ether) to yield 28b as an orange solid (58 mg, 0.13
mmol, 27%), Rf 0.49 (5% v/v MeOH in EtOAc). LCMS (ESI+) m/z
430.3 [M + H]+, retention time 2.02 min (100%). HRMS (ESI+) m/z
(calcd C25H24N3O4 [M + H]
+ = 430.1767), obsd 430.1778 (δ ppm =
2.6). 1H NMR (500 MHz, DMSO-d6) δ 12.98 (s, 1H), 9.80 (s, 1H),
7.88 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.8 Hz,
2H), 7.01 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 7.1 Hz, 2H), 6.83 (d, J = 8.2
Hz, 2H), 3.81 (s, 3H), 3.76 (s, 3H), 3.69 (s, 3H) ppm. 13C NMR (125
MHz, DMSO-d6) δ 166.3, 161.9, 159.1, 157.9, 144.5, 139.3, 130.4,
129.6, 128.7, 126.2, 124.7, 122.2, 114.2, 113.8, 113.7, 55.5, 55.2, 55.0
ppm. One quaternary 13C peak obscured. 13C NMR processed with LB
= 3 Hz. IR (solid) vmax 3294, 3154 (w, br, N−H), 2938, 2837 (w, C−
H), 1738, 1669, 1644, 1605 (w, CC), 1501 (m, N−H, C−H), 1241,
1177 (s, C−N, C−O), 1019 (m), 961 (w), 834 (s, C−H), 759, 693
(w, C−H) cm−1
N-(3,4-Bis(4-methoxyphenyl)-1H-pyrazol-5-yl)isonicotinamide
(28c). Isonicotinic acid (38 mg, 0.31 mmol) was suspended in
anhydrous DCM (2 mL). The solution was cooled to 0 °C, and oxalyl
chloride (29 μL, 0.34 mmol) was added along with a catalytic amount
of DMF. The reaction was allowed to come to room temperature and
stirred for 2 h. The volatiles were removed under reduced pressure,
and the resulting residue was resuspended in anhydrous DCM (1.25
mL). The solution was cooled to 0 °C and the aminopyrazole 5 (74
mg, 0.25 mmol) was added, followed by Et3N (122 μL, 0.875 mmol).
The reaction was stirred at 0 °C for 1 h, then allowed to warm to room
temperature and stirred overnight or until all of the aminopyrazole had
been consumed. The reaction was then diluted with DCM (20 mL),
washed with water (5 mL), then brine (3 mL), dried over anhydrous
MgSO4, and the solvent evaporated under reduced pressure. The
crude product was puriﬁed by silica gel chromatography (0−10%
MeOH in DCM) to yield 30 as a white solid (34 mg, 0.086 mmol,
34%), Rf 0.20 (10% v/v MeOH in DCM). LCMS (ESI+): m/z 401.2
[M + H]+, retention time 1.76 min (98%). HRMS (ESI+): m/z (calcd
C23H21N4O3 [M + H]
+ = 401.1614), obsd 401.1617 (δ ppm = 0.7). 1H
NMR (500 MHz, CDCl3) δ 8.76 (d, J = 4.8 Hz, 2H), 8.23 (s, 1H),
7.59 (d, J = 4.4 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.1 Hz,
2H), 6.95 (d, J = 8.2 Hz, 2H), 6.83 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H),
3.79 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3) δ 163.7, 159.7, 159.2,
151.0, 145.9 (br), 140.2, 138.6 (br), 131.0, 129.1, 124.2 (br), 123.7,
120.9, 115.0, 114.1, 108.0 (br), 55.4, 55.4 ppm. 13C NMR processed
with LB = 6 Hz. IR (thin ﬁlm) vmax 3219 (w, br, N−H), 2967, 2836,
2371 (w, C−H) 1663 (m), 1613 (w), 1525, 1508, 1297 (m, CC),
1248 (s, C−N), 1025 (w, C−O), 835 (m) cm−1.
General Procedure I. Deprotection of Aryl-methyl Ethers to
Synthesize Analogues 5, 14b−c, 25a−b, 26g−h, and 29a−c. 4,4′-
(5-Amino-1H-pyrazole-3,4-diyl)diphenol (5). A solution of 1 M BBr3
in DCM (21 mL, 21 mmol) was added dropwise over a period of 30
min to a stirred solution of 3,4-bis(4-methoxyphenyl)-1H-pyrazol-5-
amine 13a (886 mg, 3.0 mmol) in anhydrous DCM (75 mL) at 0 °C.
The reaction was stirred at 0 °C for 3.5−24 h, or until all starting
material had been consumed. The reaction was quenched with
saturated NaHCO3 at 0 °C, and the resulting precipitate was extracted
into EtOAc (50 mL). The organic phase was collected, and the
aqueous phase was re-extracted with EtOAc (3 × 25 mL). The organic
fractions were combined, washed with brine (5 mL), dried over
anhydrous MgSO4 or Na2SO4, and the solvent removed under reduced
pressure. The crude product was puriﬁed by ﬂash chromatography (0−
10% v/v MeOH in DCM) to yield 4,4′-(5-amino-1H-pyrazole-3,4-
diyl)diphenol 5 as a pale-brown solid (795 mg, 2.97 mmol, 99%), Rf
0.27 (10% v/v MeOH in EtOAc). LCMS (ESI+): m/z 269.2 [M +
H]+; retention time 1.19 min (100%). HRMS (ESI+): m/z (calcd
C15H14N3O2 [M + H]
+ = 268.1086), obsd 268.1075 (δ ppm = 4.1). 1H
NMR (500 MHz, DMSO-d6) δ 11.64 (br, s, 1H), 9.52 (br, s, 1H), 9.30
(s, 1H), 7.10 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.2 Hz, 2H), 6.71 (d, J =
8.4 Hz, 2H), 6.67 (d, J = 8.4 Hz, 2H) ppm. 13C NMR (125 MHz,
DMSO-d6) δ 156.8, 155.4, 153.1, 139.0, 130.5, 128.3, 124.2, 121.9,
115.5, 115.2, 103.8 ppm. 13C NMR processed with LB = 12 Hz. IR
(thin ﬁlm) vmax 3500−2700 (br, O−H, N−H), 2797, 2670, 2591 (w),
1613 (m), 1513 (s), 1488, 1435 (m), 1374 (w), 1261, 1234 (s), 1172
(m), 1101 (w), 1028, 969 (w), 834 (s), 756 (w) cm−1.
3-(5-Amino-4-(4-hydroxyphenyl)-1H-pyrazol-3-yl)phenol (14b).
Prepared according to general procedure I as a pale-brown foam in
quantitative yield (157 mg, 0.5 mmol) and used without further
puriﬁcation. LCMS (ESI+) m/z 268.2 [M + H]+, retention time 1.25
min (95%). HRMS (ESI+) m/z (calcd C15H14N3O2 [M + H]
+ =
268.1086), obsd 268.1075 (δ ppm = 4.1). 1H NMR (500 MHz,
MeOD) δ 7.11 (app t, J = 7.9, 7.9 Hz, 1H), 7.07 (d, J = 8.6 Hz, 2H),
6.82 (ddd, J = 8.7, 1.2, 1.0 Hz, 1H), 6.79 (m, 3H), 6.71 (ddd, J = 8.2,
2.6, 1.0 Hz, 1H) ppm. 13C NMR (125 MHz, MeOD) δ 158.5, 157.3,
153.0, 143.3, 133.3, 132.0, 130.5, 125.0, 119.9, 116.7, 116.1, 115.5,
106.6 ppm. 13C NMR spectrum processed with LB = 3 Hz. IR (thin
ﬁlm) vmax 3396−3290 (w, br, O−H, N−H), 2923, 2853 (s, C−H),
1714, 1606, 1579 (w), 1455 (m), 1377 (w), 1260 (m, C−N), 1097,
1030 (m, C−O), 874 (w), 802 (m) cm−1.
4-(5-Amino-3-(3-ﬂuorophenyl)-1H-pyrazol-4-yl)phenol (14c).
Prepared according to general procedure I, except that only 3.5
equiv of 1.0 M BBr3 in DCM were used. The crude product was
puriﬁed by ﬂash chromatography (0−10% v/v MeOH in DCM) to
yield 14c as a cream-colored amorphous solid (255 mg, 0.95 mmol,
95%), Rf 0.22 (10% v/v MeOH in DCM). LCMS (ESI+) m/z 270.2
[M + H]+, retention time 1.56 min (100%). HRMS (ESI+): m/z
(calcd C15H13FN3O [M + H]
+ = 270.1037), obsd 270.1024 (δ ppm =
1.9). 1H NMR (500 MHz, MeOD) δ 7.28 (m, 1H), 7.15 (d, J = 7.7
Hz, 1H), 7.06 (m, 3H), 6.98 (app t, J = 10.0 Hz, 1H), 6.81 (d, J = 8.6
Hz, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 164.1 (JC−F = 242.8
Hz), 157.6, 154.8 (br), 140.1 (br), 133.8, 132.5, 131.3, 124.6, 124.3,
116.8, 115.6, 115.0 (JC−F = 22.5 Hz), 107.7 ppm.
13C NMR processed
with LB = 12 Hz. IR (thin ﬁlm) vmax 3300 (br, m, O−H, N−H), 2962,
2936, 2856, 2794 (w, C−H), 1614, 1578, 1524 (s, CC), 1488, 1445
(m), 1265, 1236, 1215 (s, C−N), 1171 (m, C−O)), 867, 838, 788,
686 (m) cm−1.
4-(5-Amino-4-(3′-amino-[1,1′-biphenyl]-3-yl)-1H-pyrazol-3-yl)-
phenol (25a). Prepared according to general procedure I, except that
only 3.5 equiv of 1.0 M BBr3 in DCM were used. The crude product
was puriﬁed by ﬂash chromatography (2−10% v/v MeOH in DCM)
to yield 25a as a brown amorphous solid (30 mg, 0.089 mmol, 50%),
Rf 0.05 (10% v/v MeOH in DCM). LCMS (ESI+) m/z 343.3 [M +
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H]+, retention time 1.37 min (100%). HRMS (ESI+): m/z (calcd
C21H19N4O [M + H]
+ = 343.1553), obsd 343.1541 (δ ppm = 3.6). 1H
NMR (500 MHz, MeOD) 7.46−7.40 (m, 2H), 7.38 (app t, J = 7.6 Hz,
1H), 7.22 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 8.6 Hz, 2H), 7.11 (app t, J =
7.7 Hz, 1H), 6.86 (s, 1H), 6.83 (d, J = 7.7 Hz, 1H), 6.75 (d, J = 8.6 Hz,
2H), 6.68 (dd, J = 8.0, 2.2 Hz, 1H) ppm. 13C NMR (125 MHz,
MeOD) δ 158.9, 154.2 (br), 149.0, 143.2, 142.4 (br), 134.9, 130.4,
130.3, 130.1, 129.8, 129.43, 129.35, 125.8, 122.7 (br), 118.1, 116.4,
115.7, 115.2, 106.4 ppm. 13C NMR processed with LB = 6 Hz. IR
(thin ﬁlm) vmax 3341, 3206 (br, m, N−H, O−H), 2984 (m, C−H),
1604 (s, N−H, CC), 1522, 1505 (CC), 1470 (m, CC), 1266,
1242 (C−O), 1173 (w, C−H), 837 (m, C−H), 786 (m, C−H), 701
(m, C−H) cm−1.
3′-Amino-5-(5-amino-3-(4-hydroxyphenyl)-1H-pyrazol-4-yl)-
[1,1′-biphenyl]-2-ol (25b). Prepared according to general procedure I.
The crude product was puriﬁed by ﬂash chromatography (0−10% v/v
MeOH in DCM) to yield 25b as a white solid (25 mg, 0.07 mmol,
46%), Rf 0.07 (10% v/v MeOH in DCM). LCMS (ESI+) m/z 359.2
[M + H]+, retention time 1.21 min (100%). HRMS (ESI+) m/z (calcd
C21H19N4O2 [M + H]
+ = 359.1508), obsd 359.1505 (δ ppm = 0.8). 1H
NMR (500 MHz, MeOD) δ 7.21 (d, J = 8.7 Hz, 2H), 7.12−7.06 (m,
2H), 7.04 (dd, J = 8.2, 2.2 Hz, 1H), 6.91−6.85 (m, 2H), 6.82 (d. app t,
J = 7.6, 1.4 Hz, 1H), 6.75 (d, J = 8.7 Hz, 2H), 6.66 (ddd, J = 7.9, 2.3,
1.0 Hz, 1H) ppm. 13C NMR (125 MHz, MeOD) δ 158.7, 154.3 (br),
154.0, 148.1, 142.1 (br), 140.8, 133.2, 130.6, 130.1, 129.7, 125.7, 123.6
(br), 120.7, 117.9, 117.4, 116.3, 115.3, 106.0 (br) ppm. One
quaternary 13C signal obscured by peaks 130−129 ppm. 13C NMR
processed with LB = 3 Hz. IR (thin ﬁlm) vmax 3374−3200 (br, s, O−H,
N−H), 1612, 1510 (s, CC), 1442, 1399 (m, C−N), 1268 (s, C−N),
1174 (m, C−O), 1111, 1032 (w, C−O), 836 (s), 700 (w) cm−1.
4,4′-(5-((Pyridin-4-ylmethyl)amino)-1H-pyrazole-3,4-diyl)-
diphenol (26g). Prepared according to general procedure I, except
that the reaction was allowed to warm to room temperature and stirred
for 2 h before being quenched with saturated NaHCO3 solution. The
crude product was puriﬁed by ﬂash chromatography (0−10% v/v
MeOH in DCM) to yield 26g as a white solid (51 mg, 0.14 mmol,
61%), Rf 0.10 (10% v/v MeOH in DCM). LCMS (ESI+) m/z 359.2
[M + H]+, retention time 1.65 min (100%). HRMS (ESI+) m/z (calcd
C21H19N4O2 [M + H]
+ = 359.1508), obsd 359.1508 (δppm = 0.0). 1H
NMR (500 MHz, DMSO-d6) δ 11.63 (s, 1H), 9.54 (s, br, 1H), 9.32 (s,
br, 1H), 8.44 (d, J = 6.0 Hz, 2H), 7.32 (d, J = 5.6 Hz, 2H), 7.08 (d, J =
8.4 Hz, 2H), 7.03 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 6.67
(d, J = 8.4 Hz, 2H), 5.21 (t, J = 5.6 Hz, 1H), 4.31 (d, J = 6.0 Hz, 2H)
ppm. 13C NMR (125 MHz, DMSO-d6) δ 155.7, 155.8, 153.9, 151.3,
149.2, 139.2, 130.8, 128.4, 123.8, 122.5, 121.4, 115.6, 115.3, 103.4, 46.1
ppm. 13C NMR processed with LB = 2.0 Hz. IR (solid) vmax 3629,
2414, 3210 (w, N−H, O−H), 2905, 2585 (w, C−H), 1602, 1575 (m,
CC), 1537, 1513, 1479 (s, N−H, C−H), 1437, 1418 (m), 1385 (w,
C−O), 1246 (s, C−O, C−N), 1157 (m, C−O), 1026, 1006 (m), 835
(s, C−H) 799, 661 (m) cm−1.
4,4′-(5-(((1H-Imidazol-4-yl)methyl)amino)-1H-pyrazole-3,4-diyl)-
diphenol (26h). Prepared according to general procedure I. The crude
product was puriﬁed by ﬂash chromatography (1−20% v/v MeOH in
DCM) to yield 26h as a white solid (118 mg, 0.34 mmol, 68%). LCMS
(ESI+) m/z 348.2 [M + H]+, retention time 1.26 min (100%). HRMS
(ESI+): m/z (calcd C19H18N5O2 [M + H]
+ = 348.1461), obsd
348.1468 (δ ppm = 2.0). 1H NMR (500 MHz, MeOD) δ 7.60 (d, J =
1.2 Hz, 1H), 7.16 (d, J = 8.7 Hz, 2H), 7.02 (d, J = 8.6 Hz, 2H), 6.94
(d, J = 1.2 Hz, 1H), 6.76 (d, J = 8.6 Hz, 2H), 6.70 (d, J = 8.7 Hz, 2H),
4.31 (s, 2H, 14-CH2) ppm.
13C NMR (125 MHz, MeOD) δ 158.7,
157.3, 155.3 (br), 142.8 (br), 137.3, 136.2, 132.2, 129.9, 125.1, 123.1,
118.2 (br), 116.7, 116.2, 105.8, 41.9 ppm. 13C NMR processed with
LB = 3 Hz. IR (thin ﬁlm) vmax 3228 (s, br, O−H, N−H), 2929 (m, br,
C−H), 2471 (m), 1613, 1589 (m, CC), 1527, 1511 (s), 1445, 1379
(m, br, C−N), 1260 (s, br, C−N), 1171, 1104 (m, C−O), 974 (m),
836 (s), 739 (w) cm−1.
N-(3,4-Bis(4-hydroxyphenyl)-1H-pyrazol-5-yl)benzamide (29a).
Prepared as a tan powder (43 mg, 0.105 mmol, quant) according to
general procedure I. No chromatographic puriﬁcation was required.
LCMS (ESI+) m/z 372.2 [M + H]+, retention time 1.58 min (100%).
HRMS (ESI+): m/z (calcd C22H18N3O3 [M + H]
+ = 372.1348), obsd
372.1344 (δ ppm = 1.1). 1H NMR (500 MHz, MeOD) δ 7.87 (d, J =
7.7 Hz, 2H), 7.56 (t, J = 7.4 Hz, 1H), 7.47 (app t, J = 7.6 Hz, 2H), 7.24
(d, J = 8.6 Hz, 2H), 7.10 (d, J = 8.1 Hz, 2H), 6.76 (d, J = 8.7 Hz, 2H),
6.71 (d, J = 8.6 Hz, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 170.8,
159.0, 157.5, 145.1 (br), 142.4 (br), 135.2, 133.1, 131.9, 130.2, 129.6,
128.7, 124.5, 122.5 (br), 116.4, 116.3, 115.7 (br) ppm. 13C NMR
processed with LB = 12 Hz. IR (thin ﬁlm) vmax 3254 (s, br, O−H, N−
H), 2973, 2927 (w, C−H), 1656 (m, CO), 1614 (m, CC), 1510
(s, br, N−H), 1439 (m, CC), 1371 (m), 1263 (s, br, C−O, C−N),
1173 (m, C−O), 836 (m, C−H), 710 (w) cm−1.
N-(3,4-Bis(4-hydroxyphenyl)-1H-pyrazol-5-yl)-4-hydroxybenza-
mide (29b). Prepared according to general procedure I. The crude
product was puriﬁed by ﬂash chromatography (1−10% v/v MeOH in
DCM) to yield 29b as a cream-colored amorphous solid (29 mg, 0.074
mmol, 81%). LCMS (ESI+) m/z 372.2 [M + H]+, retention time 1.59
min (100%). HRMS (ESI+) m/z (calcd C22H18N3O4 [M + H]
+ =
388.1297), obsd 388.1286 (δ ppm = 2.8). 1H NMR (500 MHz,
MeOD) δ 7.76 (d, J = 8.4 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H), 7.09 (d, J
= 8.8 Hz, 2H), 6.83 (d, J = 8.4 Hz, 2H), 6.75 (d, J = 8.4 Hz, 2H), 6.71
(d, J = 8.8 Hz, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 170.4,
162.5, 158.9, 157.48, 144.8 (br), 143.0 (br), 131.9, 130.9, 130.2, 125.9,
124.6, 122.8 (br), 116.4, 116.3, 116.1, 115.5 (br) ppm. 13C-NMR
processed with LB = 12 Hz. IR (thin ﬁlm) vmax 3204 (br, m, O−H, N−
H), 1648, 1607, 1587 (m, CC), 1529 (s), 1441 (m), 1261, 1236,
1172 (s, C−N, C−O), 1022, 1010 (w, C−O), 837 (m), 764 (w) cm−1
N-(3,4-Bis(4-hydroxyphenyl)-1H-pyrazol-5-yl)isonicotinamide
(29c). Prepared according to general procedure I, except that 1.0 M
BBr3 in DCM was added at −78 °C and then the reaction was allowed
to warm slowly to 0 °C and then stirred overnight at room
temperature. The crude product was puriﬁed by ﬂash chromatography
(1−10% v/v MeOH in EtOAc) to yield 29c as an oﬀ-white solid (42.3
mg, 0.114 mmol, 87%). LCMS (ESI+) m/z 373.2 [M + H]+, retention
time 1.30 min (98%). HRMS (ESI+): m/z (calcd C21H17N4O3 [M +
H]+ = 373.1301), obsd 373.1306 (δ ppm = 1.3). 1H NMR (500 MHz,
MeOD) δ 8.72 (s, br, 2H), 7.82 (d, J = 4.5 Hz, 2H), 7.23 (d, J = 8.5
Hz, 2H), 7.08 (d, J = 8.5 Hz, 2H), 6.76 (d, J = 8.5 Hz, 2H), 6.72 (d, J
= 8.5 Hz, 2H) ppm. 13C NMR (125 MHz, MeOD) δ 168.3, 159.1,
157.7, 150.9, 143.6 (br), 143.0 (br), 131.9, 130.2, 124.3, 123.2, 122.4
(br), 116.5, 116.4, 115.6 (br) ppm. One quaternary 13C signal
unresolved. 13C NMR processed with LB = 6 Hz. IR (thin ﬁlm) vmax
3440−3230 (br, s, O−H, N−H), 1666, 1614 (m), 1526, 1508 (C
C), 1415 (m), 1264 (s, C−N), 1175 (m, C−O), 837 (s), 751, 685 (w)
cm−1
Molecular Biology, Biophysical, and Biochemical Methods.
Expression and Puriﬁcation of CYP121. The CYP121 (Rv2276) gene
was expressed using a pHAT2/CYP121 expression clone in Escherichia
coli C41(DE3) cells as the His6-tagged construct, following previously
described conditions,7,27 with minor modiﬁcations. Expression was
typically performed on a 10 × 1 L scale. C41 (DE3) E. coli cells were
transformed with pHAT/CYP121 and cultured overnight in LB
medium containing ampicillin (100 mg/L). Expression cultures of
terriﬁc broth (TB) medium containing ampicillin (100 mg/L) were
inoculated using an overnight culture of the transformant cells (0.4%
v/v) and grown at 37 °C, 200 rpm until an OD600 = 0.5−0.6, at which
point the temperature was reduced to 23 °C. CYP121 gene expression
was induced with IPTG (0.15 mM), and heme synthesis was
supported with δ-aminolevulinic acid (0.1 mM). Cultures were
incubated for 24 h, and then cells were harvested by centrifugation
(9000g, 4 °C, 20 min) and stored at −20 °C until puriﬁcation. Pellets
were defrosted and resuspended in chilled 50 mM potassium
phosphate buﬀer (pH 8.0), containing 50 mM KCl, 10%v/v glycerol,
and commercial protease inhibitors (cOmplete EDTA-free protease
inhibitor cocktail tablets, Roche (1 tablet/50 mL), PMSF (1 mM), and
benzamidine hydrochloride (1 mM)) (buﬀer A). Cells were lysed by
sonication at 0 °C (30 s on/60 s oﬀ, 12 cycles) using a Sonics Vibra-
Cell 505 sonicator (Sonics and Materials Inc., CT, USA). Cell debris
was pelleted by centrifugation (40000g, 30 min, 4 °C), and the
supernatant was immediately loaded onto a freshly recharged HisTrap
FF aﬃnity column (GE Healthcare, Little Chalfont UK). Aﬃnity
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chromatography was performed using an ÄKTA puriﬁer (GE
Healthcare) at 18 °C. Protein and P450 heme absorbance (A280 and
A417, respectively) were monitored, and CYP121 was eluted with a
linear gradient of imidazole (0−200 mM) in buﬀer A. The purity of
fractions collected was assessed by SDS-PAGE. Pure fractions were
combined and dialyzed into 50 mM Tris-HCl (pH 7.2), containing
500 mM KCl and 1 mM EDTA (buﬀer B) over 24−48 h using a Slide-
A-Lyser (ThermoScientiﬁc, Hemel Hempstead UK) dialysis cassette.
Dialyzed protein was concentrated using a Vivaspin (10000 MWCO)
ultraﬁltration column at 6000g, 4 °C, and then stored at −80 °C until
further use. Impure protein fractions were pooled, dialyzed into buﬀer
A to remove imidazole, and repuriﬁed by a second HisTrap FF aﬃnity
column, as described above. Protein concentration and purity was
determined by SDS-PAGE and amino acid analysis (Protein and
Nucleic Acid Chemistry Facility [PNAC], Department of Biochem-
istry, University of Cambridge). Repeated aﬃnity chromatography
steps meant that the previously cited anion exchange and gel ﬁltration
chromatography steps were not required to obtain suﬃciently pure
protein.
Expression and Puriﬁcation of Mtb CYP125, CYP126, CYP142,
CYP143, and CYP144. Plasmid vectors encoding N-terminal His6-
tagged CYP125 (pET15b/Rv3545c) and CYP126 (pET15b/Rv0778)
were provided by Dr. Kirsty McLean (Manchester Institute of
Biotechnology, University of Manchester). CYP1257 and
CYP12627,68 proteins were expressed and puriﬁed in E. coli
C41(DE3) cells according to the literature. CYP142,53 CYP143, and
CYP144-TRV4 proteins were prepared according to the literature and
provided by Dr. Kirsty McLean (Manchester Institute of Biotechnol-
ogy, University of Manchester).
Ligand Screening by UV−Visible Spectroscopy. UV−vis screening
was performed using a CARY400 UV−vis spectrophotometer (Varian,
CA, USA). Ligands were prepared as DMSO-d6 stock solutions (1−
100 mM) and added to protein (5 μM) solutions (198 μL) or to
buﬀer alone to give a ﬁnal DMSO-d6 concentration of 1% v/v.
CYP121 was prepared in 50 mM Tris-HCl (pH 7.2), 1 mM EDTA
buﬀer. CYP125, CYP126, CYP142, CYP143, and CYP144 were
prepared in 50 mM Tris-HCl (pH 7.5), 100 mM KCl buﬀer. CYP124
was prepared in 100 mM potassium phosphate (pH 7.0), 100 mM KCl
buﬀer. Spectra were recorded between 800 and 250 nm at 25 °C. Any
spectral interference from the inherent absorbance of added ligands/
solvent was removed by subtracting spectra collected for protein-free
samples of the same ligands/solvent in buﬀer. The diﬀerence in Soret
wavelength maximum (Δλmax) of the respective P450s Soret band
(λmax) in the presence of ligands compared to that obtained for a 1%
v/v DMSO-d6 control was used to identify type I or type II heme-
binding interactions. Changes in the Soret less than ±1 nm were
considered within experimental error.
Competition assays were performed to detect the binding
interactions of ligands that did not perturb that heme cofactor. A
known type II inhibitor, typically clotrimazole (5−50 μM) or
econazole (5−50 μM), was added to assay solutions to achieve a
ﬁnal DMSO-d6 concentration of 1% v/v. The diﬀerence in the red-shift
of the Soret band between competition assays and that found for the
known type II ligand in the absence of competing ligands was used to
determine competitive binding. Buﬀer control spectra were collected
to account for any inherent absorbance of added ligands/solvent and
all solutions were inspected and found to be free of precipitate. All
spectra were generated using Origin software (OriginLab, North-
ampton, MA) and processed using Microsoft Excel (Microsoft Oﬃce,
2010) and GraphPad Prism 5.01 (GraphPad Software, San Diego,
USA).
Optical Titrations. Optical titrations to determine KD values were
carried out a Varian Cary 400 UV−vis spectrophotometer (Varian,
CA, USA) according to a previously described procedure.17 Assays
were performed in reduced volume (200 μL) quartz cuvettes with a
path length of 1 cm (Starna, Essex, UK). Ligands were prepared as
DMSO-d6 stock solutions, and proteins (5 μM ﬁnal concentration)
were diluted in the corresponding buﬀer as described in the ligand
screening by UV−vis spectroscopy protocol above. Aliquots (0.2−1.0
μL) of ligand stock solutions were added directly to cuvettes
containing either protein solutions, or buﬀer alone, to achieve ﬁnal
concentrations of 100 nM to 1 mM. The ﬁnal DMSO-d6 concentration
did not exceed 1% v/v of the assay solution. Spectra were recorded
between 800 and 250 nm at 25 °C after the addition of each aliquot of
ligand. Buﬀer control spectra were subtracted manually from protein
spectra during processing or saved as a baseline for automatic
subtraction from protein spectra. Diﬀerence spectra were generated by
subtracting the initial ligand-free protein spectrum from each
successive titration spectrum. The maximum change in absorbance
for each diﬀerence spectrum was then plotted against ligand
concentration and ﬁtted using either a one-site binding model
hyperbolic eq (eq 1), or a modiﬁed version of the Morrison eq (eq
2) for tight binding inhibitors.58 All spectral analysis was done using
Origin software (OriginLab, Northampton, MA), and data were
processed using Microsoft Excel (Microsoft Oﬃce, 2010). Plots and
curve ﬁtting were performed using GraphPad Prism 5.01 (GraphPad
Software, San Diego, USA).
= × +A A L K L( )/( )obs max D (1)
= × + +
− + + − × ×
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In eqs 1 and 2, Aobs is the observed change in absorbance, Amax is the
maximum absorbance change at saturation, E is the total enzyme
concentration, and L is the concentration of ligand.
Competition Optical Titrations for Non-heme Binding Ligands.
The KD values of non-heme binding ligands were calculated from the
change in the apparent KD of a known type II ligand, typically 4,4′-(5-
(((1H-imidazol-4-yl)methyl)amino)-1H-pyrazole-3,4-diyl)diphenol
26h, when it was titrated into proteins (5 μM) in the presence of the
non-heme binding ligand (50 μM). Optical titrations were performed
and processed as described above, except that the non-heme binding
ligand was added initially to the ligand-free protein and buﬀer control
cuvettes. Data were ﬁtted using either eqs 1 or 2 to determine the KD
(apparent) of 26h, and then the KD of competitive ligand was
calculated according to eq 3.59
= +K K K(app) /(1 [B])DA DA DB (3)
In eq 3, KD
A(app) is the apparent binding aﬃnity calculated from
the competition titration, KD
A is the binding aﬃnity of the known
inhibitor, KD
B is the binding aﬃnity of the non-heme binding ligand,
and [B] is the concentration of the non-heme binding ligand.
Isothermal Titration Calorimetry. ITC experiments were per-
formed on a MicroCal iTC200 (Malvern Instruments, Malvern UK)
instrument at 25 °C. Ligands were prepared as stock solutions in
DMSO-d6, diluted to 0.5−2.5 mM depending on solubility, and
titrated into CYP121 (50 μM). Both ligands and CYP121 were
prepared in the same 50 mM Tris-HCl (pH 7.5) buﬀer, containing 1
mM EDTA and a ﬁnal concentration of 10% v/v DMSO-d6. Titrations
were comprised of 19 × 2.0 μL injections of ligand solution at 60−90 s
intervals. An initial 0.2 μL injection was made and the data discarded
during analysis. Control titrations were also performed (ligand into
buﬀer) to measure any heats of dilution or buﬀer mismatch. Control
titrations were subtracted from ligand titrations during data processing.
Binding isotherms were integrated to give the enthalpy change of each
injection and plotted against the molar ratio of ligand added to the
sample cell. Titrations were ﬁtted using a one-site binding model using
Origin Analysis Software, setting the stoichiometry to N = 1 for weak
binding compounds, or allowing N to vary for potent compounds
which showed high goodness of ﬁt.
Native Mass Spectrometry. The following experimental protocol
was followed for ligands 6, 19a, and 25a: Protein stock solutions (10
μM) were prepared by dilution of puriﬁed proteins (300−500 μM) in
200 mM ammonium acetate buﬀer (pH 7.0). Samples were buﬀer
exchanged by size exclusion chromatography using Micro Biospin 6
columns, molecular weight cutoﬀ 6 kDa (BioRad, Hemel Hempstead,
UK). Ligands were prepared as stock solutions in DMSO-d6 at 50, 100,
and 2500 μM concentrations. Ligand−protein samples were prepared
by diluting protein stocks (10 μL) and ligand stocks (1 μL) with
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ammonium acetate buﬀer (9 μL) to give ﬁnal concentrations of 5 μM
CYP121, 2.5−125 μM ligand, and 5% v/v DMSO-d6. An identical
protocol was followed for ligands 24a, 25b, and 26a, except that
concentrations of CYP121 (8.7 μM) and DMSO-d6 (2.175% v/v)
were altered. The concentrations of ligands was adjusted to maintain
the same ligand-to-protein ratios. Mass spectra were recorded on a
Synapt HDMS instrument (Waters UK Ltd., Manchester, UK).
Capillaries for nanoESI− were purchased from ThermoFisher (Hemel
Hempstead, UK). Capillary tips were cut under a stereomicroscope to
give inner diameters of 1−5 μm and then loaded with 2.5 μL of sample
solutions. Given below are the general instrumental conditions used to
acquire the reported spectra. However, conditions were optimized
over the course of each experiment to preserve the noncovalent
protein−ligand complex and minimize nonspeciﬁc interactions. All
measurements were carried out in a positive ion mode with ion source
temperature of 20 °C. A capillary voltage of 1.50−1.75 kV, cone
voltage of 60−80 V, and extraction cone voltage of 2.3−4.1 V were
applied to perform nanoESI. All reported spectra were collected with a
trap collision energy 12−18 V, transfer collision energy 12 V, IMS
pressure 5.02 × 10−1 mbar, and TOF analyzer pressure 1.17 × 10−6
mbar. External calibration of the spectra was achieved using cesium
iodide at 100 mg mL−1 in water. Data acquisition and processing were
performed using Micromass MassLynx v4.1. Mass diﬀerences resulting
from ligand binding were calculated relative to the relevant 5% v/v
DMSO-d6 spectra of CYP121 (5 μM). Mass diﬀerences were divided
by the molecular weight of the ligand to calculate binding
stoichiometry. The percentage of monomeric CYP121 was calculated
from the sum of the intensities of peaks corresponding to monomeric
CYP121 (m/z 3500−4750) divided by the sum of peak intensities
corresponding to both monomeric and dimeric (m/z 5250−6750)
CYP121.
X-ray Crystallography. Untagged CYP121 protein and crystals
were prepared as described previously with the following adapta-
tions.27 Crystals were prepared by vapor diﬀusion in 1.5−2.1 M
ammonium sulfate and 0.1 M sodium MES or Cacodylate from pH
5.5−6.15. Additional crystallization was also conducted on the
nanolitre scale using a Mosquito pipetting robot (Molecular
Dimensions, Newmarket, UK), and crystals were produced in the
Morpheus crystallization screen (Molecular Dimensions) in 800 nL
drops with protein-to-mother liquor at a ratio of 1:1. Ligand soaks
were carried out either by directly dissolving solid ligand at saturation
or by the addition of 2−5 mM ligand solution in DMSO to the mother
liquor and soaking was carried out for 24 h. Crystals were
cryoprotected and frozen as described previously except from
Morpheus conditions that were frozen directly. Data were collected
on beamline I24 (wavelength 0.9173/1.0118 Å) and I02 (wavelength
0.9795 Å) at the Diamond Light Source Facility (Oxfordshire, UK).
Data were processed and reﬁned as previously described. Data tables
and statistics are provided in Table S5, Supporting Information.
CYP121−ligand cocrystal structures are deposited in the Protein Data
Bank (http://www.rcsb.org/pdb/) under the accession codes: 6, 5IBJ,
7; 5EDT, 19a; 5IBF, 24a; 5IBD, 25a; 5IBE, 25b; 5IBG, 26a; 5IBI, and
26h; 5IBH. Images for presentation were rendered using an academic
version of the PyMOL Molecular Graphics System, version 1.3, 2010,
Schrödinger, LLC.
Human P450 Inhibition. Experimental determination of IC50 values
for the inhibition of human P450s by 19a, 25a, and 26a were
performed by Cyprotex (Cheshire, UK). Inhibition assays of CYP1A,
CYP2C9, CYP2C19, CYP2D6, and CYP3A4 were performed in
human liver microsomes in quadruplicate, over a 7-point ligand
concentration range (0−25 μM). The formation of metabolites from
the turnover of isoform-speciﬁc substrates (CYP2C9, tolbutamide;
CYP2C19, mephenytoin; CYP2D6, dextromethorphan; and CYP3A4,
midazolam) was monitored by LC/MS. Turnover of the CYP1A
substrate ethoxyresoruﬁn was monitored by ﬂuorescence. Activities
reported for CYP1A refer to the combined inhibition of CYP1A1 and
CYP1A2 isoforms. IC50 values were calculated relative to the vehicle
controls. IC50 values for known inhibitors (α-naphthoﬂavone,
sulfaphenazole, tranylcypromine, quinidine, ketoconazole) were
determined as a positive control and were found to be within the
expected range (Table S3, Supporting Information).
Antimycobacterial Activity Assay. Three M. tuberculosis (Mtb)
H37Rv cultures were prepared in 7H9 liquid medium supplemented
with 10% OADC enrichment (Sigma-Aldrich, Poole UK). Cultures
were incubated at 37 °C until the OD600 reached 1.00. After this
period, the bacterial suspensions were washed twice with fresh 7H9
medium and then used in the antimycobacterial activity assays. The
minimum inhibitory concentration (MIC90) of the compounds was
measure in triplicate in a 24 well plate-based format. Plates were
prepared with 2 mL of 7H10 solid medium supplemented with 10%
OADC enrichment (Sigma-Aldrich) per well. Test compounds were
prepared as stock solutions in DMSO and diluted into the 7H10
medium to achieve ﬁnal concentrations of 100, 50, 25, 12.5, and 6.25
μM of CYP121 inhibitors and a ﬁnal 1% v/v DMSO concentration.
Rifampicin was used as a positive control and tested at 3.00, 1.50, 0.75,
0.37, and 0.18 μM concentrations. Prepared Mtb suspensions (OD600
= 1.0, approximately 3.00 × 105 CFU) were aliquoted (10 μL) onto
the compound-infused solid medium and incubated at 37 °C for 2
weeks. The MIC90 was determined as the lowest concentration of
compound that resulted in 90% inhibition of bacterial growth
compared to the negative control wells, which were not treated with
compounds and contained either 0% or 1% v/v DMSO.
Molecular Modeling and Docking. Lead compound 2, retrofrag-
ments 5 and 6, and all Ar1, Ar2, and Ar3 analogues were prepared
using the LigPrep v3.2 and Epik v3.0 functions of Schrödinger suite
software (Schrödinger LLC, NY), selecting to include metal binding
states when generating ligand ionization states. Ligands were docking
into the crystal structure of CYP121 bound to lead 2 (PDB 4KTL) or
the previously reported ligand 4-(1H-1,2,4-triazol-1-yl)quinolin-6-
amine (PDB 4G1X). Proteins were prepared using the internal
Protein Preparation function of the Schrödinger suite software.
Ionization states were generated to be compatible with metal-binding
interactions, and the heme-iron was manually adjusted to the ferric
(+3) oxidation state. All water molecules were removed from the
structure PDB 4G1X. Duplicate energy minimized (OPLS 2005)
structures of PDB 4KTL were prepared either with all water molecules
removed or retaining the axial heme−water ligand only. Ar1 and Ar3
analogues were docked using core constraints to replicate the position
of the aminopyrazole ring of lead 2. Ar2 analogues were docked using
core constraints to replicate the heme binding interactions of the 4-
(1H-1,2,4-triazol-1-yl)quinolin-6-amine ligand in PDB 4G1X. Images
were generated using the PyMOL Molecular Graphics System, version
1.3, 2010 (Schrödinger, LLC).
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